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Abstract  
Zirconium-89 (
89
Zr), a radionuclide with a half-life of 78.4 hours, is suitable for 
imaging tumours using positron emission tomography (PET) when labelled with 
monoclonal antibodies. 
89
Zr can be produced from Yttrium-89 (
89
Y) by a process of 
cyclotron bombardment with 
89
Y(p, n)
89
Zr reaction. Purification and radiolabelling 
processes must be developed before 
89
Zr can be used for monoclonal antibody PET 
imaging.  
The main aim of this study was to produce 
89
Zr using various types of 
89
Y solid 
targets through irradiation in a 12 MeV medical cyclotron at low currents using 
89
Y(p, n)
89
Zr reaction for PET imaging in a preclinical condition. Five techniques of 
89
Y solid targets were prepared for the production of 
89
Zr. Gamma spectrum analyses 
determined energy peaks of 511 keV and 909 keV indicating that 
89
Zr radionuclide 
had been successfully produced. 
89
Zr was then purified through a hydroxamate resin 
column and radiolabelled to a monoclonal antibody (trastuzumab). Experiments on 
biodistribution together with PET imaging of female balb/c nude mice having the 
HER2 positive LS174T colorectal tumour was undertaken to validate the successful 
radiolabelling procedure between 
89
Zr and trastuzumab. PET images at 24 hours 
showed a selective accumulation of 
89
Zr-Df-Trastuzumab in tumour-bearing mice 
with good tumour tracer uptake in the right flank, as well as cardiac uptake, a 
significant presence of HER2 receptor expression on the heart, demonstrated that the 
conjugated Df-Trastuzumab was successfully labelled with 
89
Zr.  
  
ii 
 
In addition, the capability of the hydroxamate resin column as a new potential 
column was investigated for 
68
Ga purification and radiolabelling in a 
68
Ga generator. 
Hydroxamate resin column was used to trap 
68
Ga in alkaline solution and the solution 
was purified and eluted from hydroxamate resin column using citrate buffer at pH 4 
as an extraction agent. It was then labelled to a monoclonal antibody to produce 
68
Ga 
radiopharmaceutical for PET imaging. The first series of experiments on different 
quantities of hydroxamate resin column indicated that 50 mg of the resin was suitable 
for the optimum extraction of 
68
Ga radionuclide. Series elution tests of 
68
Ga from the 
hydroxamate resin column using various buffers including acetate, citrate and citrate 
in hydrochloric acid (HCl) with different concentrations were performed. The results 
indicated that 0.1 M citrate buffer was suitable for 
68
Ga elution and comparable to 
0.5 M HCl which is currently being used as 
68
Ga extraction agent from 
68
Ge/
68
Ga 
generator. Experiments on 
68
Ga radiopharmaceutical radiolabelling reported that 
68
Ga-Df-Trastuzumab radiolabelling was successful according to TLC and HPLC 
analysis results; however, weak radiolabelling efficiency was found for 
68
Ga-
Pentetreotide radiolabelling. 
In conclusion, 
89
Zr was produced through irradiation at 10 µA using 
89
Y(p, n)
89
Zr 
reaction in a 12 MeV medical cyclotron and was successfully radiolabelled to 
trastuzumab for PET imaging in a preclinical condition. In addition, the potential of 
hydroxamate resin to be used as a new column in a 
68
Ga generator was promising, 
where 
68
Ga was purified and eluted from a hydroxamate resin column using 0.1 M 
citrate buffer at pH 4 as an extraction agent. It was successfully labelled to a 
monoclonal antibody to produce 
68
Ga radiopharmaceutical for PET imaging. 
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Chapter 1: Introduction 
1.1 Radioactivity 
Radioactivity refers to a spontaneous emission of radiation from atomic nuclei, either 
from the unstable atom or as a consequence of a nuclear reaction. Radioactivity is a 
decomposition process where unstable atomic nuclei spontaneously release energetic 
subatomic particles to form nuclei with a higher stability. The energy and particles 
which are released during the decomposition process are called radiation. There are 
three major types of radioactivity emitted by a radioactive substance, namely: 
 Alpha Radiation - Alpha radiation has an atomic mass of 4 and a charge of 
+2 (a helium nucleus). It contains a stream of positively charged particles 
which are also called alpha particles. When an alpha particle is ejected from 
a nucleus, the mass number of the nucleus decreases by four units and 
the atomic number decreases by two units. For example: 
ThHeU 23490
4
2
238
92   
The helium nucleus is the alpha particle. Although alpha particles are 
normally highly energetic, they travel only a few centimetres in the air and 
are then stopped by a sheet of paper or the outer layer of dead skin. 
 Beta Radiation - Beta radiation is a stream of electrons, called beta particles. 
When a beta particle is ejected, a neutron in the nucleus is converted to a 
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proton, so the mass number of the nucleus is unchanged, but the atomic 
number increases by one unit. For example: 
PaeTh 23491
0
1
234
90   
The electron is the beta particle. Beta particles may travel metres in air and 
several millimetres into the human body. Most beta particles may be stopped 
by a small thickness of a light material such as aluminium or plastic. 
 Gamma rays are high-energy photons with a very short wavelength (0.0005 
to 0.1 nm). The emission of gamma radiation results from an energy change 
within the atomic nucleus. Gamma emission does not change either the 
atomic number or the atomic mass. Alpha and beta emissions are often 
accompanied by gamma emission, as an excited nucleus drops to a lower 
and more stable energy state. Gamma particles travel in a wave-like pattern 
at the speed of light. They can only be stopped by a dense material such as 
lead, steel, concrete or several metres of water. 
Apart from the natural process of unstable nuclei decomposition in nature (which is 
also known as natural radioactivity), there is another process of unstable nuclei 
decomposition that is prepared in the laboratory, known as induced radioactivity. In 
this process, positron (a particle with the same mass as an electron, but a charge of 
+1 instead of -1) emission is a common mode of decay in induced radioactivity but 
not observed in natural radioactivity. Basically, positron emission is used in 
preparing radioactive isotopes in the lab by using bombardment reactions in order to 
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convert a stable nucleus into a radioactive one. Bombardment reactions can be used 
to produce very heavy elements which do not occur in nature. 
Radiation can also be artificially produced in conventional X-ray machines and CT 
scanners, while radioisotopes can be produced in nuclear reactors or particle 
accelerators such as medical cyclotrons. Radioactivity has many applications in 
medicine, both in therapy and imaging. Medical imaging uses either structural or 
functional imaging. Structural imaging includes x-rays, computed tomography (CT) 
and magnetic resonance imaging (MRI); whereas functional imaging typically 
involves the Nuclear Medicine modalities of single photon emission computed 
tomography (SPECT) and positron emission tomography (PET). Nuclear medicine 
makes use of the tracer technique whereby targeted radioisotopes emit radiation with 
sufficient energy to enable them to be detected outside of the body. When these 
radioisotopes are attached to biologically active molecules, the resulting compounds 
are known as radiopharmaceuticals. They can either localize in certain body tissues 
or follow a particular biochemical pathway [1].  
Radiopharmacology is the study and preparation of radiopharmaceuticals 
(radioactive pharmaceuticals) used in the field of nuclear medicine as tracers in the 
diagnosis and therapeutic treatment of many diseases. It consists of two parts, 
specifically; a radionuclide (which is a radioactive isotope that can be injected safely 
into the body) and a pharmaceutical which acts as a carrier molecule delivering the 
isotope to the area to be treated or examined within the body. Currently, about 95% 
of radiopharmaceuticals are used for diagnostic purposes and around 5% are used for 
radionuclide therapy [2-4]. In order for a radiotracer to be used safely in humans, for 
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imaging or therapy, it must meet high quality standards that include chemical and 
radiochemical purity, sterility and freedom from pyrogenic material. For functional 
nuclear medicine imaging there are few ideal radiopharmaceuticals [5]. Table 1.1 
outlines the ideal diagnostic radiopharmaceutical for imaging. The ability to measure 
regional biochemical functions requires a careful design process with these principles 
in mind. However, in reality, it is not possible to meet all of these criteria. For 
example, all decay processes involve the emission of particles, as in the case of the 
pure γ-emitters which emit Auger electrons during some segment of the decaying 
process. Thus, in addition to the quest of designing an ideal radiopharmaceutical in 
the development of a biochemical probe area, the following three factors must be 
considered [6], specifically: (i) the radiotracer must be able to bind preferentially to a 
specific site; (ii) the radiotracer must be sensitive to minor changes in biochemistry 
and (iii) if possible, the specific biochemical change should be a function of a 
specific disease that matches that sensitivity. 
 
 
 
 
 
 
  
5 
 
Table 1.1 
Properties of Ideal Diagnostic Radiopharmaceutical for Imaging [6] 
 
Many radiotracers have been synthesised to probe metabolic turnover such as oxygen 
consumption, glucose utilisation and amino acid synthesis. Enzymatic activity, 
neurotransmission, receptor density and occupancy have all been measured through 
appropriately designed radiotracers. It should be emphasised that the development of 
radiotracers for PET fundamentally violates rule No. 2 (a) in Table 1.1 for the ideal 
diagnostic radiopharmaceutical for imaging, since PET radionuclides emit β+ 
particles by nature. However, the resulting coincident γ rays from the β+ annihilation 
form the basis for the technique. 
Additionally, in consideration of the above principles, a plan must be considered as 
to how to insert the radionuclide into the molecule at a point in the synthetic process 
       Properties Expectations 
1) Easy availability Be readily available at a low cost. 
2) Particle Emission  (a) Diagnostic purpose - Be a pure gamma emitter, i.e. 
no particle emission such as α and β, as these 
particles contribute a radiation dose to the patient 
while not providing any diagnostic information.  
(b) Therapeutic purpose – Particles such as α and β are 
very useful for treating radiation damage of 
abnormal cells. 
3) High Target-to-Nontarget 
Activity Ratio 
To provide maximum efficacy in the diagnosis (therapy) 
and minimum radiation dose to the patient. 
4) Possess proper metabolic 
activity  
Ideal radiopharmaceutical should possess the proper 
metabolic activity, in that it follows or is trapped in the 
metabolic process of interest. 
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with minimal handling, yet still be late enough in the synthesis to minimise loss due 
to chemical yield and radioactive decay. For these reasons, the preparation of 
radiopharmaceuticals requires good planning and techniques which are not 
encountered in traditional synthetic chemistry.  
In diagnosis, radioactive substances are administered to patients and the radiation 
emitted is detected. The diagnostic tests involve the formation of an image using a 
gamma camera or PET. 
 
1.2 Positron Emission Tomography (PET) 
1.2.1 Introduction 
Positron emission tomography (PET) is a type of diagnostic medical imaging 
technology that uses a nuclear medicine imaging modality to produce a three-
dimensional image of functional processes in the body. It detects gamma rays 
emitted by a positron-emitting radioisotope or radionuclide, which is introduced into 
the body on a metabolically active molecule. The functional images produced of 
metabolic activity in space are then reconstructed by computer analysis. PET is 
commonly used for diagnostic purposes to determine the level of cancer inside the 
body. PET scanners nowadays are mainly aided by results from a CT X-ray scan 
performed on the patient at the same time using the same machine. Usually, in order 
to conduct a scanning procedure, a short-lived positron emitting radioisotope tracer is 
used and injected into the body of a living subject (usually into blood circulation). 
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However, the radioisotope tracer has to be chemically incorporated into a 
metabolically active molecule before it can be injected into the blood circulation. 
Before the patient or research subject is placed in the imaging scanner, there is a 
waiting period so that the metabolically active molecule accumulates and becomes 
concentrated in tissues of interest. The most commonly used molecule for this 
scanning procedure is fluorodeoxyglucose (FDG), a sugar, for which the waiting 
period is typically an hour. 
At the beginning of  the 1950s, Wren et al. proposed the idea of using coincidence 
technique to image positron emitting radionuclides [7]. With this technology, they 
wanted to study 
64
Cu in brain tumours using opposing sodium iodine detectors. The 
Anger camera was launched in  the market in 1954 and was quickly applied for 
positron emitters [8]. Na(I) detectors with coincidence measurements were used in 
clinical investigations during the 1960s [9]. In 1970, a very important progression in 
this field was accomplished through the introduction of the tomography principle 
[10]. The PET technique is thus the outcome of two Nobel Prize awards, specifically: 
the tracer principle (de Hevesy in 1943) and the tomographic principle (Houndsfield 
and Cormack in 1979) [11]. 
Since PET images generate physiological and functional information to the observer 
and the anatomic structures are sometimes hardly distinguished, PET is nowadays 
often combined with CT in order to yield the anatomical information [3]. An 
example of PET facilities at one of the cancer centres in Victoria, Australia is shown 
in Figure 1.1. 
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Figure 1.1 PET facilities at Peter MacCallum Cancer Centre, Victoria, Australia 
1.2.2 Basic Principle 
PET uses gamma rays produced by positrons annihilating with electrons emitted 
from positron-emitting radionuclides or radiopharmaceuticals, which are then 
introduced into the body on a metabolically active molecule [12]. Images of 
metabolic activity in space are then reconstructed by computer analysis, aided by 
results from a CT X-ray scan performed on the patient at the same time, in the same 
scanner machine. PET is based on the coincidence detection principle of the two 
annihilation photons emitted after positron decay [13]. A radioactive isotope, 
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together with an excess of protons, may disintegrate through positron decay. A 
proton in the nucleus is converted into a neutron and at the very same moment a 
positron (β+) and a neutrino (v) is emitted. The positron has the same mass as an 
electron but the opposite electric charge, i.e. it is the antiparticle of an electron. In the 
case of 
89
Zr, positron decay would look like the following: 
89
Zr  =     Y + β+ + v 
The energy released in the decay is divided between the positron and neutrino (and 
the residual energy of the daughter), which means that the positron energy is not 
monoenergetic but emits in a range of energies. The neutrino is always ejected 
simultaneously with the positron but is not detected. For radionuclides used in PET, 
the range of the positron in tissue is in the order of 1-10 mm [14]. Finally, when the 
positron reaches thermal energy, it interacts with an electron to form an unstable 
formation - positronium. Positronium eventually decays by emitting two anti-parallel 
annihilation photons corresponding to the rest masses of the electron and positron 
respectively, i.e. 511 keV each [15]. Due to inelastic collisions between the positron 
and atomic electrons, the positron can change its direction substantially from one 
collision to another. 
The PET camera consists of a ring of detectors placed around the object to examine. 
If these two annihilation photons are registered in a very short period of time (~5-15 
ns) the algorithms assume that anywhere along this line an event has happened, 
which refers to line of response (LOR). By calculating all LORs, the place where the 
annihilation occurred can be reconstructed. This is basically the principle of 
coincidence systems. Notice that this location does not refer to the location where the 
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positron decay took place, but rather to the line along which the decay occurred [16]. 
The spontaneous decay of a positron emitter produces a positron, which travels a 
certain distance (depending on its energy) to finally react with one electron of a 
surrounding atom which is called annihilation. Consequently, two gamma photons 
are emitted (511 keV each, emitted at 180
o
 to each other). Figure 1.2 shows the basic 
principles of positron decay and its following annihilation. The generation of these 
gamma rays forms the basis of PET. 
 
 
Figure 1.2 Basic principle of positron decay and the following annihilation [17] 
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1.2.3 Immuno-PET 
Immuno-PET, a combination of monoclonal antibodies (mAbs) and PET, associates
 
the high resolution and sensitivity of PET imaging with the
 
specificity of a mAb. 
This occurs in order to improve diagnostic tumour characterisation that enables the 
confirmation of tumour targeting and the
 
quantification of mAb accumulation by 
radioactivity uptake in a modified therapeutic approach [16, 18]. Furthermore, 
immuno-PET might also have an important role in the characterisation and 
optimisation of new potential
 
mAbs for diagnosis and therapy [19]. Each mAb can 
target to an extracellular matrix component or specific tumour
 
cell surface marker for 
use in immuno-PET. This then permits the development of new potential imaging 
probes based on mAb. Apart from that, PET also has the potential
 
of molecular 
interactions quantification, in instances where immuno-PET is used as an 
introduction to the therapy with the approved mAbs. 
In a modified therapeutic method, immuno-PET enables the confirmation of tumour 
targeting and the quantification of mAb accumulation. Therefore, patients who have 
the best chance to benefit from the therapy based on mAb could be selected, whereas 
treatment schedules can be adjusted to improve treatment efficiency and reduce 
harmfulness.  
Currently, intact mAbs are the format of choice for therapeutic procedure because of 
their long residing time in humans, ranging from a few days to weeks, compared to 
mAb fragments that have a much faster blood clearance.  However, the optimal 
format for diagnostic purpose is still under review. Innovative approaches for 
optimal diagnostic procedure include the pretargeting techniques that involve 
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separating the targeting antibody from the consequent delivery of an imaging or 
therapeutic agent that binds to the tumour-localised antibody [20]. 
1.2.4 Positron Emitters for Immuno-PET 
A positron emitter which is suitable to be used for immuno-PET has to fulfil several 
requirements. First and foremost, the positron emitter should have suitable decay 
characteristics for optimum resolution and quantitative accuracy. Secondly, the 
production ought to be easy and cheap so as to allow efficient and stable coupling to 
mAbs. Finally, maintenance of the antibody‟s in vivo binding and biodistribution 
characteristics is important, while the half-life (t1/2) of the positron emitter should be 
well-suited with the time needed for a mAb to achieve optimal tumour-to-nontumour 
ratios. Table 1.2 shows the positron emitters which are suitable for immuno-PET, to 
be precise: gallium-68 (
68
Ga; t1/2 = 1.13 hours), fluorine-18 (
18
F; t1/2 = 1.83 hours), 
copper-64 (
64
Cu; t1/2 = 12.7 hours), yttrium-86 (
86
Y; t1/2 = 14.7 hours), bromine-76 
(
76
Br; t1/2 = 16.2 hours), zirconium-89 (
89
Zr; t1/2 = 78.4 hours), and iodine-124 (
124
I; 
t1/2 = 100.3 hours) [21]. 
68
Ga and 
18
F are short-lived positron emitters, so they can 
only be used in combination with mAb fragments or in pretargeting methods. 
89
Zr 
and 
124
I, on the other hand, are predominantly suitable in combination with 
conjugated mAbs because of their long half-lives which allow imaging at later time 
points for gaining optimum information. The long half-life of a positron emitter is 
also an added advantage in terms of logistics related to transportation. However, a 
possible disadvantage of the use of a long-lived positron emitter is a higher radiation 
burden to patients. However, as scanners are becoming more sensitive nowadays, 
this aspect will become less critical. 
76
Br and 
124
I can be coupled directly with mAbs, 
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while the others require indirect labelling methods, using bifunctional chelates or 
other prosthetic groups. 
 
Table 1.2  
Characteristics of positron emitters used in preclinical and clinical 
radioimmunoscintigraphy studies [21] 
              Intrinsic spatial 
  Positron 
 
Half-life 
Main β+ energies  
   
resolution loss 
  emitter  Production (hours) (keV) (%)   (mm) 
  
       
  
68
Ga 
 
68
Ge/
68
Ga 
generator 
1.13 1,899 87.9 
 
2.4 
  
       
  
18
F 
18
O(p,n) 1.83 634 100 
 
0.7 
  
 
20
Ne(d, 
     
  
64
Cu 
64
Ni(d,2n) 12.7 653 17.4 
 
0.7 
  
 
64
Ni(p,n) 
     
  
86
Y 
86
Sr(p,n) 14.7 1,221 11.9 
 
1.8 
  
   
1,545 5.6 
  
  
76
Br 
75
As(3He,2n) 16.2 871 6.3 
 
5.3 
  
 
76
Se(p,n) 
 
990 5.2 
  
  
   
3,382 25.8 
  
  
   
3,941 6 
  
  
89
Zr 
89
Y(p.n) 78.4 897 22.7 
 
1 
  
       
  
124
I 
124
Te(p,n) 100.3 1,535 11.8 
 
2.3 
  
 
124
Te(d,2n) 
 
2,138 10.9 
  
    
125
Te(p,2n)         
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Another important consideration in the choice of positron emitter is whether the mAb 
becomes internalized after binding to the target antigen. Degradation of 
76
Br- and 
124
I-labelled mAbs upon internalization results in rapid clearance of these 
radionuclides from the target cells, and therefore the PET image shows less tumour 
contrast and does not reflect the actual mAb distribution. In contrast, the positron 
emitters are trapped intracellularly in lysosomes when 
68
Ga, 
64
Cu, 
86
Y, and 
89
Zr 
labelled mAbs are being processed. Thus, when selecting a positron emitter for 
immuno-PET applications, the occurrence of these residualisations should be taken 
into account. For example, imaging of trastuzumab, bevacizumab and cetuximab can 
best be performed using a residualizing positron emitter.  
Four important PET radionuclides (
11
C, 
13
N, 
15
O and 
18
F) were known to all of 
medical society and this trend is still ongoing. However, apart from these 
radioisotopes, many other PET radionuclides were prepared and some of them 
entered the human application phase due to the need for tracing the related elements 
in human diseases and conditions. Some others were used in radiolabelled form and 
demonstrated interesting diagnostic tools in various biological phenomena.  
Usually, radionuclides which are suitable for labelling to monoclonal antibodies to 
be used in immuno-PET imaging studies are produced in a cyclotron. 
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1.3 Cyclotron 
1.3.1 Introduction 
A cyclotron is a particle accelerator that makes use of electric and magnetic fields to 
accelerate ions in a small space. Cyclotrons accelerate charged particles using a high-
frequency with alternating voltage. A vertical magnetic field causes the particles to 
spiral almost in a circle so that they re-encounter the accelerating voltage many 
times. A cyclotron consists of two D-shaped regions known as dees; where in each 
dee there is a magnetic field perpendicular to the plane of the page. There is a 
uniform electric field pointing from one dee to the other in the gap separating the 
dees. A charge is accelerated by the electric field when it is released from the rest in 
the gap and carried into one of the dees. The charge which is caused by magnetic 
field in the dee follows a half-circle that carries it back to the gap [22]. When the 
electric field in the gap is reversed, the charge is once again accelerated across the 
gap while the charge is in the dee. The cycle continues with the magnetic field in the 
dees continually bringing the charge back to the gap and every time the charge 
crosses the gap it picks up speed. This phenomenon causes the half-circles in the 
dees to increase in radius and, finally, the charge emerges from the cyclotron at high 
speed. 
The electric field is generated by the application of an electric potential difference to 
two electrodes (called dees and counter-dees) which are connected to the alternating 
current source. A high voltage is applied to hydrogen or deuterium gas to generate 
negative ions in the ion source which is placed in the centre of the cyclotron. By 
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applying an electrical field, negative ions are extracted from the centre of the 
cyclotron. The counter dee is negatively charged when the dee is positively charged. 
As a result, the ion is accelerated towards the dee by the electric field [23]. 
Cyclotrons are one of the earliest types of particle accelerators to be developed and 
currently used for the preparation of a wide variety of radionuclides that find 
application in SPECT as well as in PET. Consequently, the cyclotron-produced 
radioisotopes are in high demand within a worldwide market. 
The first cyclotron dedicated to medical applications was installed at Washington 
University in St. Louis, in 1941 and produced radioactive isotopes of phosphorus, 
iron, arsenic and sulphur. A cyclotron in Boston also provided a steady supply of 
radionuclides for medical purposes during World War II. In the middle of  the 1950s, 
a group at Hammersmith Hospital in London put into operation a cyclotron wholly 
dedicated to radionuclide production [24]. 
Cyclotrons come in many sizes depending on the function and the scope of the work 
to be performed in each facility. For example, the widely used PET radionuclides can 
be prepared in large quantities in a cyclotron with energy ranging from 9 to 19 MeV, 
whereas higher energy machines (~30 MeV) are needed for preparation of the 
commonly used SPECT radionuclides. The basic characteristics of all cyclotrons are 
the same, having an ion source, an acceleration chamber and a magnetic field to 
produce ions and accelerate them along a circular trajectory. Figure 1.3 shows a 
deuteron machine designed to produce only 
15
O for PET. The machine shown in 
Figure 1.4 is a 500 MeV cyclotron which is located at TRIUMF in Vancouver, 
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Canada. This 500 MeV cyclotron is a huge facility and a place where a wide variety 
of radionuclides are produced and other experiments are carried out [24]. 
 
 
Figure 1.3 A small single isotope cyclotron machine [24] 
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Figure 1.4 A large multipurpose research cyclotron machine [24] 
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Based on the scope of the work to be performed, five categories of cyclotrons were 
formally defined by a task group on the PET site and facility planning set up by the 
American Association of Physicists in Medicine (AAPM). It is obvious that there is 
really a continuum of facilities and the lines of definition are purely arbitrary [25]. 
Categories have been defined based on the assumption that a cyclotron will be in 
place in the facility and the differences will be in the mission and scope of the 
facility. Table 1.3 outlines the categories of the cyclotron facility [24]. 
 
Table 1.3  
Types of Cyclotron Facility [24] 
Type II  Cyclotron facility with radionuclide production for PET 
Similar to Type I, this type of facility also has a cyclotron in the proton energy 
range of 9–19 MeV, with the production of FDG as the principal objective. 
However, this facility is designed to produce other short-lived positron emitters, 
e.g. 
11
C, 
13
N and 
15
O, convert them into radiopharmaceuticals and distribute them 
locally. The facility may also distribute FDG to nearby hospitals with little 
involvement in basic radiotracer development research and nearly complete 
dependence on the vendor for maintenance, equipment upgrades, and the 
development of new radiotracers. 
Type III  Cyclotron facility with a research support staff 
Along with a cyclotron in the 13–19 MeV range and automated synthesis modules, 
this facility has a scientific support staff of chemist(s), physicist(s), or other 
scientists capable of developing procedures and radiopharmaceuticals that have 
been described in the literature. The major emphasis is to provide 
radiopharmaceuticals for routine patient studies, but some independent research 
can be carried out, including biodistribution and biokinetic animal studies with 
micro-PET. In addition to the production of the four traditional PET radionuclides, 
  
20 
 
mentioned earlier, this type of facility may also produce other radionuclides such 
as 
123
I, 
124
I, 
64
Cu and 
86
Y. 
Type IV  Radionuclide production and distribution facility 
This type of facility is devoted to the large scale production of radionuclides and 
radiopharmaceuticals for distribution to users. If FDG is the major product, then 
the cyclotron is probably a small one. If other radioisotopes such as 
201
Tl, 
123
I, 
124
I, 
67
Ga, 
64
Cu, 
86
Y and others are being produced, the cyclotron should be larger(~30 
MeV) than those used only for PET. Separate laboratory areas may be required for 
target preparation, recovery and processing. Separate laboratories or similar places 
should also be required for sterile setup, quality control (QC) and shipping. There 
are also possibilities of setting up cyclotron centres dedicated to the production of 
a single radionuclide such as 
103
Pd for therapy. 
Type V  Cyclotron facility with an extensive research program 
The facility will have a team of research scientists performing basic research on 
developing new radiotracers and procedures, along with a larger (30 MeV) 
cyclotron used for the production of PET and SPECT radionuclides and 
radiopharmaceuticals. Considerable space is allocated for laboratories and animal 
facilities. There is little or no pure clinical work done, but there may be an 
extensive clinical research program. This program may involve production of non-
traditional PET radioisotopes such as 
64
Cu, 
86
Y, 
123
I, and 
124
I as well as many other 
radionuclides that can be produced by proton (p, xn), deuteron (d, xn) or alpha (α, 
xn) reactions.  
 
In summary, if the cyclotron is used for radionuclide production and scientific or 
industrial applications, a multi particle, variable energy and variable beam current (a 
few nA up to a few hundred μA) accelerator with several beam lines is the preferred 
cyclotron to be installed. In a word, a cyclotron can be divided into two classes; one 
with low energy (which is also known as medical cyclotron and produces short lived 
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PET isotopes such as 
18
F, 
15
O and 
11
C), while the other with higher energy produces 
SPECT isotopes such as 
67
Ga, 
111
In and 
201
Tl. 
In 2006, the International Atomic Energy Agency (IAEA) reported that there are 262 
entries for cyclotrons operating in 39 member states of the IAEA. This is an increase 
of 7% over the 246 reported in the 2002 cyclotron directory. This can be compared to 
the 350 or more cyclotrons believed to be presently operating in the world, which are 
involved in some aspects of radionuclide production. The number of cyclotrons have 
increased recently, not only in developed countries, but also even more in the 
developing countries [26].  
1.3.2 Targets 
A cyclotron target is a container where the target material (gas, liquid or solid 
materials) is introduced in order to be irradiated in a cyclotron. There are some key 
parameters which have to be considered for target body design, specifically: 
- The minimal energy needed to generate the radioactive atom that is the 
threshold energy for the reaction. 
- The energy where the maximum cross-section (probability for the nuclear 
reaction to occur) is obtained. 
- The physical form of the target material: gas, liquid or solid. Heat transfer 
properties and potential effects due to heating while irradiation takes place 
should be carefully considered for each particular case. 
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- The chemical which is formed from the target material. 
- The physical form of the product. 
- The chemical form of the product. 
- The ease of separation of the product from the target.  
Target material can be gas, liquid or solid depending on the radioisotope of interest. 
Targets specially designed for the production of the most common positron emitters 
(
18
F, 
11
C, 
13
N and 
15
O) are implemented in commercially available cyclotrons and the 
design to improve its performance has been optimized for many years. 
89
Zr is an 
example of a non-conventional positron emitter which is produced from a solid target 
of 
89
Y). 
1.4 Zirconium-89  
In recent years, there has been increased interest in such non-conventional positron 
emitters [27-31] and one of them is
 89
Zr [31-34]. Large-scale production procedure of 
89
Zr and its stable coupling to mAbs have been developed since the introduction of 
the long-lived positron emitter 
89
Zr as a residualizing radionuclide for immuno-PET 
[18, 35-37]. In order to have a successful diagnostic in PET imaging for solid 
tumours, a radionuclide‟s half-life must be suitable for target accumulation and 
nonspecific clearance. 
89
Zr has a half-life of 78.4 h (3.3 d) with a positron emission 
β+ (897 keV, 23%) decay and electron capture (77%). 89Zr is produced by cyclotrons 
from the nuclear reaction 
89
Y(p, n)
89
Zr, but the separation of 
89
Zr requires both 
solvent extraction and ion-exchange chromatography [38-40]. A simplified 
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production method using the 
89
Y(d, 2n)
89
Zr reaction requires only a one-step ion-
exchange separation. Theoretically, all the bifunctional chelating agents, such as 
DTPA and DOTA derivatives, for 
111
In and 
90
Y-labeling can be used for 
89
Zr-
labeling of biomolecules [41]. Due to 
89
Zr‟s long half-life, it is an attractive isotope 
for 
89
Zr-labeling of biomolecules. 
Zirconium is a metallic element which has a positive ionic charge and 4+ oxidation 
state [36]. The isotope 
89
Zr was first found to be well suited to the field of immuno-
PET by O‟Brien and Link [42]. It has been known for many years that 
Desferrioxamine binds well to Zirconium and that the terminal amino group can be 
used as a linker without affecting Zirconium binding [36]. However, the ability for 
89
Zr to chelate with any given chelating agent is based on the ability to have a high 
specificity, highly pure radioisotope [35]. 
Shure and Deutsch were the first to produce 
89
Zr  at M.I.T. via (d, 2n) reaction on 
Y2O3 in 1951 [43]. At that time, production via a (p,n) reaction on a foil of 
89
Y as 
target material took place as a preferable production as the natural abundance of 
100% 
89
Y makes it ideal [44]. 
1.5 PET in Cancer Diagnosis 
Cancer is a class of disease in which abnormal cells in the body display uncontrolled 
growth (division beyond the normal limits), invasion (intrusion on and destruction of 
adjacent tissues), and sometimes metastasis (spreading to other locations in the body 
via lymph or blood). There are differences between cancers and benign tumours 
where benign tumours are self-limited, and do not invade or metastasize [45]. 
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In many cases, a PET scan produces digital images that can identify many of the 
most common forms of cancers including lymphoma, melanoma, breast, lung and 
colorectal. In principle, PET is a medical imaging technology that images the biology 
of disorders at the molecular level before anatomical changes are visible. A PET scan 
is very different from an X-ray, MRI, CT or ultrasound. A PET scan can distinguish 
between benign and malignant disorders in contrast to other imaging technologies 
which merely confirm the presence of a mass. A PET scan can also detect 
abnormalities in cellular activity before there is any anatomical change. Once cancer 
is diagnosed, the PET scan is an essential “next step” by which to adequately stage 
the cancer, thereby identifying the primary tumour and the extent, if any, of the 
metastases. Furthermore, PET can help physicians monitor the treatment of disease. 
For instance, chemotherapy leads to changes in cellular activity and is observable by 
PET before structural changes can be measured by X-ray, MRI, CT or ultrasound. As 
a consequence, before an evaluation can be made using other imaging technologies, a 
PET scan might help to provide physicians with another tool to evaluate treatments, 
leading to a modification in treatment. PET also plays a role in identifying the 
recurrence of cancer. Malignant processes can be separated from scarring, edema and 
necrosis since PET is dependent on metabolic and not structural changes. 
Breast cancer is a disease in which abnormal cells in the breast tissues multiply and 
form an invasive or malignant tumour which can attack and damage the tissue around 
them and spread to other parts of the body through the lymphatic or vascular 
systems. Breast cancer is known to be related to human epidermal growth factor 
receptor-2 (HER2) [46]. HER2 is a transmembrane tyrosine kinase receptor 
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belonging to the family of epidermal growth factor receptors. It is encoded by the 
HER2/neu proto-oncogene located on chromosome 17q21 [47]. HER2 is 
overexpressed in approximately 25–30% of all breast cancer cases [48, 49]. HER2 
overexpression stimulates cancer cell growth and correlates with a shorter relapse-
free interval and overall survival time [50]. The unfavourable prognosis associated 
with HER2 overexpression has been confirmed by numerous studies [46]. HER2 
overexpression is determined immunehistochemically. Some cancers express high 
levels of growth factors as well as their receptors. The growth of cells of breast 
cancer is regulated by the autocrine or paracrine stimulation of HER2. 
Breast cancer is also a disease prevalent throughout the world and studies on imaging 
and therapy in variety preclinical and clinical models are being undertaken. One of 
the latest drugs to become available is a monoclonal antibody called Herceptin® 
(Trastuzumab) [51, 52]. 
1.6 Monoclonal Antibodies 
Monoclonal antibodies (mAbs) are monospecific antibodies for the reason that they 
are made by one type of immune cell which is cloned from a unique parent cell. The 
applications of monoclonal antibodies are limited by the number of different 
receptors found on any given cell. Radiolabelled mAbs have shown considerable 
potential for diagnosis and treatment of cancers; in particular, solid tumour cancers 
[37, 53, 54]. Nowadays, hundreds of monoclonal antibodies (mAbs) and mAb 
fragments are under clinical development because of their excellent potential for the 
systemic treatment of cancer and other pathological conditions [55-57].  
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Monoclonal antibodies (mAbs) have been approved for therapeutic use in a broad 
range of medical indications and form the most rapidly expanding category of 
pharmaceuticals, especially in oncology [58]. Intact mAbs typically achieve optimal 
tumour-to-non-tumour ratios at 2-4 days after injection, but mostly 1-6 hours after 
injection for the smaller fragments. Presently, nine mAbs have been approved by the 
FDA for cancer therapy, all being intact mAbs which are listed in Table 1.4. Five of 
the mAbs have been approved for treatment of haematological malignancies, 
specifically: rituximab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab 
tiuxetan, and tositumomab. Another four mAbs have been approved for therapy of 
solid tumours. These are: trastuzumab, cetuximab, bevacizumab, and panitumumab 
respectively. Trastuzumab is used for treatment of metastatic breast cancer, while 
cetuximab, bevacizumab, and panitumumab have been approved for treatment of 
metastatic colorectal cancer. Cetuximab and bevacizumab have also been approved 
for the treatment of head and neck cancer and non-small cell lung cancer, 
respectively. These „„solid tumour mAbs‟‟ are most effective when combined with 
chemotherapy or radiotherapy which interfere with signal transduction pathways by 
targeting growth factors or their receptors. Furthermore, most of the free therapeutic 
mAbs can also act via other effector mechanisms such as induction of apoptosis, 
complement-depending cytotoxicity or antibody-dependent cellular cytotoxicity. 
Gemtuzumab has been armed with the supertoxic drug ozogamicin to increase its 
therapeutic potency, whereas ibritumomab tiuxetan (Zevalin
TM
) and tositumomab 
(Bexxar
TM
) are radiolabelled mAbs containing the β-emitters 90Y and 131I, 
respectively. Apart from the aforementioned mAbs, one naked mAb and one 
radioimmunoconjugate have been approved in China [59]. The therapeutic value of 
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the mAbs has been outlined in several excellent reviews [55, 60, 61]. Clinical 
successes with the aforementioned therapeutic mAbs have boosted research and 
development on new mAbs directed against validated and novel targets [62]. In 
2007, Reichert and Valge-Archer  reported on 206 unique therapeutic mAbs in 
clinical trials during the time period 1980-2005 by commercial companies worldwide 
for a variety of cancer [56].  
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Table 1.4  
Monoclonal Antibodies Approved for Cancer Treatment [58] 
 
FDA  
Approved 
Generic name  
(trade name) 
Target Type Indication 
1997 Rituximab 
(Rituxan) 
CD20 Chimeric IgG1 Lymphoma 
1998 Trastuzumab 
(Herceptin) 
HER2/neu Humanized IgG1 Breast cancer 
2000 Gemtuzumab 
ozogamicin 
(Myelotarg)
a
 
CD33 Humanized IgG4 
conjugated to 
calicheamicin 
Acute myeloid 
leukemia 
2001 Alemtuzumab 
(Campath-1H) 
CD52 Humanized IgG1 Chronic lymphatic 
leukemia 
2002 
90
Y-Ibritumomab 
tiuxetan 
(Zevalin
TM
)
a
 
CD20 
90
Y-radiolabelled 
murine IgG1 
 
Non-Hodgkin‟s 
lymphoma 
2003 
131
I-Tositumomab 
(Bexxar
TM
)
a
 
CD20 
131
I-radiolabelled 
murine IgG2a 
Non-Hodgkin‟s 
lymphoma 
2004 Bevacizumab 
(Avastin) 
VEGF  Humanized IgG1 Colorectal cancer 
2006    Non-small cell 
lung cancer 
2004 Cetuximab 
(Erbitux) 
EGFR  Chimeric IgG1  Colorectal cancer 
2006    Head and neck 
cancer 
2006 Panitumomab 
(Vectibix) 
EGFR  Human IgG1 Colorectal cancer 
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Trastuzumab (Herceptin®) is a humanised monoclonal antibody that is specific to 
human epidermal growth factor receptor 2 (HER2) breast cancer cells [51, 52]. 
Trastuzumab consists of two antigen-specific sites that bind to the juxtamembrane 
portion of the extracellular domain of the HER2 receptor and that prevent the 
activation of its intracellular tyrosine kinase [63]. The remainder of the antibody is 
human IgG with a conserved Fc portion. A number of promising mechanisms by 
which trastuzumab might decrease signalling include: prevention of HER2-receptor 
dimerisation, inhibition of shedding of the extracellular domain, immune activation 
and increased endocytosis of the receptor [64].  Pertuzumab, which is a newer 
antibody that binds farther from the cell membrane, appears to be more efficient 
because of increased inhibition of heterodimerisation; however this is not the only 
mechanism of the action of trastuzumab [65, 66]. Preclinical models suggested that 
trastuzumab recruits immune effector cells that are responsible for antibody-
dependent cytotoxicity [67]. The finding that animals deficient in immune-cell–
activating Fc receptors (on effector cells) do not have a response to trastuzumab 
provides support for this hypothesis [68]. Preoperative administration of trastuzumab 
has been reported to increase tumour infiltration by lymphoid cells and modulation 
of in vitro antibody-dependent cytotoxicity [69]. Ongoing studies are examining the 
effect of combining trastuzumab with HER2-targeted vaccines and activated CD8+ 
lymphocytes to make use of the immunomodulatory facets of trastuzumab [70]. 
Antibodies to the HER2 receptor might serve as targeted delivery mechanisms for 
conjugated toxins or radioisotopes [71]. 
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Studies in an animal model of breast cancer in which HER2 is overexpressed indicate 
that angiogenesis may be inhibited by modulating proangiogenic and antiangiogenic 
factors from trastuzumab which induces normalisation and regression of the 
vasculature [72, 73]. Heregulin (a ligand of HER3 and HER4) regulates the 
production of vascular endothelial growth factor (VEGF), and a HER-family receptor 
blockade leads to reductions in VEGF [74]. A preliminary clinical trial designed to 
increase this effect by combining trastuzumab with bevacizumab, which 
simultaneously reduces VEGF, displayed promising activity against HER2-positive 
breast cancer [75, 76]. Clinical trials found patients with HER2 receptor over-
expression benefited most by trastuzumab therapies; thus, these patients would 
benefit most by 
89
Zr labelled trastuzumab studies [33, 51, 77]. The pharmacology of 
trastuzumab works on both the extracellular and intracellular functions of the cancer 
cell [51, 78]. With regard to the extracellular surface, the antibody will bind the 
HER2 receptor thus prohibiting the growth factor signal to connect to the cell. The 
lack of a growth factor specific to HER2 receptors binding to the receptor has a 
cascading effect within the cell, as it will not be instructed to switch on the genes that 
will result in proliferation [51]. Therefore, the binding of trastuzumab will cause 
stasis of the cancer cells preventing tumour growth. There are ongoing studies being 
conducted to further investigate the role trastuzumab plays in breast carcinoma, in 
particular, metabolism in vivo [79, 80]. 
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1.7 Bifunctional Chelates for Metal Nuclides 
Radiolabeling of metal nuclides to small molecules, proteins, monoclonal antibodies, 
peptides and nanoparticles are compulsory for active investigation on both diagnostic 
and therapeutic applications. Consequently, they require a common variable that is 
needed for appropriate chelation chemistry for adequate sequestration of the metallic 
radionuclide that is equal to the intended application. Metallic radioisotopes will not 
bind directly to an antibody nor maintain stability in vivo. Therefore, a chelating 
agent is necessary to ensure ligation between the biological tracer and the radioactive 
marker [41, 54]. This form of chemical is known as a bifunctional chelating agent 
and acts as a linker for immuno-PET binding between antibodies and radioisotopes 
[41, 54]. The chelating agents have been termed “bifunctional chelating agents” since 
they have a metal binding moiety function and also possess a chemically reactive 
functional group. The utility of metallic radionuclides is crucial for the development 
of metal chelating agents in order to effectively provide a handle on their behaviour. 
The chelating agent formed then provides for the sequestration of the metallic 
radionuclide while the latter aspect provides the requisite chemistry for covalent 
attachment to a targeting vector of interest, such as small molecules peptides 
(octreotide) [81],  proteins (monoclonal antibody, Zevalin) [82], or nanoparticles 
[83]. 
There are numbers of fundamental criteria that must be met in the design of 
bifunctional chelating agents. The main criterion is based on the stability of the metal 
complex. Obviously, the consequences of loss or dissociation of the radionuclide are 
associated with toxicity in the case of therapeutics and poor image qualities for 
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diagnostics. Other fundamental coordination chemistry criteria such as: (1) charge; 
(2) matching cavity size of the chelating agent with the ionic radius of the 
radionuclide; (3) providing the appropriate chelate denticity or number of donor 
binding groups and (4) providing donor binding groups of appropriate chemical 
character are also important elements. It is also critical to consider two additional 
properties, specifically: the rate at which the metal complex forms and the rate of 
dissociation. All of these criteria are correlated. Cavity size must accommodate the 
ionic radius of the radionuclide, which requires donor groups to align with optimal 
binding to the metal ion in such a way as to adequately encapsulate the ion thereby 
providing high stability and limiting dissociation. The suitable radiometals are varied 
in properties and coordination chemistry, unfortunately there is no bifunctional 
chelating agent suitable for all radionuclides [84]. 
After a bifunctional chelating agent (BFCA) has been prepared, validation of its 
suitability for biological applications still remains to be executed. There are a number 
of properties that can be used to certify a novel BFCA, such as: (1) thermodynamic 
stability constants; (2) transchelation studies; (3) acid catalyzed dissociation 
constants; and (4) serum stability studies. These properties provide some information 
that can be used to suggest potential in vivo suitability. Serum stability can be a 
helpful tool as is model use to predict and eliminate from contention those BFCAs 
that are unsuitable for in vivo applications. However, none of these properties is 
predictive of actual in vivo stability of the radiolabelled compound. To measure real 
in vivo stability of the radiolabelled compound, validation and evaluation in an 
appropriate animal model is crucial. The meaning of appropriate animal model is 
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variable, however it clearly should reflect closely to the ultimate intended biological 
application. Nevertheless, no in vitro model system replicates all of the ongoing 
processes and components of a living organism, just as the therapeutic efficacy of a 
macromolecule cannot be predicted from in vitro results [85]. 
Despite all considerations, the development of bifunctional chelating agents has been 
rooted in making derivations from well-established and defined inorganic chemistry 
chelating agents such as diethylenetriamine pentaacetic acid (DTPA) and 
ethylenediamine tetraacetic acid (EDTA). Fundamental thermodynamic stability 
constants are known for these ligands with a variety of metal ions that have provided 
a starting point for their derivation into an array of bifunctional chelating agents [86].  
One of the earliest reports of a BFCA conjugated to an antibody made use of a 
natural product, desferrioxamine, for radiolabeling with 
111
In [87]. Desferrioxamine 
and related compounds are well-known chelators of Fe(III), and thus, their derivation 
for use with In(III) and Ga(III) has precedence. Desferrioxamine has been 
investigated for conjugating 
89
Zr through an elegant protocol that exploits that same 
Fe(III)/(II) chemistry for antibody labeling in support of immunoPET applications 
[36, 54]. The Fe(III) complex was formed at first with the desferrioxamine, then 
activated for conjugation through extension of the terminal amine with succinic 
anhydride followed by conversion of the formed carboxylate into an active ester [36]. 
After conjugation, the Fe(III) was displaced with 
89
Zr by a reduction process. 
Desferrioxamine (also known as desferrioxamine B, desferoxamine B, desferal or 
Df) is a bacterial siderophore produced by the actinobacter Streptomyces pilosus. It 
has medical applications as a bifunctional chelating agent used to remove excess iron 
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from the body [39]. As suggested by previous research, desferrioxamine is the 
bifunctional chelating agent of choice as a linker for binding radionuclide with mAb 
[54]. The utility of this approach has been demonstrated through high-quality 
89
Zr–
mAb–PET images and quantification results reported in preclinical [37, 44, 88-90] 
and clinical studies [91-95]. In these studies, typically 370 kBq and 37–74 MBq 
89
Zr–mAb was used for immuno PET in mice and humans, respectively. In both 
preclinical and clinical studies neither pharmacokinetic changes nor a specific 
accumulation in non-target organs were observed, except for an uptake in catabolic 
organs such as the liver and kidneys. The incidence of a high radiation dose to the 
patient is the only concern which is inherent to the use of long-lived positron emitters 
like 
89
Zr and 
124
I, as these might limit repeated applications of 
89
Zr–immuno-PET 
[91]. Desferrioxamine is an attractive chelate because it has been used clinically in a 
safe way for many years [91, 92, 94]. 
1.8 Radiolabeling of 
89
Zr  
89
Zr labelling of antibodies can be achieved through various types of chelators, 
primarily desferrioxamine B (Df) which can form a stable chelate with 
89
Zr through 
the 3 hydroxamate groups [54]. Generally, mAbs are conjugated with a bifunctional 
derivative of Df via an amide linkage for subsequent labeling with 
89
Zr [96]. The 
hydroxamate groups within Df need to be temporarily blocked with Fe(III) before 
mAb conjugation. Consequently, Fe(III) is removed by transchelation to EDTA 
before the conjugate is exposed to 
89
Zr. The choice of Df as the chelator for 
89
Zr is 
attractive because it has been safely used in the clinic for many years. Neither 
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adverse reactions nor significant changes in blood and urine values were observed 
after injection of Df-containing conjugates from either past or ongoing clinical 
studies. Moreover, no antibody responses directed against the Df chelate were 
observed, demonstrating that its immunogenicity is quite low [92]. 
Despite the success of this approach, the multi-step technique procedure is quite 
complicated and time-consuming which makes it challenging to produce 
89
Zr-
labelled mAbs in compliance with the current Good Manufacturing Practice (cGMP) 
for clinical investigations. A novel bifunctional chelate was reported for 
89
Zr 
labeling: ρ-isothiocyanatobenzyl-desferrioxamine B (Df-Bz-NCS) [97] with labeling 
of 
89
Zr has been significantly simplified into a 2-step procedure (the initial strategy 
has 6 steps) [36]. Coupling of Df-Bz-NCS to mAbs was very efficient and it has been 
reported that a reproducible chelate:mAb with a ratio of 1.5:1 could be obtained 
using only a three-fold molar excess of Df-Bz-NCS [97]. Such a low chelate:mAb 
ratio can avoid alteration of the pharmacokinetics or immunoreactivity of the mAb. 
By comparing the 2 techniques of preparation, the rate of 
89
Zr complexation was 
comparable, indicating that different chemical linkages (e.g. S instead of O in the 
side chain which might be involved in 
89
Zr
4+
 coordination) have little influence on 
the radiochemistry. Almost quantitative complexation was achieved after a 30 minute 
incubation period at room temperature at the optimal pH (7.0), with no resulting 
impairment of the immunoreactivity of the mAbs.  
The need for protection of radioimmunoconjugates against radiation damage during 
storage has been demonstrated in various studies [36, 98]. The presence of the 
antioxidant ascorbic acid during storage of high-dose 
90
Y/
131
I-labelled mAbs has 
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been proven to be advantageous. Nevertheless, ascorbic acid cannot be used for 
89
Zr-
labelled mAbs storage since it can cause detachment of 
89
Zr from Df by reducing 
Zr
4+
 to Zr
2+
 [36]. It was suggested that 
89
Zr-Df-mAb can best be stored at 4°C in 
sodium acetate buffer in the presence of the antioxidant gentisic acid. It is worth 
noticing that under certain storage conditions, the 
89
Zr-Df-mAb conjugate is slightly 
less stable than the conjugate obtained from the 6-step strategy. Particularly, the 
integrity of the radioimmunoconjugates can be impaired by the presence of Cl
−
 in the 
storage buffer. This is probably due to radiation-induced formation of OCl
−
 which 
can react with the thiol group of the enolised thiourea unit that can lead to a series of 
events such as coupling reactions and cleavage of methionyl peptide bonds. 
Apart from the two abovementioned methods, an investigation on the reaction 
between N-(S-acetyl)thioacetyl-Df (SATA-Df) and maleimide-conjugated mAb was 
also carried out [99, 100]. However, the resulting conjugates were found to be 
unstable in human serum at 37°C [36]. Several thiol-reactive Df ligands were tested 
recently for labeling mAbs in a site-specific manner [101]. In this study, engineered 
mAbs containing selectively-positioned cysteine residues were used where the amino 
group of Df was acylated by various chemicals in order to obtain thiol-reactive 
reagents maleimidocyclohexyl-desferrioxamine (Df-Chx-Mal), iodoacetyl-
desferrioxamine (Df-Iac) and bromoacetyl-desferrioxamine (Df-Bac), respectively. 
Df-Chx-Mal led to the conjugate Df-Chx-Mal-thio-trastuzumab, while Df-Bac and 
Df-Iac alkylated the thiol groups of thio-trastuzumab by nucleophilic substitution. 
Each Df-modified thio-trastuzumab conjugate was labelled with 
89
Zr in high yield 
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and the resulting tracers exhibited good tumour-to-blood ratio in a breast cancer 
model [102]. 
1.9 PET imaging with 
89
Zr  
In PET imaging, the need for stable chelation chemistry remains an important 
consideration with this element since uncomplexed and unlabelled radioisotopes 
localise in the bone and will consequently deliver a high radiation dose to the bone 
marrow [103]. Considering the success of 
90
Y-labelled mAbs in clinical 
radioimmunotherapy [104, 105], 
86
Y-labelled mAbs are currently being developed in 
preclinical models for clinical dosimetry purposes [106, 107]. The half-life of 
90
Y is 
nearly 4 times greater than that of 
86
Y, and therefore, predicting 
90
Y dosimetry of 
slowly clearing antibody may not be feasible or even appropriate. For these reasons, 
89
Zr was explored as being one of the possible radionuclides that could be used for 
dosimetry analysis of 
90
Y-labelled mAbs [16]. Clinically used antibodies such as: 
HER1-targeted cetuximab [108], VEGF-targeted bevacizumab [90], and CD-20-
targeted ibritumomab tiuxetan have been labelled with the 
89
Zr-Df conjugate [94]. 
All the above studies demonstrated the use of 
89
Zr-labelled antibodies in quantitative 
PET imaging. In addition, the tumour localization of the 
89
Zr-mAb was similar to 
that of the 
111
In/
90
Y-mAb. Due to the feasibility in production and purification of 
89
Zr 
labelled mAb, clinical studies were performed with CD44V6-specific chimeric mAb, 
U36 labelled with 
89
Zr [92]. In this study, 
89
Zr-U36 was evaluated in patients having 
squamous cell carcinoma of the head and neck (HNSCC), who were at high risk of 
developing neck lymph node metastases. All primary tumours (n =17), as well as 
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lymph node metastases in 18 of 25 positive levels (sensitivity 72%) and in 11 of 15 
positive sides (sensitivity 73%), were detected using PET radioimmunoimaging. 
Interpretation of PET was correct in 112 of 121 operated levels (accuracy 93%) and 
in 19 of 25 operated sides (accuracy 76%). For CT/MRI, sensitivities of 60% and 
73% and accuracies of 90% and 80% were found per level and side, respectively. 
89
Zr-immunoPET demonstrated a sensitivity of 85% and accuracy of 95% as 
compared to sensitivity of 62% and accuracy of 88% for 
18
F-FDG-PET. Thus, this 
study demonstrated the utility and advantages of 
89
Zr PET radioimmunoimaging in a 
clinical setting in comparison with CT/MRI and 
18
F-FDG [92]. Similarly, all known 
tumour lesions previously identified by 
18
F-FDG were successfully imaged by 
89
Zr-
Df-Zevalin in a pilot PET imaging study in a patient having Non-Hodgkin‟s 
lymphoma [94]. 
1.9.1 
89
Zr imaging with Epidermal Growth Factor Receptor 
(EGFR) 
The epidermal growth factor receptor (EGFR) is a 170 kDa protein which plays a 
critical role in tumour cell proliferation, differentiation and survival [109, 110]. 
EGFR is a member of the ErbB family with its overexpression being associated with 
a number of cancers such as lung cancer, breast carcinoma, colon carcinoma and 
bladder cancer [111, 112]. Furthermore, EGFR expression is often associated with 
more aggressive tumours, poor prognosis, and resistance to treatment with cytotoxic 
agents. For this reason, EGFR is one of the most extensively-studied targets in 
oncology and many mAbs have been developed against EGFR for cancer therapy 
[113]. 
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Cetuximab (Erbitux) is a chimeric IgG1 mAb that can block EGFR activation by 
binding to the ligand-binding domain. Cetuximab induces internalization of EGFR, 
thus preventing downstream signalling [114]. 
89
Zr-labelled cetuximab has been 
investigated in several preclinical studies [37, 108]. In the early report, 
89
Zr-
cetuximab PET was used as a scouting procedure before radioimmunotherapy (RIT) 
to confirm tumour targeting and allow estimation of radiation dose delivery to 
tumours and normal tissues [108]. It was concluded that 
89
Zr-cetuximab could serve 
as a surrogate for scouting the biodistribution of 
90
Y-cetuximab and 
177
Lu-cetuximab 
in tumour-bearing mice. 
In another study, a difference between
 89
Zr-cetuximab uptake in the tumours and in 
vivo EGFR expression level in mouse models was observed. This suggested that 
additional pharmacokinetic or pharmacodynamic mechanisms may influence the 
tumour uptake of cetuximab, as well as the therapeutic efficacy of this agent [37]. It 
was recommended that these additional mechanisms may explain why receptor 
expression levels alone are insufficient to predict patient response to anti-EGFR 
therapies. Numerous studies have discovered that a majority of tumours responding 
to EGFR kinase inhibitors harbor activating mutations in the EGFR kinase domain 
[115]. Therefore, imaging of EGFR mutant expression might be more useful in 
selecting the right patient population for modified treatment, as well as accurately 
predicting the therapeutic response [116]. 
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1.9.2 
89
Zr imaging with Vascular Endothelial Growth Factor 
(VEGF) 
Vascular endothelial growth factor (VEGF) is a potent mitogen in embryonic and 
somatic angiogenesis. VEGF plays an important role in both normal vascular tissue 
development and many disease processes such as tumour development and 
metastasis [117]. Overexpression of VEGF and/or VEGF receptors (VEGFRs) has 
been implicated as being a marker of poor prognosis in various clinical studies [118]. 
The humanized anti-VEGF mAb, bevacizumab (i.e. Avastin), can block VEGF-
induced tumour angiogenesis and has been approved by the FDA to treat multiple 
metastatic cancers [119]. 
In 2007, 
89
Zr-labelled bevacizumab was investigated in nude mice bearing human 
ovary cancer SKOV-3 xenograft tumours [90]. Comparing 
89
Zr-bevacizumab and 
89
Zr-IgG, which served as a control, PET showed an uptake of 
89
Zr-bevacizumab in 
well-perfused organs at 24 h post-injection and clear tumour localization after 72 h. 
The uptake of 
89
Zr-bevacizumab was significantly higher than that of 
89
Zr-IgG, 
suggesting target specificity of the tracer. Recently, 
89
Zr-bevacizumab was also 
successfully used to detect the early anti-angiogenic tumour response to treatment 
with a Hsp90 inhibitor, indicating that 
89
Zr-bevacizumab PET can be a sensitive and 
non-invasive technique for monitoring the antitumour effect [120]. 
1.9.3 
89
Zr imaging with CD44v6 
CD44 is a cell-surface glycoprotein involved in a wide variety of biological 
processes such as: adhesion of cells to extracellular matrix proteins, homotypic 
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adhesion, lymphocyte-endothelial cell interactions, lymphohematopoiesis, T cell 
activation/adherence, metastasis formation, cytokine release and lateral movement of 
cells [121, 122]. The CD44 protein family is composed of several isoforms which are 
encoded by standard exons and many alternatively spliced variant exons that are 
expressed in a tissue-specific manner. The splice variant v6 of CD44 (denoted as 
“CD44v6”) has been implicated in tumourigenesis, tumour cell invasion, and 
metastasis [123, 124]. Although CD44v6 is expressed only in a subset of normal 
epithelial tissues, such as prostate glands and thyroid, homogeneous expression of 
CD44v6 has been found in various solid tumour types such as squamous cell 
carcinoma of the head and neck (HNSCC), esophageal, skin, cervical, and lung 
cancer respectively [125]. Additionally, heterogeneous expression of CD44v6 has 
been found in adenocarcinomas of the stomach, breast, colon, lung and pancreas. 
In order to avoid human anti-mouse immune responses, the chimeric IgG1 derivative 
of a murine mAb (U36 which binds to CD44v6) was constructed. 
186
Re-labelled 
chimeric mAb (cmAb), termed as “cU36”, was then tested in phase I trials which 
showed promising anti-tumour effects in patients with HNSCC [126, 127]. 
Subsequently, 
89
Zr-labelled cU36 was investigated in xenograft-bearing mice [36]. 
Further, 
89
Zr-cU36 was also tested for the first time in HNSCC patients who were at 
high risk of having neck lymph node metastases [92]. Serial PET scans after 
injection of 2.0 mCi of 
89
Zr-cU36 successfully detected the primary head and neck 
tumours, as well as metastases in the neck, which is as good as CT or MRI in terms 
of sensitivity. Conversely, a few patients developed an antibody response directed 
against cU36, even though no evidence was found for antibody reactions against the 
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chelate. Moreover, 
89
Zr-cU36 was not able to detect micrometastases in patients 
which were comparable to the findings of a previous biodistribution study with the 
mAb U36 [128]. In another study of cU36, it was reported that 
89
Zr-labelled mAbs 
are more suitable for scouting of therapeutic doses of 
90
Y-labelled mAbs, while 
124
I-
labelled mAbs are better for scouting of 
131
I- and 
186
Re-labelled mAbs [88]. 
Radiation dosimetry estimation in patients injected with 
89
Zr-cU36 revealed that 
89
Zr-cU36 was safe and well-tolerated in all patients [91]. The continuous 
improvement of new clinical PET/CT scanners may allow the acquisition of better-
quality PET images with a lower injected radioactivity dose, even though the 
malicious radiation dose was estimated to be around 40 mSv for patients in this 
study. This would consequently limit repeated applications of 
89
Zr immuno-PET. In a 
recent study, different 
89
Zr-labeling chemistry was compared between the 2-step and 
6-step methods, for PET imaging of cU36 in a mouse model [97]. This indicated that, 
for both tracers, a high level accumulation of 
89
Zr-labelled cU36 in the tumours and a 
low level of tracer uptake in normal tissues were observed. 
1.9.4 
89
Zr imaging with HER2 
HER2 overexpression is determined using immunohistochemistry and fluorescence 
in situ hybridization (FISH) at the time of diagnosis of the primary tumour. Non-
invasive imaging of HER2 expression and localisation of HER2-overexpressing 
tumour lesions using immuno-PET could be a practical method in the clinic to guide 
HER2-targeted therapy. 
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Trastuzumab (i.e. Herceptin®), an anti-HER2 mAb, has been extensively 
investigated for imaging applications over the last decade [109, 129]. Trastuzumab 
was approved by the FDA to treat HER2-positive breast cancer. In one study, clinical 
grade 
89
Zr-trastuzumab was developed for potential clinical immunoPET imaging 
applications [93]. In nude mice bearing HER2-positive tumours, 
89
Zr-trastuzumab 
exhibited excellent tumour uptake (~30%ID/g) with high tumour-to-nontumour 
ratios. The biodistribution pattern of 
89
Zr-trastuzumab was similar to that of 
111
In-
trastuzumab, which was reported in a previous clinical study [130]. In addition, 
89
Zr-
trastuzumab was very stable in both buffer solutions and human serum. 
The first-in-human study of 
89
Zr-labelled trastuzumab for PET imaging of HER2-
positive lesions has been reported [131]. The tracer showed excellent tumour uptake 
which allowed detection of most of the known lesions and some lesions that had not 
been detected earlier. This occurred where the dose of trastuzumab for optimal PET 
imaging performance was chosen to be 37 MBq of 
89
Zr-trastuzumab in a total of 50 
mg protein for trastuzumab-naive patients or 10 mg protein for patients that are 
already on trastuzumab treatment.  
Another study indicated that trastuzumab pharmacokinetics and organ distribution 
can also be heavily affected by an extensive tumour load [132]. Consequently, a 
study concentrating on a more patient-tailored trastuzumab dosing schedule on the 
basis of tumour volume in addition to bodyweight should be considered in the future. 
It could be deliberated that such dose-dependent pharmacokinetics may not be 
appropriate to 
89
Zr-labelled antibodies which bind to other cancer-related targets. 
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1.9.5 
89
Zr imaging with PSMA 
Prostate-specific membrane antigen (PSMA) is a 100 kDa type II transmembrane 
glycoprotein and PSMA is one of the best characterised targets in oncology [133]. 
PSMA expression levels have been shown to exhibit a positive correlation with 
development of castration resistance, resistance to hormone-based therapies and 
increased tumour progression. Even though PSMA expression has also been detected 
in a selectively limited range of normal tissues, including: renal proximal tubule, 
benign prostatic epithelium, the brain and small bowel, these normal tissue sites only 
express PSMA at levels 2-3 orders of magnitude, which is lower than that observed 
in more than 95% of clinical prostate cancer specimens [134]. Additionally, 
expression of PSMA in normal tissues is highly polarized to the apical or luminal 
sides of various tissues which are not readily accessible to circulating mAbs, 
therefore making anti- PSMA mAbs functionally tumour-specific. 
Recently, a study on quantification of PSMA expression in vivo of 
89
Zr-labelled anti-
PSMA mAb, J591, was reported for immuno-PET [135]. PET imaging of male 
athymic nude mice bearing subcutaneous LNCaP (PSMA-positive) or PC-3 (PSMA-
negative) tumours was conducted and 
89
Zr-J591 provided an excellent image contrast 
for delineating the LNCaP xenografts a few days after tracer administration. 
Interestingly, a “multimodality” approach to image PSMA expression has also been 
carried out using 
89
Zr-J591, which may potentially be used in the clinic to non-
invasively identify and quantify PSMA-positive prostate tumours in patients [136].  
Cerenkov luminescence imaging (CLI) of tumours in vivo, using a small animal 
optical scanner, was carried out. This procedure took advantage of the phenomenon 
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known as the Cerenkov Effect, where the emission of light from a transparent 
substance travels through the material with a speed faster than the speed of light in 
that material. The results obtained from immuno-PET studies correlated well with 
those obtained from optical scans in a quantitative manner. CLI can be used to image 
radionuclides that do not emit either positrons or γ-rays and are thereby unsuitable 
for use with current nuclear imaging modalities. Therefore, it may serve as a 
potential new imaging modality for rapid and high-throughput screening of 
radiopharmaceuticals. 
1.9.6 
89
Zr imaging with other targets 
A number of other proteins have also been investigated using 
89
Zr-based PET. 
Hypoxic tumour cells are resistant to radiotherapy and various chemotherapeutic 
agents. Carbonic anhydrase IX (CAIX), an endogenous hypoxia-related protein, is 
upregulated in many tumour types [137]. Therefore, pre-therapeutic assessment of 
intratumoural hypoxia may allow for selection of patients having intensified 
treatment regimens. Recently, 
89
Zr radiolabelled with an anti-CAIX antibody 
fragment (cG250-F(ab‟)2), was reported to allow visualization of tumour hypoxia 
with PET in a xenograft tumour model, which correlated spatially to the microscopic 
distribution of CAIX-expressing cells [138]. This study suggested a potential role of 
89
Zr-cG250-F(ab‟)2 for non-invasive imaging of hypoxia in head and neck 
carcinomas, upon which subject further investigation in the future can be deliberated.  
In one report, expression of the insulin-like growth factor 1 receptor (IGF1R) was 
measured by PET with 
89
Zr-labelled R1507, a mAb against IGF1R [139]. Excellent 
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contrast and prominent tracer uptake in the tumour was observed in a mouse bearing 
triple-negative breast cancer tumours. This may enable future patient selection for 
IGF1R-targeted therapy in the clinic since currently there is no effective therapeutic 
regime for this sub-population of breast cancer patients. 
Single-walled carbon nanotubes (SWCNTs) have unique properties which make 
them suitable for applications in a wide variety of imaging modalities such as: 
radionuclide-based imaging, Raman spectroscopy, photoacoustic tomography, MRI 
and near-infrared fluorescence [140, 141]. Recently, SWCNTs were conjugated to an 
antibody, E4G10, which specifically binds to the monomeric vascular endothelial 
cadherin (VE-cad) epitope expressed in angiogenic tumour vessels, and labelled with 
89
Zr [142]. Dynamic and longitudinal PET imaging of this agent in LS174T human 
colorectal tumour-bearing mice demonstrated rapid blood clearance and target-
specific tumour accumulation. A single construct could be designed to incorporate 
both imaging and therapeutic agents onto the same platform due to the large surface 
areas of SWCNTs. Moreover, it was suggested that a single agent may potentially be 
employed to image or treat a variety of different tumour types since VE-cad is 
expressed by the tumour vasculature. 
To date, a wide variety of mAbs have been labelled with 
89
Zr and several of these 
89
Zr labelled mAbs have entered clinical investigation with promising results. It is 
expected that, in the future, many new PET tracers based on 
89
Zr will be developed 
with the comprehensive availability of 
89
Zr and simpler chemistry for radiolabeling. 
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1.10 Hydroxamate Resin Column 
In a growth development of a sustainable 
89
Zr labelled monoclonal antibody, a 
construction of hydroxamate resin column will enable the 
89
Zr to be purified from its 
impurities. This will accordingly result in extraction of the radioisotope into elution 
to be labelled to a monoclonal antibody conjugated with a bifunctional chelating 
agent. The first synthesis of a hydroxamate resin was reported by Herscheid et al. in 
1983 for use in a 
52
Fe/
52m
Mn generator [143]. Subsequently, in 1994, Meijs et al. 
studied the separation of 
89
Zr from 
89
Y starting material through a hydroxamate resin 
column using oxalic acid as an extraction agent [35].  
Nevertheless, the availability of 
89
Zr for column testing is limited in Australia due to 
its cost and no cyclotron producing is available at this time. As a result, 
68
Ga is the 
isotope of choice following the design of the column.  
1.11 Gallium-68 
With a half-life of 1.13 hr, 
68
Ga decays from 
68
Ge via electron capture. 
68
Ga 
electrochemistry consists of 3 available valence electrons. 
89
Zr, the final isotope to be 
tested in a future study, has a half-life of 78 h and a valency of 4+. The 
68
Ge/
68
Ga 
generator is easily accessible within a PET centre and makes an easy alternative as 
89
Zr is not currently available. The ultimate aim is to develop a novel procedure for 
production of 
89
Zr labelled monoclonal antibodies and to improve the specificity of 
detecting cancer cells via PET imaging. However, in order for this to be achieved, a 
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viable hydroxamate exchange column that will bind 
68
Ga was constructed to prove it 
can bind 
89
Zr. 
The 
68
Ge/
68
Ga generator is a closed system and due to the nature of decay of the 
parent and daughter isotope, purification is inherent within the system [144]. The 
column bound with 
68
Ge is constructed from Tin-Dioxide polyethylene and uses non-
metallic parts such as polyethylene tubing to ensure no carriers are added. The 
column simply has 0.6M hydrochloric acid passed through it and 80% 
68
Ga abundant 
elution is produced. The breakthrough of 
68
Ge, which is considered a radiochemical 
impurity, has been referenced as 0.002% by the manufacturer [144]. Thus, straight 
after the elution of 
68
Ga it is possible to bind it to the monoclonal antibody 
deferoxamine complex. In conclusion, the purification of 
68
Ga before chelation with 
an antibody is negligible when compared to the purification processes of 
89
Zr.  
1.12 Statement of research 
The first activity in this research was the preparation of Yttrium-89 (
89
Y) solid 
targets followed by production of Zirconium-89 (
89
Zr) in a medical cyclotron using 
89
Y as a starting material. The 
89
Zr was then dissolved in hydrochloric acid (HCl) and 
loaded to a hydroxamate resin column in order to purify the 
89
Zr from its impurities 
and then labelled to a monoclonal antibody in clinical condition to be used for small 
animal PET imaging study. 
 
 
  
49 
 
Table 1.5  
Decay Characteristics of 
89
Zr [53] 
 
 
Decay characteristics of 
89
Zr, including half-life, percentage abundance and energies 
of the decay types are shown in Table 1.5 [53]. 
89
Zr has good gamma energies 
allowing imaging using PET scanners. Without this property, visualisation of the 
antibodies would not be possible. Another factor to consider is the daughter nuclides 
formed by the positron decay of 
89
Zr; 
89
Y. This isotope is stable and will not cause 
any damage in vivo [34]. The 
89
Zr has been chosen in this study because of its ideal 
physical characteristics and suitable properties for immuno-PET, such
 
as its long 
half-life of 3.27 day. This is well-matched with the time
 
needed for conjugated mAbs 
to reach the tumour site, as intact antibodies need around 2 to 4 days to penetrate a 
solid tumour [36, 53, 145]. In contrast, to achieve good visualisation, a large dose 
would need to be administered. This is costly and, more importantly, dangerous to 
the patient with regard to radiation exposure [88]. The most commonly used PET 
radionuclides are 
18
F and 
11
C which have short half-lives of 110 min and 20 min 
respectively. These radionuclides are not suitable to be used to detect solid tumours 
as they would undergo appreciable radioactive decay before reaching the centre of 
the tumour [14]. Although 
18
F-FDG is used to find tumours since the FDG molecule 
Isotope Half Life Energy Abundance 
Zirconium-89 78.4hr  
(3.27 day) 
 0.909 MeV 
1.202 MeV 
1.622 MeV 
99.9% 
0.014% 
0.070% 
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targets quickly, the clearance time of radioimmunoconjugates is relatively long. 
Thus, good target-to-blood ratios are not achieved within 24 h after administration 
given the relatively short half-life of 
18
F [53, 54, 146]. 
124
I, on the other hand, has a 
half-life of 4.2 days, but there are considerable isotopic enrichment costs involved. In 
addition, there is the added danger of exposure of thyroid tissue (in particular) to free 
radioactive iodine. 
89
Zr fits perfectly within the range of antibody localisation with 
its 78.4 h half-life [36]. Thus far, one of the greatest challenges preventing 
89
Zr from 
becoming a widely used radioisotope for Immuno-PET is its purification from other 
impurities. Firstly, the bombardment of the yttrium metal target results in a large 
number of radiochemical impurities, along with the radionuclide impurity of trace 
88
Zr around 0.01% [36]. The target itself contains a copper metal backbone as well as 
trace amounts of titanium, iron and gadolinium [36]. After bombardment, trace 
products of Zinc-65, Vanadium-48, Cobalt-56 and Terbium-156 are formed 
respectively to the trace metals located on the target [36]. These unwanted impurities 
must be separated from 
89
Zr as they might compete in the labelling step with the 
antibodies [35]. The latest method of removing these impurities uses a hydroxamate 
column [36]. In 1990, O. T. Dejesus concluded that the hydroxamate column can 
produce 99.9% carrier free 
89
Zr. However, the extraction technique was found to be 
quite difficult for purification process as the Zirconium was ionically bonded to the 
column, which a stronger anion exchanger is needed to remove it [53]. In 2003, 
Verel et al. successfully transchelated 97% of the total activity from the hydroxamate 
column using 1 mol/L oxalic acid over 5 separate elutions with an initial 40% yield 
in the first two elutions and a purity of > 99.9% [36].  However,  two main issues 
arise from the use of oxalic acid as an extraction chemical for purifying 
89
Zr. Firstly; 
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oxalic acid is highly toxic to the human body, causing decalcification of blood which 
is crucial to neural and muscle function, as well as renal tubule obstruction via 
calcium oxalate precipitation [34]. Hence, the in vivo use of 
89
Zr bound oxalic acid 
cannot be considered. It was demonstrated that removing the oxalic acid required the 
use of another strong anion exchange column and flushing a large volume of water 
through the column, followed by chloride exchange using HCl [36]. The resultant 
acid solution can now be boiled off at 110C under a continuous stream of argon and 
then reconstituted in 0.9% NaCl solution [36]. Following this purification process, a 
carrier-free, purified 
89
Zr was then able to be bound to a monoclonal antibody 
desferrioxamine (Df) complex [54]. 
In this research, production of 
89
Zr in a medical cyclotron was undertaken using 
89
Y 
as a starting material and purified using a hydroxamate resin column to be labelled to 
a monoclonal antibody in a preclinical condition, which finally can be used for small 
animal PET imaging study.  
1.13 Aims of the research 
The specific aims of all studies in this research are: 
- To develop an efficient method for making a solid target of 89Y to produce 
89
Zr more effectively. 
- To study a production of 89Zr in a medical cyclotron using 89Y as a starting 
material. 
- To develop a separation column for the purification of 89Zr.  
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- To develop a method of 89Zr isolation and purification.  
- Quality control and validation using PET imaging of the labelled compound. 
- To examine the potential of hydroxamate resin to be used as a column in a 
68
Ga generator for purification and radiolabelling of 
68
Ga. 
The ultimate goal of this research was to create a shortcut in the long and complex 
steps of the purifying and labelling procedures by avoiding the use of oxalic acid as 
an extraction chemical for purifying 
89
Zr. This would achieve a result near the Good 
Manufacturing Practice (GMP) standard.  
The development in separation and purification of longer-lived 
89
Zr PET 
radioisotopes and its labelling to a monoclonal antibody can be adapted to many 
other applications within the disciplines of nuclear medicine. This refers particularly 
to heavy PET radioisotopes that have previously been avoided due to inherent 
impurities upon cyclotron production. There are some research questions which need 
to be answered in this research such as:- 
- Can 89Y prepared in-house be used as a solid target in production of 89Zr? 
- How good is hydroxamate resin column to isolate and purify 89Zr? 
- Can oxalic acid be replaced by other chemicals to elute 89Zr from a 
hydroxamate resin column? 
- How effective is Trastuzumab-Df-89Zr labelling compound to be used in 
vivo? 
PET is a dedicated imaging modality which produces a three-dimensional image of 
functional processes in the body. Currently, PET is widely being used in nuclear 
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medicine area. Radioisotopes used in PET send out a positron that eventually finds 
an electron, forming a complex atom called positronium that rapidly decays and 
emits two annihilation photons. A PET camera detects the 511 keV photons that are 
emitted at 180° from each other and enable the production of a three–dimensional 
image [11]. Immuno-PET, a combination of monoclonal antibodies (mAbs) and PET, 
is an attractive tumour imaging option as it has the potential to improve diagnostic 
tumour characterisation by combining the high sensitivity and resolution of PET/CT 
imaging with the specificity of a mAb localisation [147]. In fact, each of the mAbs 
that targets a specific tumour cell is a candidate for use in immuno-PET, allowing for 
the development of a new generation of mAb-based imaging probes. 
Zirconium is a transition metal in Group IVB of the periodic table. 
89
Zr is a 
radioisotope of zirconium which decays through electron capture (77%) and positron 
emission (23%). For that reason, 
89
Zr is suitable for PET imaging with the important 
511 keV gamma radiations from positron annihilation and 909 keV gamma from the 
89m
Y de-excitation [148] respectively. Currently, 
89
Zr is widely used for 
radiolabelling studies for immuno-PET. Basically, the production of 
89
Zr is through 
cyclotron irradiation, which uses 
89
Y solid target as a starting material where the 
proton bombardment procedure to the 
89
Y solid target (which occurs in the 
cyclotron) creates 
89
Zr radionuclide. The 
89
Zr radionuclide is then purified and 
labelled with monoclonal antibody (mAb) through chelation and conjugation, thus 
enabling the radionuclide to target and bind with the mAb and finally be  ready to be 
used for PET imaging study. At the moment, the purification of 
89
Zr from its 
impurities is one of the greatest challenges for the 
89
Zr from becoming a widely used 
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radioisotope for immuno-PET. Unwanted impurities must be separated from 
89
Zr as 
they might compete in the labelling step with the mAbs [35].  
1.14 Thesis outline 
The remaining chapters of this thesis are structured as below;  
 Chapter 2 reports the production of 89Zr via cyclotron bombardment using 
five different types of 
89
Y solid target preparation. This chapter describes 
types of yttrium solid targets and methods that have been performed during 
the preparation of the solid targets. These include:  the utilisation of yttrium 
foil, compacted yttrium nitrate, electrodeposited yttrium nitrate using two 
different methods of preparation and yttrium sputtering technique. A few 
technical recommendations that can improve the yield of the targets are also 
highlighted in the last section of this chapter.  Quality control (QC) analysis 
of the radioisotope produced is also reported in this chapter.  
 Chapter 3 describes the 89Zr purification from the starting materials and other 
impurities. Purification of 
89
Zr involves the separation and elution of 
89
Zr 
radioisotopes from the soluble 
89
Y ions starting materials and other impurities 
using a hydroxamate resin column. In addition, this chapter demonstrates the 
experiments on the potential of phosphoric acid to be used as 
89
Zr extraction 
agent from hydroxamate resin column, thus labelling it with Df-Bz-NCS-
Trastuzumab. The preparation and construction of the hydroxamate resin 
column for the separation and elution process is also reported in this chapter. 
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 Chapter 4 details the experiments on radiolabelling of monoclonal antibodies 
and 
89
Zr using the novel p-isothiocyanatobenzyl-desferrioxamine B (Df-Bz-
NCS) as a bifunctional chelating agent. Firstly, the chapter describes the 
conjugation of a monoclonal antibody with the Df-Bz-NCS according to a 
slightly modified procedure from the previous work. Herceptin 
(Trastuzumab) was the monoclonal antibody of interest for this series of 
experiments as it showed a stable conjugation with the chelating agent. 
Secondly, the chapter discusses the radiolabelling of the conjugated Df-Bz-
NCS-Trastuzumab, together with 
89
Zr and QC analysis of the radiolabelled 
product.  
 Chapter 5 explains the PET imaging studies of 89Zr-labelled with a 
monoclonal antibody. 
 Chapter 6 examines the potential of hydroxamate resin to be used in a 68Ga 
generator. It demonstrates a series of experiments on the elution of 
68
Ga from 
hydroxamate resin column continued with experiments on 
68
Ga-labelled with 
Trastuzumab and Pentetreotide using hydroxamate resin column as an ion 
exchanger. 
 Chapter 7 summarises the findings of this research work, and, based on this, 
the conclusions that have been drawn. Future studies that can be developed 
from this research are also suggested.    
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 Appendix A shows the amount of 89Zr in MBq extracted from hydroxamate 
resin column using 1.0 M oxalic acid and 1.0 M phosphoric acid as extraction 
agents. 
 Appendix B indicates the amount of 68Ga in MBq from 50, 100 and 200 mg 
hydroxamate resin column using 0.01, 0.05 and 0.1 M Citrate Buffer at pH 4. 
 Appendix C demonstrates the amount of 68Ga in MBq eluted from 50 mg 
hydroxamate resin column using 0.01, 0.05 and 0.1 M HCl. 
 Appendix D exhibits the amount of 68Ga in MBq eluted from hydroxamate 
resin column using various solutions. 
 Appendix E shows PET images using 89Zr-Df with phosphoric acid as an 
extraction agent, applied to a female Balb/c nude mouse model with 
subcutaneous LS174T tumour (HER2-expressing colorectal model) on the 
right flank. 
 Appendix F indicates PET images using free 89Zr, applied to a female Balb/c 
nude mouse model with subcutaneous LS174T tumour (HER2-expressing 
colorectal model) on the right flank. 
 Appendix G demonstrates PET images using 89Zr tracer bound to mAb as 
89
Zr-Df-Trastuzumab, applied to a female Balb/c nude mouse model with 
subcutaneous LS174T tumour (HER2-expressing colorectal model) on the 
right flank. 
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 Appendix H details the publications and conference presentations from this 
research work. 
 Appendix I shows my publication paper entitled “Review on Production 
of 
89
Zr in a Medical Cyclotron for PET Radiopharmaceuticals.” 
 Appendix J shows my publication paper entitled “Establishing Reliable 
Production of the PET Isotope 
89
Zr for Research Use: From Target 
Fabrication to Preclinical Imaging.” 
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Chapter 2: Production of Zirconium-89  
2.1 Preparation of Yttrium Target 
Yttrium is introduced in a cyclotron for irradiation in order to produce 
89
Zr 
radioisotope. Yttrium targets can be prepared by various methods [149]; 
 Electron Beam Physical Vapour Deposition (EBPVD) is a form of physical 
vapour deposition in which a target anode is bombarded with an electron 
beam given off by a charged tungsten filament under high vacuum. In this 
process, atoms from the target are transformed into the gaseous phase caused 
by the electron beam. The atoms are then precipitated into solid form and 
coat everything in the vacuum chamber with a thin layer of the anode 
material (within the line of sight).  
 Sputtering technique is a process whereby atoms are ejected from a solid 
target material due to bombardment of the target by energetic particles.  
 Chemical vapour deposition (CVD) is a generic name for a group of 
processes that involve depositing a solid material from a gaseous phase.  
 Physical vapour deposition (PVD) is similar in some respects to CVD but 
differs in that the precursors are solid, with the material to be deposited being 
vaporised from a solid target and deposited onto the substrate. 
 Pulsed laser deposition (PLD) is a thin film deposition technique where a 
high power pulsed laser beam is focused inside a vacuum chamber to strike a 
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target of the material that is to be deposited. The material is then vaporised 
from the target, in a plasma plume, which deposits it as a thin film on a 
substrate. 
Dejesus and Nickles used water cooled yttrium foils to produce 
89
Zr via the (p, n) 
reaction on 
89
Y using 11 MeV protons [53]. The target was bombarded with protons 
(1 cm diameter beam) typically for 2 h with a beam current of 10 µA. The target was 
then dissolved in concentrated HCl (5 mL), as reported by Link et al., since they 
found this acid to produce less insoluble material [150]. In 1991, Zweit and collegues 
reported the production of 
89
Zr for PET from deuteron irradiation of natural yttrium 
targets. The target material, natural yttrium powder (100% 
89
Y), was pressed into 10 
mm diameter pellets ranging in thickness from 240 to 340 mg/cm
2
 which were 
placed in the target holders. The pellets were then covered with high purity 
aluminium foil of 0.005-0.36 mm thickness depending on the incident deuteron 
energy required. The beam currents used were 3 and 5 µA with irradiation times of 
12 and 20 min respectively. The energy window used for the 
89
Y (d, 2n) 
89
Zn 
reaction was from 16 to 7 MeV. This was considered to be optimum in order to 
minimize the production of the long-lived 
88
Zr produced by the 
89
Y (d, 3n) reaction 
with a threshold energy of 15.5 MeV. After bombardment, the irradiated target pellet 
was dissolved and heated in 3 mL 12 M HCl. When the target was completely 
dissolved, 1 mL of 20 % H2O2 was added to ensure the oxidation of Zr to Zr (IV). 
The heating was continued until the solution was completely dry, after which it was 
redissolved in 12 M HCl and left to cool [151]. Another 
89
Y target can be prepared 
using the sputtering technique. Meijs et al. (1994) reported that the target can be 
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prepared by sputtering a Y-layer (25 µm) on a Cu support. In this process, the Y-
atoms are ejected as a result of momentum transfer between accelerated Ar-ions and 
the Y-source. The Y-atoms cross a vacuum chamber and finally deposit on the Cu 
support. After irradiation, the Y on the Cu support is dissolved in four successive 
portions of 0.5 mL of 1 M HCl. At this HCl concentration the Cu is insoluble. To 
ensure the oxidation of Zr to the IV-oxidation state, 1 mL of H2O2 was added. 
Hereafter, concentrated HCl was added to obtain a final 3 M HCl solution, in order to 
prevent hydrolysis of the Zr-chlorocomplex [35]. Films of yttrium are usually 
produced by vapour deposition, dry processes and sputtering, but electroplating 
would be very advantageous in view of the cost and productivity. Matsuda et al. 
(1993) studied the formation of yttrium oxide by electrodeposition in organic 
electrolyte using dimethylformamide (DMF) containing YCl3 and a small amount of 
water. Firstly, yttrium metal was deposited on the substrate after which it would react 
with water to form yttrium oxide [152]. Reischl et al. (2002) on the other hand, 
performed the electrolytic deposition in 60 min with a constant current of 450 mA at 
50
o
C. The irradiated 
86
Y target material was dissolved in 3 mL of 4 % HNO3 (0.6 N) 
in a cylindrical beaker and then diluted with 47 ml of water with the pH of the 
solution being between 2.5 and 3.0. During electrolysis, a strong gas was observed 
when electrolysing an acidic aqueous solution, where hydrogen and oxygen are 
formed and the yttrium-86 was electrodeposited on the cathode [153]. In 1995, 
Kumbhar and Lokhande reported the electrodeposition of yttrium from a non-
aqueous bath. In this investigation, the electrodeposition of yttrium from nonaqueous 
(ethanol) baths was reported. The distance between anode and cathode was 0.2 cm. 
Deposition was carried out under unstirred conditions and in the potentiostatic mode. 
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The study indicated that, at room temperature, the thickness of the deposit increases 
linearly with times of up to 1 hour. The effect of temperature showed that good 
quality, uniform, white-gray deposits could be obtained up to 45
o
C [154].  In 2010, 
Sadeghi et al. reported two special sedimentation methods to deposit a thick layer of 
yttrium oxide on copper substrate for the production of 
89
Zr. A thick layer of Y2O3 
was deposited on the copper substrate (11.69 cm
2
 surface areas) by ethyl cellulose 
(EC) and methyl cellulose (MC) methods. The target was irradiated up to 20 µA 
current with 13 MeV protons and no degradation was observed. Improvement of the 
cooling system that contains a circulating flow of chilled helium in front of the 
target, in addition to the water cooling used in this work, would improve thermal 
conductivity.  Hence, it is expected to allow the usage of higher beam currents up to 
30 µA [155]. 
2.1.1 Methodology 
Most experimental components of the methods were conducted at Peter MacCallum 
Cancer Centre, East Melbourne, Victoria, Australia and the School of Electrical and 
Computer Engineering, RMIT University. Five different targets were prepared, 
namely: yttrium nitrate direct application (99.9 %; Sigma, St. Louis, MO USA), 
aqueous and non-aqueous electrodeposited yttrium nitrate, yttrium foil application 
(99.9 %, Thickness: 0.25 mm, American elements, Los Angeles, CA USA) and 
yttrium sputtering on a copper target plate using a sputtering machine (SPI-Module 
Sputter Coater, Imbros Pty. Ltd.). 
  
62 
 
Yttrium nitrate direct application - A gold target plate was cleansed with absolute 
ethanol before applying 0.4-0.5 g of yttrium nitrate covering the beaming area of the 
target plate. Aluminium foil was used to cover the target plate so as to avoid the 
yttrium nitrate which would be melted from leaking out of the target plate during 
bombardment. 
Yttrium electrodeposition in aqueous bath - Two copper plates (which served as 
anode and cathode and were able to fit the target slot in the cyclotron) were put 
together with a 0.2 cm distance to each other (Figure 2.1).  For the acidic aqueous 
bath, 4.7 % HNO3 (Merck, Whitehouse Station, NJ USA) was used to dissolve the 
yttrium nitrate. The electrodes were then put inside the bath to begin electrolysis and 
the power supply (Lab Power Supply 0-30 V 2.5 Amp Digital Display; Dick Smith 
Electronics, Melbourne, VIC Australia) is set on 0.2-0.5 A, creating a current for 60 
minutes (Figure 2.2). Further, to prepare a 10.4 mmol Y(NO3)3, distilled water was 
added. Electrolysis was started with a 0.20 Amp current for 60 minutes and then the 
electrodes were removed. The cathode plate that would have yttrium deposited on it 
was then cleansed in acetone for a minute and left to dry [153]. 
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Figure 2.1 Copper plates served as anode and cathode for yttrium-89 electrodeposition. 
 
     
 
Figure 2.2 Experiment set up for 
89
Y aqueous and non-aqueous electrodeposition. 
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Yttrium electrodeposition in non-aqueous bath - Using basically the same techniques 
as the electrodeposition with aqueous bath, two copper plates (which served as anode 
and cathode and were able to fit the target slot in the cyclotron) were put together 
with a 0.2 cm distance to each other.  For the non-aqueous bath, a 10.4 mM Y(NO3)3 
(yttrium nitrate) diluted in absolute ethanol was used. After 60 minutes electrodes 
were removed and the cathode plate that would have yttrium deposited on it was 
cleansed in acetone for a minute and left to dry [154]. 
Yttrium foil - Firstly, an aluminium target plate was cleansed with absolute ethanol 
and then 0.15 – 0.20 g of yttrium foil was cut and placed on the beaming area of the 
aluminium plate. The copper plate was then covered by a piece of aluminium foil to 
make sure the yttrium foil would not be lost during bombardment. 
Yttrium sputtering technique - A copper plate was cleansed with absolute ethanol 
and then loaded onto a target mount in a sputtering machine (Figure 2.3). A circle 
diameter of 57 mm x 57 mm yttrium metal foil and 0.25 mm thickness was then 
placed into the sputtering machine, with the distance between the top of the yttrium 
metal foil and the copper target being about 2.5 cm. Next, the black top cover 
assembly was replaced and the air admit valve on it was closed. After that, the valve 
of the argon gas line next to the pressure regulator was opened and the argon 
pressure was set to 100 kPa at the regulator. Following that, both the power on the 
sputter coater unit and on the control module were switched on which immediately 
started the rotary pump. The indication of vacuum was shown on the meter. Next, the 
yttrium was sputtered onto the copper target plate. The sputtering process took about 
10 minutes to complete (Figure 2.4). 
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Figure 2.3 Yttrium Sputtering Machine 
 
 
 
 
 
 
  
66 
 
 
Figure 2.4 Sputtering process in progress 
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2.1.2 Result 
All yttrium solid targets were successfully prepared (Figure 2.5) using various 
techniques of 
89
Y targets preparation. The preparation time and amount of 
89
Y 
produced is shown in Table 2.1. For yttrium nitrate compacting (Figure 2.5 (a)), the 
amount of yttrium nitrate used was 0.45g and around 10 minutes was spent on the 
preparation.  
Preparation time on both aqueous and non-aqueous electrodeposition took around 60 
minutes. After electrodeposition in the non-aqueous bath, the deposited yttrium 
appeared to be adhesive, thin, non-homogenous and light blue-white in colour 
(Figure 2.5 (b)); whilst after electrodeposition in the aqueous bath, the deposited 
yttrium appeared to be non-adhesive, thick and bluish in colour (Figure 2.5 (c)).  
For the preparation of yttrium foil target plate, the preparation time took around 10 
minutes and used 0.16 g of yttrium foil which was placed directly on the aluminium 
target plate (Figure 2.5 (d)).  
For the yttrium sputtering preparation technique, the final amount of yttrium 
produced was around 0.01 g after 10 minutes of the sputtering process (Figure 2.5 
(e)).  
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Figure 2.5 Yttrium-89 Solid Targets; (a) Direct Application; (b) Non Aqueous 
Electrodeposition; (c) Aqueous Electrodeposition; (d) Yttrium Foil; (e) Yttrium 
Sputtering 
 
 
Table 2.1  
Various techniques of 
89
Y targets and preparation time and amount of 
89
Y produced 
 
Yttrium preparation 
technique 
Amount of yttrium 
(g) used 
Preparation time 
(min) 
Amount of yttrium 
(g) produced 
Direct Application 0.45 10 0.45 
Aqueous 
Electrodeposition 
0.20 60 0.05 
Non Aqueous 
Electrodeposition 
0.20 60 0.05 
Foil 0.16 10 0.16 
Sputtering 0.01 10 0.01 
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For a direct application of yttrium nitrate, the amount of yttrium nitrate used was 
0.45 g and around 10 minutes was taken for the preparation. To avoid having the 
yttrium nitrate leak out of the target plate during bombardment, the target plate can 
be covered with aluminium foil.  
Preparation time on both aqueous and non-aqueous electrodeposition took around 60 
minutes because the thickness of the deposit increases linearly with time up to 1 hour 
at room temperature. It has been demonstrated from literature reviews that the effect 
of temperature could be obtained in an amount of up to 45
o
C for good quality, 
uniform, white-gray deposits [154]. The electrodeposition technique carried out in 
our lab was possible, although the yield is low in both the aqueous and non-aqueous 
baths. Collecting the deposited yttrium and packing it in a gold or aluminium target 
plate to gain a higher yttrium yield could be considered, since the initial deposition 
method produced approximately 0.05 g to be bombarded in the cyclotron. 
For the preparation of the yttrium foil target plate, yttrium foil was cut to size and 
placed directly on the targeted area of the aluminium plate using a cello tape as a 
sticker. It was covered with a piece of aluminium foil to ensure the yttrium foil 
would not fall and become lost during bombardment. Usually for a layer of 
placement, around 0.15 to 0.20 g can be placed directly on the target area of the 
aluminium plate. From our experience, up to 3 layers of yttrium foil can be placed on 
the aluminium plate to obtain a higher yield of the 
89
Zr radioisotope produced after 
bombardment in the cyclotron.  
For the yttrium sputtering preparation technique, the process requires an optimum 
diameter of 57 mm disk of the metal foil to be used as a target; this can coat a sample 
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up to about 4 cm in diameter. The final amount of yttrium produced was very low, 
around 0.01 g after 10 minutes of sputtering process. The suggested maximum 
processing time was limited to 10 minutes only because the typical time limit for the 
sputtering technique usually took not more than 5 minutes to complete. 
2.2 Production of 
89
Zr in a Cyclotron 
There are some valuable properties required in order for the radioisotope to work 
efficiently. It needs to have a long-lasting half-life in order to prevent the isotope 
from decaying before reaching the target; in addition, the isotope needs to emit 
enough energy for the gamma camera to acquire an image. As an alternative to the 
approach of modifying the antibody to match the physical characteristics of 
18
F, the 
use of longer-lived positron emitters has been explored for radioimmunoimaging 
with intact antibodies [156-158]. Table 2.2 shows the properties of selected PET 
radionuclides for radioimmunoimaging [28]. The table indicated that the half-lives of 
longer-lived positron emitters such as 
124
I and 
89
Zr have a much closer match with 
the biological half-life of most intact antibodies. Antibodies labelled with longer-
lived positron emitters can be imaged for 2-5 days after injection, when the 
radioactivity in the blood pool has been cleared and target to background ratio is 
higher. 
89
Zr is an ideal physical characteristic for immuno-PET and has been suggested for 
use in quantifying slow processes as well as deposition of monoclonal antibodies in 
tissue and tumour. The relatively low translational energy of the emitted positron for 
89
Zr results in high resolution of the image quality, which is comparable to those 
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observed with the 
18
F and 
64
Cu radionuclides, respectively [28, 30, 159]. Currently, 
89
Zr radioisotope is not widely used for immuno-PET, due to its limited availability, 
but with the use of medical cyclotron, which is commonly available in major 
hospitals and cancer centres. Hence, production of 
89
Zr can be carried out through 
cyclotron bombardment using 
89
Y as a starting material. 
 
Table 2.2  
Properties of Selected PET Radionuclides for Radioimmunoimaging [28] 
 
There are two nuclear reactions that have been explored for the production of 
89
Zr 
and typically by cyclotron bombardment of 
89
Y. The first, and most commonly used, 
is the 
89
Y(p, n)
89
Zr reaction [53, 160]. This has gained in popularity because a higher 
yield of 
89
Zr can be produced from 
89
Y, which is 100% naturally abundant in the 
earth‟s crust. Typically in this reaction, a proton beam with 14-14.5 MeV energy is 
used to bombard an yttrium foil solid target for 2-3 hours with 65-80 µA beam 
Radionuclide Half Life Production β+max in 
MeV (β+ 
yields) 
γ-energies in 
MeV 
(yields) 
Intrinsic 
spatial 
resolution 
loss (mm) 
89
Zr 
 
124
I 
 
 
18
F 
78.4 h 
 
100.2 h 
 
 
1.83 h 
89
Y(p, n)
89
Zr 
89
Y(d, 2n)
89
Zr 
124
Te(p, n)
124
I 
124
Te(d, 2n)
124
I 
125
Te(p, 2n)
124
I 
20Ne(d, α)18F 
18
O(p, n)
18
F 
0.909 
(23%) 
2.14 
(24%) 
 
0.63 
(97%) 
- 
 
0.60 (61%) 
 
 
0.14 (41%) 
1.0 
 
2.3 
 
 
0.7 
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current. Since yttrium has only one stable isotope and the product can be made 
relatively pure at low energy, this is an ideal reaction for production of 
89
Zr. The 
other reaction that has been used for the production of  
89
Zr in the cyclotron is the 
89
Y(d, 2n)
89
Zr reaction [151]. Usually in this reaction, an yttrium pellet is used and 
irradiated with a 16 MeV deuteron beam and 
89
Zr can be purified and separated from 
the target by ion exchange chromatography.  
The dominant oxidation number of zirconium is +4 which, when combined with a 
relatively small size, leads to an extensive hydrolysed aqueous chemistry with a 
largely covalent nature.  Donor ligands (ions or molecules attached to a metal atom 
by coordinate bonding) containing oxygen, nitrogen and chloride are especially 
stable, commonly creating complexes having coordination numbers of seven, eight 
and higher. High coordination numbers (seven and eight) are characteristic of 
zirconium complexes and the ligands are normally labile, which results in the great 
variety of stereochemistries. Different radiometals have significant differences in 
their coordination chemistry. While biological properties can be influenced by the 
radiometal chelate, the biodistribution of a target-specific radiopharmaceutical can be 
scientifically changed. This can be achieved by either modifying the coordination 
environment around the radiometal with a variety of chelators, or by the use of 
various coligands if the radiometal chelate contains two or more ligands. 
Table 2.3 shows the list of metallic radionuclides useful for PET imaging. Generally 
for PET imaging, it is highly desirable that the radionuclide has no radiation decays 
other than 511-keV gamma photons from positron annihilation. This will minimize 
impairment of spatial resolution due to high β+ energy and reduce the radiation 
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burden to the patient. The half-life of desired radionuclide for PET imaging should 
be long in the parent isotope, but short in the daughter isotope. Radiolabeling should 
be completed and preferably ready after around 10–30 minutes of preparation. A 
generator-based isotope would be ideal to achieve high specific activity for target-
specific radiopharmaceuticals so that their target uptake can be maximized. Using a 
generator-produced isotope is also much easier for transportation and delivery. In 
addition, the cost for parent isotope production and availability of the enriched 
source should also be considered. 
 
Table 2.3  
A selection of metallic radionuclides useful for PET imaging 
Isotope Half-life (h) Decay 
mode 
Eβ+ (keV) Production method 
61
Cu 
62
Cu 
64
Cu 
 
68
Ga 
89
Zr 
94m
Tc 
3.3 
0.16 
12.7 
 
1.1 
78.5 
0.9 
β+ (62%) 
EC (38%) 
β+ (98%) 
EC (2%) 
β+ (19%)  
EC (41%) 
β (40%) 
β+ (90%) 
EC (10%) 
β+ (23%) 
EC (77%) 
β+ (72%) 
1220, 1150 
940, 560 
2910 
 
656 
 
 
 
1880, 770 
897 
2.47 
cyclotron, 
61
Ni(p, 
n)
61
Cu 
 
62
Zn/
62
Cu generator 
 
cyclotron, 
64
Ni(p, 
n)/
64
Cu 
 
 
68
Ge/
68
Ga generator 
 
cyclotron, 
89
Y(p, n)/
89
Zr 
 
cyclotron, 
94
Mo(p,n)
94m
Tc 
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Recently, a study on establishing reliable production of the PET isotope 
89
Zr for 
research use was undertaken from target fabrication to preclinical imaging.  In this 
study, an in-house semi-automated external beamline with <40 µA at 11.7 MeV for 
120 min (degraded from 18 MeV to suppress 
88
Y & 
88
Zr co-production) produced 
89
Zr from 
89
Y(p,n)
89
Zr. End of bombardment activity (by HPGe -spectr.) of 89Zr in 
target discs, derived from multiple runs, was 1.36 GBq (±0.53 GBq [SD], n=3) 
which was 64% (±25%, n=3) of the theoretical activity, with a maximum of 1.84 
GBq (87% of theory) achieved. Recovery was 93 % (±17%, n=3), radionuclidic 
purity >99 % (n=3) and chemical purity 0.2 ppm Zr (±0.3 ppm, n=3, ICP-MS) [161]. 
Another study was carried out where 
89
Zr radionuclide was produced by irradiation 
of Y2O3, as a thick target, which was prepared by means of the sedimentation method 
and separated in 95 ± 5% radiochemical yield using anion exchange chromatography 
[162]. The target was irradiated up to 20 µA current with 15 MeV. Development of a 
cooling system that contains a circulating flow of chilled helium in front of the 
target, besides the water cooling used in this study, would improve thermal 
conductivity. Hence, it would be expected to allow the use of higher beam current up 
to 30 µA.  
The possible production routes of 
89
Zr isotope have been discussed and the 
development of the production procedure for the most suitable route using a low 
energy cyclotron has been described. For the cyclotron production of no-carrier-
added 
89
Zr, sedimented 
89
Y2O3 target was irradiated by 15 MeV protons. End of 
bombardment yielded about 60.77 MBq and 
89
Zr per µA h was experimentally 
obtained in 20 min irradiation at 20 µA. 
89
Zr integral thick target yield and nuclear 
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model calculations of the 
89
Y(p,n)
89
Zr, 
89
Y(d,2n)
89
Zr, and 
nat
Sr(a,xn)
89
Zr nuclear 
processes up to 50 MeV have also been calculated [163]. 
Degrading the proton beam to 10 MeV produces radionuclidically pure 
89
Zr with 
yields from 8 to 9 MBq/µAh [164]. This is enough for preclinical use, but the yield is 
not sufficient for either clinical use or commercial supply. The use of thinner beam 
degraders to increase the proton beam energy increases the radionuclidic yield but it 
is not yet possible to exclude the presence of radionuclidic impurities. 
2.2.1 Methodology 
All experimental components of the methods were conducted at Peter MacCallum 
Cancer Centre, East Melbourne, Victoria, Australia. Radiation protection for 
radiation safety was in accordance with the guidelines issued by the Australian 
Radiation Protection and Nuclear Safety Agency (ARPANSA). This guidance seeks 
to promote practices which protect human health and the environment from the 
possible harmful effects of radiation and to address safety concerns.  
Each of the 
89
Y solid targets which were prepared earlier in Section 2.1.1, were 
bombarded separately in a 12 MeV medical cyclotron (Oxford) for 30 minutes at 10 
µA currents using the (p, n) reaction. During irradiation, the target holder was cooled 
with water at the back side of the target. Radioactivity measurements were made by 
using a dose calibrator (Capintec CRC-15R) with a calibration factor of 465 for 
89
Zr. 
The presence of 
89
Zr was determined through gamma spectroscopy that involves the 
use of a multi-channel analyser (MCA) gamma counter to detect which gamma 
energies are present. For quantification of radioactivities, samples were counted on a 
  
76 
 
calibrated Atomlab 950-MCA Operation (BIODEX-Medical System Inc. Version 
3.42) Gamma Counter by using a dynamic energy window of 0–1500 keV for 89Zr. 
The energies of interest are those that originate from the photons with 511 keV and 
909 keV energy peaks, respectively. 
Before the bombardment procedure was carried out, a target plate covered with a 
paper was placed in a target boat of the cyclotron in order to determine the specific 
target location for bombardment (Figure 2.6).  
 
 
Figure 2.6 Determining target location before bombardment 
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Figure 2.7 shows the determination of optimum irradiation angle with 10
o
 of 
irradiation angle showing the optimum surface area for the bombardment procedure. 
This enables a greater area to be targeted for bombardment.  
 
 
Figure 2.7 Determination of optimum irradiation angle 
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Figure 2.8 shows the drawing of irradiation technique for the production of 
89
Zr 
radioisotope in the cyclotron.  
 
 
Figure 2.8 Irradiation techniques for the production of 
89
Zr radioisotope 
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Each of the 
89
Y solid targets which were prepared as described in Chapter 3 were 
then bombarded separately in a 12 MeV medical cyclotron (Figure 2.9) for 30 
minutes at 10 µA currents using the (p, n) reaction. During irradiation, the target 
holder was cooled with water at the back side of the target. Finally, 
89
Zr radioisotope 
produced after bombardment was then left overnight for cooling to allow decay of 
the short-lived isomeric product, 
89m
Zr[t1/2=4.161(17) min]. 
 
 
Figure 2.9 Cyclotron Facilities at Peter MacCallum Cancer Centre, Victoria, Australia 
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After cooling, the target was dissolved in 2.5 ml of 6 M HCl. Dissolution was 
complete within 30 min. Small traces of a black insoluble material were observed in 
the remaining suspension. These were likely to be an insoluble form of yttrium 
chloride and were found not to contain any 
89
Zr activity. The 
89
Zr solution in HCl 
was then oxidised to the IV-oxidation state with 0.1 ml H2O2 (hydrogen peroxide) 
and diluted with distilled water to set the final concentration at 2 mol/L HCl.  
2.2.2 Gamma spectroscopy of 
89
Zr 
The production of 
89
Zr must be verified. This radionuclide can be identified through 
its decay mode, emission energies and half-life. After bombardment, the samples 
were measured for their respective levels of radioactivity and then purified using a 
hydroxamate resin column. Radionuclidic purity was determined by measuring the 
energy peaks using a multi-channel analyser (MCA). The presence of gamma 
energies in the sample can be analysed by gamma spectroscopy, showing the 
presence of radioactive isotopes. To verify that 
89
Zr is actually produced, a gamma 
spectroscopy test with an MCA gamma counter is done. By measuring the peak at 
511 keV in 
89
Zr and comparing it to a known amount of 
18
F in the same experimental 
set-up and in the same region of interest (ROI) as 
89
Zr, quantification is possible. The 
ROI consisted of 21 channels (495-526 keV) around the peak of 511 keV. In this 
relative quantification, the contribution from background activity is (within a very 
good approximation) assumed to be equal. However, the contribution from the 909 
keV photons in 
89
Zr is corrected by defining a check-ROI of 21 channels located 10 
channels to the right at the ending of 511 keV ROI (542-573 keV). Within the check-
ROI, the background is subtracted to quantify only the photons originating from 909 
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keV. The counts from the check-ROI are then subtracted from the gross counts in the 
511 keV peak of 
89
Zr. The ion chamber is used to ensure that the irradiation has 
successfully produced a radioisotope. 
2.2.3 Result  
All Yttrium solid targets were successfully prepared and bombarded in a 12 MeV 
medical cyclotron (Oxford) at 10 µA beam current. The bombarded yttrium targets 
(Figure 2.10) underwent gamma spectrum analysis that determined 511 keV and 909 
keV energy peaks (Figure 2.11) indicating that 
89
Zr radionuclide had been 
successfully produced. During the bombarding process of the different targets, a 
standard setting was applied. The settings, beaming with 10 µA current for 30 
minutes, were chosen so that it would be an equal comparison for all the bombarded 
targets.  
To measure the amount of 
89
Zr radioactivity produced, a dose calibrator (Capintec), 
which was described in Section 2.2.1, was used after a cooling time period of 1 day. 
This step was undertaken to ensure that all the short half-life impurities which were 
also produced during the production of 
89
Zr had fully decayed. 
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Figure 2.10 Bombarded 
89
Y producing 
89
Zr 
 
 
Figure 2.11 Gamma spectrum analysis of 
89
Zr radioisotope 
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Table 2.4 shows a series of experiments conducted on the 
89
Zr production from 
cyclotron bombardment using 5 different techniques of yttrium target preparation. 
The data from the table indicated that using yttrium foil as a target produced the 
highest yield of 
89
Zr activity; with approximately 77 MBq after bombardment with 1 
day cooling time compared to the other methods. Production of 
89
Zr using 
compacting yttrium nitrate target produced approximately 9 MBq whilst yttrium 
sputtering bombardment produced approximately 1 MBq of 
89
Zr radioactivity. Both 
electroplating aqueous and non-aqueous targets produced approximately 0.6 MBq of 
89
Zr radioactivity each.  
 
Table 2.4 
89
Y targets and 
89
Zr produced from cyclotron bombardment  
 
 
 
Yttrium 
preparation 
technique 
Yield of yttrium  
(g) 
Preparation time  
(min) 
Irradiation time  
(min) 
Activity after 
bombardment (1 
day cooling time) 
Compact 0.45 10 30 9 MBq 
Aqueous 
Electroplating 
0.05 60 30 0.6 MBq 
Non Aqueous 
Electroplating 
0.05 60 30 0.6 MBq 
Foil 0.16 10 30 77 MBq 
Sputtering 0.01 10 30 1 MBq 
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Table 2.5 shows the no-carrier-added (NCA) specific activity of 
89
Zr from our 
experiment [161] compared to the other related publications from scientific literature 
[34, 165]. The table indicated that NCA specific activity of 
89
Zr from our experiment 
was 408 MBq/ µg (±26 MBq/µg) which comparable to published data of Holland et 
al., 2009 [34] of 196-496 MBq/µg and Hong et al., 2011 [165] of 225 (±24 MBq, 
n=6). 
 
Table 2.5  
NCA Specific Activity of 
89
Zr 
Publications from Scientific Literature Specific Activity of NCA 
89
Zr 
Scharli et al., 2012 [161] 408 MBq/µg (±26 MBq/µg) 
Holland et al., 2009 [34] 196-496 MBq/µg 
Hong et al., 2011 [165] 225 MBq/ µg (±24 MBq) 
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Chapter 3: Purification of Zirconium-89 
Purification of 
89
Zr usually involved the separation process of 
89
Zr radionuclide from 
its impurities and starting materials followed by elution of the radionuclide from the 
retention column. The development in separation and purification of longer-lived 
89
Zr PET radioisotope and its chelation with a monoclonal antibody hopefully can be 
adapted to many other applications within the disciplines of nuclear medicine. 
Details of radiopharmacy applications of purifying other radioisotopes for use in 
medical research can also be examined.  
The 
89
Zr can be dissolved in hydrochloric acid and separated from other 
radioisotopes and the target material on an ion exchange column [35, 53, 151]. In 
some cases, a wet chemical extraction preceded the ion exchange separation [150]. It 
was found that the hydroxamic function had a high specific affinity for Zr, even at 
high acid concentrations (> 1 M HCl), meaning that, at concentrations higher than 1 
M HCl, Zr is able to form complexes with hydroxamates, whereas its impurities are 
not [151]. As 
89
Zr was ionically bonded to the column, a stronger anion exchanger is 
needed to remove it. It was found that the most convenient solution for transchelating  
89Zr from the column was ≥ 0.5 M oxalic acid [35]. According to Dejesus (1990), the 
hydroxamate column can produce 99.9% carrier free 
89
Zr, but the extraction 
technique proved to be counterintuitive to the purpose of purification [53]. In 2003, 
the oxalic acid was proven to be able to successfully remove 97% of the total activity 
from the column over 5 separate elutions with an initial 40% yield in the first two 
elutions [36].  
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3.1 Preparation of Hydroxamate Resin Column 
89
Zr is purified from its radionuclidic impurities using a hydroxamate resin column. 
The column is based on a modified cation exchange where hydroxamate groups are 
introduced [143]. To receive a high proportion of these added hydroxamate groups, 
the carboxylic acid groups of the cation exchange mass are esterfied in two steps 
using 2,3,5,6-tetrafluorophenol (TFP, Acros Organics) solution (200 mg/mL in 
MeCN). Firstly, 1 g of cation exchange mass (Accell Plus CM, Waters) is suspended 
in 8 mL water for injection (WFI) and mixed well. 75 µL 3M Hydrochloric Acid 
(HCl), 1 mL TFP-solution and 384 mg of 1-(3-Dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (EDAC, Acros Organics) are then added. The pH 
measured is to be within the acceptance level of 5.7-6.0. Following that, the solution 
is mixed end over end in 1 h.  
Secondly, in the esterfication step, 105 µL 3 M HCl, 1 mL TFP-solution and 384 mg 
EDAC are added, after which the pH is again measured to be within 5.7-6.0. To 
remove EDAC and unreacted TFP, the solution is poured into a funnel having a 
suitable filter and washed with 30 mL acetonitrile (MeCN). In the meantime, the 
hydroxlaminehydrochloride solution, i.e. the solution containing the hydroxamate 
groups, is prepared. To a solution of 1 mL 1 M sodium hydroxide (NaOH) and 2 mL 
methanol (MeOH), 690 mg of hydroxylamine hydrochloride (Sigma-Aldrich) is 
added. After 5 minutes, another portion of 1 mL 1 M NaOH is added and pH was 
expected to be within the range of 5.3-5.4. The washed esterfied cation exchange 
mass is then introduced to the hydroxylamine hydrochloride solution. The acceptance 
interval of pH is now 5.1-5.2. This solution is then mixed end over end over the night 
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before being washed in a funnel with filter as above. This time, the column mass is 
washed with 140 mL sterile WFI and 70 mL MeCN. The mass is then dried for 3 h in 
a vacuum chamber at room temperature. In the final batch, after the column mass has 
dried in room temperature during low pressure, the vacuum chamber is filled with 
argon to prevent entry of humid air. After this step, the column mass could be stored 
at room temperature for up to 4 months without decreasing the labelling capacity of 
89
Zr [36]. 
For the preparation of a hydroxamate column experimental setup, an Extract-Clean 
tube (1.5 mL; Alltech) with a frit placed at the bottom (pore size, 20 µm) was packed 
with a suspension of 100 mg of hydroxamate resin column material in 0.9% NaCl 
(Sigma-Aldrich).  
3.2 Isolation and Purification of 
89
Zr 
Once the irradiation procedure in the cyclotron has been completed, the irradiated 
targets then need to be purified. Purification of 
89
Zr involves the isolation of 
89
Zr 
radioisotope from the soluble Y(III) ions starting material and other impurities and 
then eluting the 
89
Zr from the hydroxamate resin column. Before purification, each of 
the irradiated targets was dissolved in hydrochloric acid (HCl) in different 
concentrations, respectively. 
89
Zr produced from yttrium foil is dissolved in 12 M 
HCl [53, 150] and 
89
Zr prepared from yttrium nitrate and electrodeposited yttrium is 
dissolved in 3 M hydrochloric acid [35]. For 
89
Zr produced from the yttrium 
sputtering bombardment, 1 M of HCl is sufficient for washing out the 
89
Zr from the 
copper plate. Hydrogen peroxide (H2O2) can be added to ensure complete oxidation, 
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however it was found not to affect the separation or subsequent chelation chemistry 
[34]. The solution was then diluted with distilled water or more concentrated HCl 
was added to ensure that the final concentration of 
89
Zr was 2 M HCl. 
Before starting the purification process, the hydroxamate column is rinsed with 4 M 
HCl and distilled water, which was initiated by connecting vacuum tubes (Becton 
Dickinson) to the column with a 10 mL syringe pump (Figure 3.1). Then, 100 mg of 
the hydroxamate column mass is suspended in 0.9% NaCl (Sodium Chloride) before 
being packed into the column. Thereafter, the column is rinsed with 5 mL MeCN, 10 
mL 0.9% NaCl and 2 mL 2 M HCl.  
The 
89
Zr solution was then transferred to the pre-washed hydroxamate resin column. 
To ensure that as many impurities as possible are absent from the resin, the column is 
washed with 6 mL 2 M HCl and 6 mL of distilled water. This separation protocol 
will cause the 
89
Zr to bind to the column and the remaining impurities will then be 
eluted and discarded. The zirconium isotopes were subsequently slowly eluted with 
2.5 mL of 1 mol/L oxalic acid. The activity of the elution was then measured in the 
dose calibrator and sent for spectrum analysis using MCA gamma counter. 
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Figure 3.1 Experiment setup for purification of 
89
Zr 
 
3.3 Result 
Table 3.1 shows the 
89
Zr production from cyclotron bombardment using 5 different 
techniques of yttrium target preparation and its extraction from hydroxamate resin 
column using 1 M oxalic acid. The table indicated that oxalic acid extracted more 
than 80% of 
89
Zr radioactivity from the column for all types of yttrium targets.  For 
compact yttrium nitrate, which was producing 9 MBq amount of 
89
Zr radioactivity, 
the amount of 
89
Zr trapped in the hydroxamate resin column was 1 MBq and the 
activity extracted was 8 MBq. The percentage of 
89
Zr extracted from hydroxamate 
resin column calculated when using compact yttrium nitrate as a starting target 
material was approximately 88.9%. Both aqueous and non-aqueous targets, which 
produced radioactivity approximately 0.6 MBq 
89
Zr each, showed the lowest 
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percentage of 
89
Zr radioactivity, with 83.3% (0.5 MBq) extracted from the column. 
For yttrium foil which was producing approximately 77 MBq amount of 
89
Zr 
radioactivity, the amount of 
89
Zr trapped in the hydroxamate resin column was 6 
MBq and the activity extracted was 71 MBq, which was the highest elution 
percentage of 92.3%. For yttrium sputtering bombardment which produced 
approximately 1 MBq of 
89
Zr radioactivity, the activity trapped in the hydroxamate 
resin column measured in the dose calibrator was 0.1 MBq and the activity extracted 
using 1 M oxalic acid was 0.9 MBq (90.0%). 
 
Table 3.1  
89
Zr produced and purified using 1 M oxalic acid 
 
When 
89
Zr acquired from bombarding 
89
Y is being eluted after loading it to a 
hydroxamate resin column, the 
89
Zr is bound to the resin if 2 M HCl or less is added. 
This technique could be used to get rid of its impurities. This occurs when loading 
the 
89
Zr, lower concentrations of hydrochloric acid should be used for higher yield 
Yttrium 
preparation 
technique 
Activity after 
bombardment (1 
day cooling time) 
Activity  
extracted using 
1 M oxalic acid 
Activity trapped 
in the column 
% Extracted 
Compact 9 MBq 8 MBq 1 MBq 88.9 
Aqueous 
Electroplating 
0.6 MBq 0.5 MBq 0.1 MBq 83.3 
Non Aqueous 
Electroplating 
0.6 MBq 0.5 MBq 0.1 MBq 83.3 
Foil 77 MBq 71 MBq 6 MBq 92.3 
Sputtering 1 MBq 0.9 MBq 0.1 MBq 90.0 
  
91 
 
(using <2 M solution 99.5% 
89
Zr will bind). If a higher concentration of hydrochloric 
acid is used when loading, the affinity with the resin will decrease [34]. The 
89
Zr is 
dissolved in HCl and, according to a previous study, hydrogen peroxide is added to 
keep it in an oxidised state before loading it to the column [35, 36]. Nevertheless, it 
was not found to affect the separation or subsequent chelation [34] because in an 
aqueous solution, Zr(IV) ions dominant and the Zr(IV)+4e
-→Zr(0) reaction has a 
reduction potential of E
o
=−1.51 V versus the standard hydrogen electrode [166]. 
Experiments in which H2O2 was omitted showed no difference in the observed 
separation and chelation chemistry of the isolated 
89
Zr samples. 
Hydroxamate resin column was chosen in this experiment because of the relative 
ease of preparation and simplicity. It resulted in a higher Zr-recovery (> 95% in 2 
mL of 1 M oxalic acid) and a better radionuclidic purity [35]. 
3.4 Alternative 
89
Zr Extraction Agent 
In this research, a few protocols relating to the isolation and purification of 
89
Zr from 
its impurities were studied without the use of oxalic acid as an extraction agent. The 
methodology for this part of the whole research project predominantly followed the 
work published by Holland et al. (2009) and Vosjan et al. (2010), in which a step-by-
step revised method to conjugate and radiolabel monoclonal antibodies with 
89
Zr is 
outlined [32, 34].  
For production of 
89
Zr, 
89
Y foil target which was described in Chapter 2 was 
irradiated for two and a half hours in a medical cyclotron (Oxford, 12 MeV) using 10 
µA beam current. Post-irradiation, the target was dissolved in 4 mL of concentrated 
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hydrochloric acid (HCl) whilst heat was applied to instigate the dissolution process. 
The presence of 
89
Zr was determined via gamma spectroscopy, which involves the 
use of a MCA gamma counter as described in Chapter 2 (Section 2.2.2) in order to 
detect which gamma energies are present.  
Once the presence of 
89
Zr had been verified, it was purified by chemically separating 
it from the 
89
Y target material. A hydroxamate resin column was prepared by 
activating the carboxylate groups of the silica-based weak cation exchange resin 
(Waters Accell Plus CM) as described in Section 3.1.   
A Sep-Pak Accell Plus QMA Plus Light cartridge contains a silica-based, 
hydrophilic, strong anion-exchanger with large pore size (300 Å), 37–55 μm particle 
size, 0.22 mmol/g ligand density with surface functionality of –
C(O)NH(CH2)3N(CH3)3
+
Cl
– 
was used to trap and convert [
89
Zr]Zr-oxalate to 
[
89
Zr]Zr-chloride. The anion exchange cartridge was pre-washed with 6 mL MeCN, 
10 mL 0.9% saline and 10 mL H2O before use.  
3.4.1 
89
Zr Extracted as [
89
Zr]Zr-phosphate 
Phosphoric acid, also known as orthophosphoric acid or phosphoric (V) acid, is a 
mineral (inorganic) acid having the chemical formula H3PO4 where the molecules 
can combine with themselves to form a variety of compounds which are also referred 
to as phosphoric acids.   
There are various kinds of phosphoric acids and phosphates. The phosphoric 
acids constitute the largest and most diverse group of the many phosphorus oxoacids. 
  
93 
 
The simplest phosphoric acid series begins with monophosphoric (orthophosphoric) 
acid, continues with many oligophosphoric acids such as diphosphoric 
(pyrophosphoric) acid and, finally, concludes with the polyphosphoric acids. 
However, phosphoric acid units can bind together into rings or cyclic structures, 
chains (catenas) or branched structures, with various combinations. Each of these can 
form phosphates (salts or esters). One of the commonest uses of phosphoric acid is 
for rust removal. It can also potentially be used for removal of 
89
Zr from a 
hydroxamate resin column. 
The first experiment involved using phosphoric acid as an extraction agent.  The 
89
Zr 
was separated from the dissolved target materials in the hydroxamate column using 
2.5 mL 1.0 M of phosphoric acid as an extraction agent to form [
89
Zr]Zr-phosphate. 
Firstly, the 
89
Zr solution was loaded to the pre-washed hydroxamate resin column. 
The column was then washed with 6 mL 2 M HCl and 6 mL of sterile WFI and the 
89
Zr activity was slowly eluted with 4 successive portions of 0.5 M phosphoric acid 
(4 x 0.5 mL) and each 
89
Zr-phosphate vial was then measured in a dose calibrator as 
described in Chapter 2 (Section 2.2.1).  
3.4.2 
89
Zr Extracted as [
89
Zr]Zr-chloride 
Hydrochloric acid (HCl) is a clear, colourless solution of hydrogen chloride in water. 
It is highly corrosive and also a strong mineral acid. HCl has many industrial uses 
and is found naturally in gastric acid. Meijs et al. (1994) [35] have described lengthy 
procedures for the production of [
89
Zr]Zr-chloride from purified [
89
Zr]Zr-oxalate, 
involving decarboxylation of the excess oxalic acid with H2O2 in 6 M HCl (aq) at 
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80°C followed by drying of the reaction mixture. Holland et al. (2009) found that 
[Zr
IV
(C2O4)4]
4−
 can be removed from a solution with 100% efficiency by trapping on 
an activated a Sep-pak QMA strong anion exchange cartridge [34]. The majority 
(>99.8%) of the oxalic acid is then removed by washing the cartridge with a large 
volume of distilled water, and the activity eluted with 100% recovery of 
89
Zr by 
chloride ion exchange with 300-500 μL of 1.0 M HCl (aq.). Standard 0.9% saline can 
also be used to elute the 
89
Zr activity, but the recovery of activity was found to be 
less efficient. The oxalic acid can also be removed rapidly by boiling the eluate at 
110°C under a continuous stream of argon, then reconstituted in 0.9% saline or 0.1 M 
HCl for further labelling studies. The time taken for the entire procedure of the 
formation of [
89
Zr]Zr-chloride requires more than 1 hour. 
Firstly, 
89
Zr was separated from the dissolved target materials in the hydroxamate 
column using 2 mL 1.0M of oxalic acid as an extraction agent to form [
89
Zr]Zr-
oxalate. Following that, [
89
Zr]Zr-oxalate solution was loaded onto an activated Sep-
Pak Accell Plus QMA Plus Light cartridge. The cartridge was then washed with 40 
mL of distilled water and finally, 
89
Zr was eluted from the cartridge as [
89
Zr]Zr-
chloride with 0.5 mL, 1.0 M HCl solution. The [
89
Zr]Zr-chloride in 1.0 M HCl was 
then further diluted to 0.1 M using H2O. 
3.4.3 Result 
Following irradiation of 
89
Y-foil targets (99.9%, 0.254 mm thick, American 
Elements) at low currents in a medical cyclotron (Oxford, 12 MeV), approximately 
425 MBq 
89
Zr was produced after 2.5 hours of irradiation. The bombarded target was 
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then left overnight for cooling and underwent gamma spectrum analysis that 
determined 511 keV and 909 keV energy peaks, indicating that 
89
Zr had been 
successively produced. 
Approximately 200 MBq each out of the overall amount of 
89
Zr solution was loaded 
to two pre-washed hydroxamate resin columns to wash out as much of the impurities 
as possible in the resin, using 6 mL 2 M HCl and 6 mL of sterile WFI. The zirconium 
isotopes from each resin column were slowly eluted; the first resin column with 0.5 
mL 1 M oxalic acid and the second resin column with 0.5 mL 1 M phosphoric acid 
for each fraction in 5 fractions. This finally resulted in having the 
89
Zr radionuclide 
with a total of 2.5 mL in 1 mol/L phosphoric acid and oxalic acid, respectively. The 
radioactivity of each elution was then measured in the dose calibrator.  
Extraction data are shown in Table 3.2 using either 1.0 M oxalic acid or 1.0 M 
phosphoric acid.  The extraction data indicated that when using 1.0 M oxalic acid as 
an extraction agent, approximately average amount of 180.4 MBq 
89
Zr was extracted 
from the hydroxamate resin column and average activity of 19.6 MBq 
89
Zr was 
trapped in the column when 200 MBq 
89
Zr was loaded to the column. The overall 
percentage of 
89
Zr extracted from the hydroxamate resin column, when using 1 M 
oxalic acid as an extraction agent, was 90.2%. For the extraction of 
89
Zr using 1.0 M 
phosphoric acid, approximately 140.2 MBq average amount of 
89
Zr (70.1%) was 
extracted from the hydroxamate resin column of 200 MBq 
89
Zr, where approximately 
59.8 MBq average amount of 
89
Zr was still trapped in the column. The 
89
Zr was 
extracted as [
89
Zr]Zr-phosphate. The average amount of 
89
Zr radioactivity eluted 
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from the column is shown in a bar chart in Figure 3.2 and further calculation is 
shown in Appendix A. 
As a result of the experiments that were undertaken for this study, it was ascertained 
that it is possible to use phosphoric acid as an alternative extraction agent for the 
separation and purification of 
89
Zr. 
 
Table 3.2  
Extraction of 
89
Zr using 1.0 M oxalic acid and 1.0 M phosphoric acid 
 
89
Zr Extraction 
Activity in 
the column 
Activity  
extracted  
Activity 
trapped in 
the column 
 
% 
89
Zr 
Extracted 
1.0 M Oxalic Acid 200 MBq 180.4 MBq 19.6 MBq 90.2 % 
1.0 M Phosphoric Acid 200 MBq 140.2 MBq 59.8 MBq 70.1 % 
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Figure 3.2 Amount of 
89
Zr in MBq extracted from hydroxamate resin column using 1 M 
oxalic acid and 1.0 M phosphoric acid 
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Chapter 4: Radiolabelling of Zirconium-89 
Over the past 20 years, attempts have been made to label proteins and antibodies 
with 
89
Zr using DTPA derivatives and porphyrins as chelating agents [150, 167], as 
well as desferal (Df) conjugates [99, 100]. The process incorporates Df-groups onto 
monoclonal antibodies in a two-step procedure. Firstly, maleimide groups were 
incorporated into the protein with the assistance of succinimidyl-4-(N-
maleimidomethyl) cyclohexane-1-carboxylate (SMCC). In the second step, the 
thioester of Df formed by conjugation to SATA was further converted to a free thiol 
with hydroxylamine to facilitate reaction with the maleimide groups of the antibody 
by subsequent radiolabelling with 
89
Zr. The final purified product was obtained 
through gel filtration [99, 100]. This protocol was further modified by formation of 
N-succinyldesferrioxamine B of Df (N-SucDf) as an intermediate [36]. In this 
process, the hydroxamate groups of N-sucDf were temporarily blocked by formation 
of the Fe(III) complex, known as N-sucDf-Fe complex. It was then esterified and 
coupled to antibodies. Fe(III) was then removed by reduction to Fe(II) and 
transchelation to EDTA. Finally, the mAb-N-sucDf was radiolabelled with 
89
Zr at pH 
7.2-7.4 after 30 min incubation at room temperature [36]. Later in 2010, Perk et al. 
introduced the novel BFC p-isothiocyanatobenzyl-desferrioxamine B (Df-Bz-NCS) 
as a new bifunctional chelate for facile radiolabelling of monoclonal antibodies with 
89
Zr for immuno-PET imaging [97]. Its performance was then compared in 
89
Zr for 
immuno-PET with the reference bifunctional TFP-N-sucDf [36]. It was demonstrated 
that the novel Df-Bz-NCS allows efficient and easy preparation of optimally 
performing 
89
Zr-labelled mAbs, thereby facilititating further exploration of 
89
Zr-
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immuno-PET as an imaging tool, with oxalic acid being used as  an extraction agent 
to extract the 
89
Zr from the hydroxamate resin column [97]. The step-by-step 
procedure was then described for the facile radiolabelling of mAbs or other proteins 
with 
89
Zr using p-isothiocyanatobenzyl-desferrioxamine B (Df-Bz-NCS). First, Df-
Bz-NCS is coupled to the lysine-NH2 groups of a mAb and pH was adjusted to 9.0. 
Following that, the conjugation was purified using PD-10 desalting column gel 
filtration. The pre-modified mAb is then labelled at room temperature by the addition 
of 
89
Zr-oxalic acid solution followed by purification using PD-10 column gel 
filtration to remove the unlabelled product and oxalic acid from the labelled 
compound. The achievements indicate that all reagents and procedures are in place to 
allow broad-scale clinical application of immuno-PET with 
89
Zr labelled intact mAbs 
[32].  
For a further experiment in radiolabelling, a high amount of 
89
Zr activity was needed, 
hence yttrium foil was chosen as a target for bombardment on the 12 MeV medical 
cyclotron. Firstly, an aluminium target plate was cleansed with absolute ethanol and 
then 0.20 gram of 
89
Y-foil starting material (0.1 mm, 100 % natural abundance) was 
cut and placed on the beaming area of the aluminium plate using a cello tape as a 
sticker. The copper plate was then covered by a piece of aluminium foil to make sure 
the yttrium foil would not become lost during bombardment. It was then irradiated in 
a 12 MeV medical cyclotron at 10 µA current for 2.5 hours. During irradiation, the 
target was placed in a holder and cooled with water. 
89
Zr was produced via the 
89
Y(p, 
n) 
89
Zr transmutation reaction [34]. The 
89
Zr produced was then left overnight for 
cooling. 
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After 24 h, the 
89
Zr produced from yttrium foil was taken out from the target boat in 
the cyclotron and dissolved in 12 M HCl. The solution was then diluted with distilled 
water to ensure that the final concentration of 
89
Zr was 2 M HCl. The 
89
Zr solution 
was subsequently loaded to the pre-washed hydroxamate resin column. To ensure 
that as many impurities as possible were absent from the resin, the column was 
washed with 6 mL 2 M HCl and 6 mL of sterile WFI. Under these conditions, 
89
Zr 
remained bound to the resin, whereas 
89
Y and the other radionuclidic metal 
impurities were eluted. The zirconium isotopes were then slowly eluted with 2.5 mL 
of 1 mol/L oxalic acid. The activity of the elution was then measured in the dose 
calibrator and sent for spectrum analysis using MCA gamma counter. 
4.1 Conjugation of Herceptin (Trastuzumab) with p-
isothiocyanatobenzyl-desferrioxamine (Df-Bz-NCS) 
Herceptin® (Trastuzumab) was conjugated with the novel bifunctional chelate p-
isothiocyanatobenzyl-desferrioxamine B (Df-Bz-NCS) according to a modified 
procedure of Perk et al. [32, 97]. Firstly, Df–Bz–NCS is coupled to the lysine–NH2 
groups of Trastuzumab when a threefold molar excess of Df-Bz-NCS (in 20 μl 
DMSO) was added to the Trastuzumab (2–10 mg in 1 ml 0.1 M NaHCO3 buffer, pH 
9.0). The mixture was then incubated for 30 min at 37°C which finally produced the 
conjugated Df-Bz-NCS-Trastuzumab. Non-conjugated chelate was then removed by 
size exclusion chromatography using a PD-10 column (GE Healthcare Life Sciences) 
with 0.25 M sodium acetate or 0.9% sodium chloride 5 mg/mL (pH 5.0) as eluent for 
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purification purposes. The Df-Bz-NCS-Trastuzumab can be stored in the freezer at -
20
o
C until the day of radiolabelling for at least 2 weeks. 
4.2 
89
Zr Radiolabelling with Df-Bz-NCS-Trastuzumab 
The conjugated Df-Bz-NCS-Trastuzumab was labelled with 
89
Zr according to the 
modified procedure of Perk et al. with a slight modification [32, 97]. Firstly, about 
200 µL [
89
Zr]Zr-oxalic acid solution was pipetted into a reaction vial, followed by 
the addition of 200 µL 1 M oxalic acid and 90 µL 2 M Na2CO3 into the vial. The vial 
was then incubated for 3 min at room temperature. Following that, 0.30 mL 0.5 M 
sodium acetate, 0.71 mL pre-modified Df-Bz-NCS-Trastuzumab and 0.70 mL 0.5 M 
sodium acetate was successively pipetted into the reaction vial. The pH of the 
labelling reaction should be in the range of 6.8-7.2 in order to give optimal labelling 
efficiency. The mixture was incubated for 1 h at room temperature while gently 
shaking the reaction vial which finally produced the radiolabelled 
89
Zr-Df-Bz-NCS-
Trastuzumab. Finally, 
89
Zr-Df-Bz-NCS-Trastuzumab was purified by size exclusion 
chromatography using a PD-10 column (GE Healthcare Life Sciences) with 0.25 M 
sodium acetate (pH 5.0) as the mobile phase for purification purposes. To begin the 
89
Zr-Df-Bz-NCS-Trastuzumab purification procedure through size exclusion 
chromatography, the following steps were undertaken. Firstly, the PD-10 column 
was rinsed with 20 mL of 0.25 M sodium acetate (pH 5.4-5.6). The radiolabelled 
reaction mixture was then pipetted into the column, discarding anything that passed 
through. A further 1.5 mL of 0.25 M sodium acetate (pH 5.4-5.6) was pipetted 
through, discarding anything further that passed through, with a final rinse of 2 mL 
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of 0.25 M sodium acetate (pH 5.4-5.6), this time collecting the purified 
89
Zr-Df-
Trastuzumab.  
4.3 Quality Control Analyses 
Radionuclidic and radiochemical purity was analysed using Thin Layer 
Chromatography (TLC) and High Performance Liquid Chromatography (HPLC) 
machines as shown in Figure 4.1. The TLC and HPLC system used for this study was 
a LC-10Avp Shimadzu model; Mobile phase: 0.1 M Phosphate Buffer pH 6.2-7.0, 
0.87 % w/v NaCl, 0.065 % sodium azide; Column: Waters BioSuite 5u 125 HR SEC, 
300 x 7.8 mm, 5µ; Temperature: Ambient; Flow rate: 0.65 mL/min; Detector: UV at 
280 and 254 nm and scintillation Injection volume: 100 µL with run time of 30 
minutes. The preparation of the mobile phase was 7.80 g NaH2PO4.2H2O and 8.90 g 
Na2HPO4.2H2O and 8.70 g NaCl and 0.65 g sodium azide to 1000 mL with Milli-Q 
water. 
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Figure 4.1 LC-10Avp Shimadzu model for TLC and HPLC Analyses  
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4.4 Result 
4.4.1 Production and Purification of 
89
Zr 
89
Zr was produced from the 
89
Y(p,n)
89
Zr transmutation reaction by proton 
bombardment of commercially available, high purity (99.9%, 0.254 mm thick, 
American Elements) 
89
Y-foil on the small cyclotron. A total yield of 400 MBq 
89
Zr 
was produced after 2.5 hours of irradiation with proton beam energy of 12 MeV and 
10 µA beam current. After the end of bombardment, the target was then left 
overnight for cooling and subsequently dissolved in 12 M HCl. Dissolution was 
complete within 10 min. About 200 MBq out of the overall amount of 
89
Zr solution 
was loaded to the pre-washed hydroxamate resin column to wash out as many 
impurities as possible in the resin using 6 mL 2 M HCl and 6 mL of sterile WFI. The 
zirconium isotopes were slowly eluted with 0.5 mL of the oxalic acid for each 
fraction in 5 fractions, which finally resulted in a 
89
Zr radionuclide totalling of 2.5 
mL of 1 mol/L oxalic acid. The activity of the elution was then measured in the dose 
calibrator which showed that more than 85% of the 
89
Zr radionuclide was eluted 
from the hydroxamate resin column. 
4.4.2 Conjugation of Herceptin (Trastuzumab) with p-
isothiocyanatobenzyl-desferrioxamine (Df-Bz-NCS) 
Firstly, when the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine B (Df-
Bz-NCS) was conjugated with Herceptin (Trastuzumab), Df-Bz-NCS was coupled to 
the lysine groups of a mAb. The condition of this conjugation step comprised the 
  
105 
 
addition of a three-fold molar excess of Df-Bz-NCS to the mAb solution, a reaction 
at pH 9.0, followed by incubation at 37°C for 30 min. The reaction after incubation 
resulted in a reproducible chelate:mAb substitution ratio of about 1.5:1. This was 
assessed by trace labeling with 
89
Zr in a standard solution of Zr-oxalate. Figure 4.2 
shows the HPLC analysis result with a high peak between 10 to 15 minutes in 280 
nm UV length on the conjugated Df-Trastuzumab suggesting that the Df-Bz-NCS 
was successfully conjugated with Trastuzumab. 
 
 
Figure 4.2 HPLC analysis result on conjugated Df-Trastuzumab 
 
 
4.4.3 
89
Zr Radiolabelling with Df-Bz-NCS-Trastuzumab 
In the next step, Df-Bz-NCS-mAbs were labelled with 
89
Zr in 0.25 M HEPES buffer. 
After 60 min of incubation at room temperature at pH 6.8–7.2, the amount of 89Zr 
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trans-chelated from oxalate to Df-Bz-NCSmAb was always more than 85% (mean, 
91.9±4.6%). Labelling efficiency was distinctly higher at pH 6.8 and 7.2 than at pH 
6.0, 6.2, and 7.4. The radiochemical purity was always >95% (mean, 97.5±0.7%; 
determined with ITLC and confirmed by HPLC) [97]. For radiolabeling analysis, a 
TLC test showed a high peak in the origin representing the labelled compound. A 
very low peak was observed in the solvent front representing the unlabelled 
compound (Figure 4.3). This would suggest that the mAb was sucessfully labelled 
with 
89
Zr having a very high radiolabelling performance. For radiochemical analysis 
using HPLC test analysis, an overlapping peak was observed in both 
89
Zr and 
trastuzumab between 10 to 15 minutes in 280 nm UV, indicating that the conjugated 
monoclonal antibody was successfully labelled with 
89
Zr (Figure 4.4).  
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Figure 4.3 TLC analysis result of 
89
Zr-Df-Trastuzumab 
 
 
 
Figure 4.4 HPLC analysis result of 
89
Zr-Df-Trastuzumab 
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Typically, total yields of 400 MBq 
89
Zr were produced after 2.5 hours of irradiation 
with proton beam energy of 12 MeV and 10 µA beam current. After the end of 
bombardment, the target was then left overnight for cooling to allow for decay of the 
short-lived isomeric product, 
89m
Zr [t1/2=4.161(17) min] and other impurities. After 
24 h, the 
89
Zr produced from yttrium foil was taken out of the target boat in the 
cyclotron and dissolved in 12 M HCl. Dissolution was complete within 10 min but 
traces of a small black insoluble material were observed in the solution. This material 
is likely to be an insoluble form of yttrium chloride and was found not to contain any 
89
Zr activity. Subsequently, the 
89
Zr which was dissolved in 12 M HCl solution has 
to be diluted with distilled water down to 2 M of HCl concentration. This procedure 
has to be undertaken because the 
89
Zr ions which were loaded to the pre-washed 
hydroxamate resin column were found to be sensitive to the concentration of HCl 
used. When using ≤ 2 M HCl concentration, the 89Zr(IV) loading efficiency was 
found to be > 99.9 %. However, at higher HCl concentrations, (3-6 M), the binding 
affinity of 
89
Zr to the hydroxamate resin decreases and at 6 M HCl, less than 26.0% 
of the activity was bound to the column. Higher concentrations of HCl were used to 
elute the 
89
Zr from the hydroxamate resin column but the fact that they were 
unsuccessful indicates that the elution of 
89
Zr from the hydroxamate resin column 
appears to be insensitive to acid concentration in contrast to resin loading [34]. 
Figure 4.5 shows the schematic representation of the conjugation involved in the 
conjugating process between Df-Bz-NCS and Trastuzumab [97].  This indicates that 
when the bifunctional chelate Df-Bz-NCS was conjugated with Trastuzumab, Df-Bz-
NCS is coupled to the lysine groups of a mAb where the addition of a three-fold 
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molar excess of Df-Bz-NCS to the mAb solution had taken place to finally produce 
the conjugated monoclonal antibody. 
 
 
Figure 4.5 Schematic representation of monoclonal antibody (mAb) conjugation with a 
new bifunctional chelate Df-Bz-NCS [97] 
 
Figure 4.6 shows the schematic representation of the radiolabelling process between 
the conjugated 
89
Zr and Df-Trastuzumab. This demonstrates that when the 
89
Zr was 
introduced to the conjugated monoclonal antibody, 
89
Zr was bound to the 
hydroxamate group of the conjugated Df-Trastuzumab which  finally produced the 
radiolabelled compound [97]. 
 
 
Figure 4.6 Schematic representation of labeling of conjugated mAb with 
89
Zr [97] 
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Chapter 5: Zirconium-89 PET Imaging 
After the monoclonal antibody had been successfully labelled with 
89
Zr, the complex 
was studied for the effectiveness of the complex in binding with the specific tumours 
and the potential effectiveness of the complex in PET imaging for detection and 
monitoring of treatment responses.  
It is essential to evaluate the effectiveness of the monoclonal antibody labelled with 
89
Zr in animals before a targeted imaging technique can be used in humans in order 
to evaluate biodistribution, tumour concentration and PET detection capabilities. The 
radiopharmaceutical can then be assessed with in vivo studies [32, 36, 79, 88, 93, 
108] using animals such as mice [36, 79, 93, 108] followed by human studies [21, 
94]. In 2007, Sampath et al. used Balb/c nude mice, transplanted with the human 
breast cancer tumour cell line, SKBR-3, into the dorsal region of the mice left flank 
to investigate the biodistribution and concentration of the Trastuzumab-N-sucDf-
89
Zr 
in the tumour site and the ability of the PET scanner to detect tumours using this 
complex. The tumour was grown to 0.5-0.8 cm in diameter and the mice were then 
injected via the tail vein with 200 µg of the 
89
Zr labelled monoclonal antibody, 
Trastuzumab-N-sucDf-
89
Zr and imaged right after injection, then 2 to 48 hours after 
injection [168]. The use of a mouse model is an important preliminary step in 
translating bench research into a means of identifying and perhaps subsequently 
treating cancer in human subjects. 
Several preclinical immuno-PET from previous studies have been performed with 
89
Zr-labelled mAbs as a prelude to clinical trials. These included, for example: the c-
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mAb U36 [36], DN30 (anti-cMet), G250 [89], cetuximab [108], ibritumomab 
tiuxetan [94], rituximab, bevacizumab [90] and trastuzumab [169]. Also, for 
89
Zr-
labelled mAbs, sensitive tumour detection and accurate quantification with PET were 
demonstrated [44], while PET with 
89
Zr-labelled mAbs appeared to be able to predict 
the biodistribution of 
90
Y- or 
177
Lu-labelled mAbs for RIT [44, 108]. Remarkably, 
the anti-VEGF mAb 
89
Zr-bevacizumab also showed selective tumour uptake, 
possibly because of the proportion of human VEGF associated with extracellular 
matrix components [90]. Numerous clinical applications can be envisioned for this 
VEGF-specific tracer. Several other VEGF [170, 171] and VEGFR [172] PET 
imaging probes became available very recently. The introduction of an animal model 
allows the radionuclide to be assessed in the context of a full biological system.  
A feasibility study has been performed in order to determine the optimal dosage and 
time of imaging of the monoclonal antibody 
89
Zr-trastuzumab to enable PET imaging 
of human epidermal growth factor receptor 2 (HER2)-positive lesions. 14 patients 
with HER2-positive metastatic breast cancer received 37 MBq of 
89
Zr-trastuzumab 
of one of three doses, namely; 10 or 50 mg for those who were trastuzumab-naive 
and 10 mg for those who were already on trastuzumab treatment. The patients were 
sent for at least two PET scans between days 2 and 5. The study showed that the best 
time for assessment of 
89
Zr-trastuzumab uptake by tumours was 4–5 days after the 
injection [131]. The trastuzumab-naive patients required a 50 mg dose of 
89
Zr-
trastuzumab for optimal PET-scan results and patients already on trastuzumab 
treatment required only a 10 mg dose of 
89
Zr-trastuzumab. The accumulation of 
89
Zr-
trastuzumab in lesions allowed PET imaging of most of the known lesions, as well as 
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some that had been undetected earlier. PET scanning after administration of 
89
Zr-
trastuzumab at appropriate doses allowed visualization and quantification of uptake 
in HER2-positive lesions in patients with metastatic breast cancer. 
Several clinical trials with 
89
Zr-labelled mAbs have recently taken place, including a 
study of 
89
Zr-trastuzumab for the detection of HER-2–positive tumour lesions in 
breast cancer patients and for the quantification of HER-2 expression levels [169]. 
The highest uptake was found in HER2 positive tumours at 144 hours post injection 
(40% ID/g tissue for 
89
Zr-trastuzumab and 47% ID/g for 
111
In-ITC-DTPA-
trastuzumab) compared to 8% ID/g tissue in HER2 negative control tumours. Liver 
uptake was low (8–12% ID/g tissue). Preliminary results from the first patients in 
that study showed excellent tumour tracer uptake and a resolution that was much 
better than that observed in previous SPECT studies with 
111
In-trastuzumab [130].  
In in vivo validation, a study where the 
89
Zr-Df-trastuzumab localised in mice bodies 
was undertaken. The use of a mouse model is an important preliminary step in 
translating bench research into a means of identifying and perhaps subsequently 
treating cancer in human subjects.  
5.1 Methodology 
All experimental components of the methods were conducted at Peter MacCallum 
Cancer Centre, East Melbourne, Victoria, Australia. A small animal PET scanner 
(Philips Mosaic) was used to conduct PET imaging study of the radiolabelled 
compounds. The imaging aperture is 20 cm and the axial length is 12 cm. The system 
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has high spatial resolution (2 mm), with high sensitivity and large transverse imaging 
field-of-view of 12.8 cm.  
5.1.1 Tumour Model  
The labelled radiopharmaceuticals underwent in vivo testing in female Balb/c nude 
mice models that have a low immune system but no diseases, with LS174T (HER2-
expressing) tumours. PET imaging was performed on them to determine if the label 
was successful in vivo in providing useful information from the images. A Balb/c 
nude mouse was injected subcutaneously on the right flank with the HER2 positive 
LS174T colorectal tumour. Two weeks later when the tumour reached a volume of 
approximately 180 mm
3
, or the size of the tumours had grown to 0.5-0.8 cm in 
diameter, the imaging studies of 
89
Zr-Df-Trastuzumab uptake were performed.  
5.1.2 Preclinical Imaging of Tumour Model 
The female Balb/c nude mouse with the HER2 positive LS174T colorectal tumour 
was injected via the tail vein with 200 µL of 1.85 MBq 
89
Zr-Df-trastuzumab in saline 
solution. The mouse was then anaesthetised in 3% isofluorane in 50% oxygen in air 
and placed on the bed of a Philips Mosaic small animal PET scanner (Figure 5.1). 
Image data was acquired over 10 minutes; with corrected decay & randoms, and a 3-
D RAMLA algorithm was used in reconstructing images [173]. The mouse was 
imaged by PET scanner at 24 hours post-injection. 
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Figure 5.1 Small Animal PET Facilities at Peter MacCallum Cancer Centre, Melbourne, 
Australia 
5.2 Result 
For PET imaging experiments, the PET images in Figure 5.2 show the in vivo 
behaviour of the 
89
Zr-Df-Trastuzumab with phosphoric acid as an extraction agent in 
female Balb/c nude mice models, with LS174T (HER2-expressing) tumours. The 
images were taken at 24 and 48 hours post-injection. The tumour uptake of 
radiolabel at that time was noted.  The quality of the image was limited by a low 
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activity of radiolabel. It appeared that most of the activity is localised in the liver. 
This could be due to its being 
89
Zr-Df conjugation. 
 
 
Figure 5.2 Small animal PET images using 
89
Zr-Df with phosphoric acid as an extraction 
agent at 24 and 48 hours after injection 
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Figure 5.3 shows the PET images of the free 
89
Zr in female Balb/c nude mice 
models, with LS174T (HER2-expressing) tumours, where the mouse was injected 
with 1.85 MBq (200 µL) of free 
89
Zr. The images were taken at 1, 4 and 24 hours 
post-injection respectively. Following that, the skeletal uptake of free 
89
Zr was noted 
at 24 hours post-injection and it was expected that free 
89
Zr would be localised in the 
bone.  
 
 
Figure 5.3 PET images using free 
89
Zr, applied to a female Balb/c nude mouse model 
with subcutaneous LS174T tumour (HER2-expressing colorectal model) on the right 
flank 
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Next, the experiment on biodistribution and imaging of the female Balb/c nude 
mouse with the HER2 positive LS174T colorectal tumour, which was injected via the 
tail vein with 200 µL of 1.85 MBq 
89
Zr-Df-trastuzumab in saline solution, showed a 
selective accumulation of 
89
Zr-Df-Trastuzumab in tumour-bearing mice. The images 
at 24 hours show good tumour tracer uptake in the right flank, as well as cardiac 
uptake, which is a consequence of HER2 receptor expression on the heart suggesting 
that monoclonal antibody was successfully labelled with 
89
Zr. (Figure 5.4). 
 
 
Figure 5.4 PET images using 
89
Zr tracer bound to mAb as 
89
Zr-Df-Trastuzumab, applied 
to a female Balb/c nude mouse model with subcutaneous LS174T tumour (HER2-
expressing colorectal model) on the right flank 
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5.3 Discussion 
HER2, which is a member of the ErbB tyrosine kinase receptor family, contributed in 
cell survival, metastasis, angiogenesis, differentiation, proliferation [109, 111, 129]. 
Overexpression of HER2 has been found in a wide variety of human cancers. 
In our in vivo validation, a study where the 
89
Zr-Df-trastuzumab was localised in 
mice bodies has been undertaken. PET imaging was performed on them to determine 
if the label was successful in vivo in providing useful information from the images. 
Experiments on PET imaging of the female Balb/c nude mouse with the HER2 
positive LS174T colorectal tumour with 
89
Zr-Df-trastuzumab were meant to validate 
the radiolabelled 
89
Zr with monoclonal antibody (mAb). This disclosed the fact that 
radiolabelled 
89
Zr with mAb showed an uptake to the targeted organ.  
For the labelling of Df-Trastuzumab with [
89
Zr]Zr-phosphate, the in vivo results 
following injection of the radioimmunoconjugate into female Balb/c nude mice 
models, with LS174T (HER2-expressing) tumours showed no uptake in the tumour 
that was located on the right flank at 24 and 48 hours respectively. The activity 
appears to have accumulated in the liver, suggesting that the label has denatured in 
vivo forming 
89
Zr-Df conjugation. 
For the labeling of Df-Trastuzumab with [
89
Zr]Zr-chloride, there was no uptake of 
the 
89
Zr-Df-Trastuzumab to the tumour, suggesting that the monoclonal antibody was 
not labelled with 
89
Zr. However, skeletal uptake of the tracer was noted at 24 hours 
post-injection, suggesting that free 
89
Zr was localised in the bone. 
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For immuno-PET, there are two common methods of excretion and/or degradation of 
the radiotracer, namely: demetalation/ligand dissociation and hydrolysis of the linker 
group between the mAb and the metallo-chelate. For these situations, PET imaging 
data would demonstrate that high liver accumulation may be expected if 
89
Zr ions are 
lost from potential [
89
Zr]Zr-Df-mAb immune-PET conjugates via demetalation. On 
the other hand, rapid renal excretion may be anticipated if the [
89
Zr]Zr-Df-mAb 
complex remains intact, which would then decrease background tissue accumulation 
and enhance image contrast [34]. 
For the labeling of Df-Trastuzumab with [
89
Zr]Zr-oxalate, the result showed a 
selective accumulation of 
89
Zr-Df-Trastuzumab in tumour-bearing mice, where the 
images at 24 hours show good tumour tracer uptake in the right flank. Apart from 
that, there was also an indication of cardiac uptake, a consequence of HER2 receptor 
expression on the heart, in accordance with the known pharmacokinetics of 
trastuzumab [174]. The image was a little noisy but considering the injected dose, 
delayed imaging and the low positron yield for 
89
Zr, the quality of PET image was 
acceptable. Options for other reconstruction algorithms more suited to low counts 
might reduce noise in the image if needed. The selective and accumulation uptake of 
the compound to the tumour, as well as cardiac uptake, demonstrated that 
monoclonal antibody was labelled with 
89
Zr. 
Essentially, the exact mechanisms underlying such dose-dependent pharmacokinetics 
of 
89
Zr-trastuzumab are unknown; but one possible explanation is that it involves 
rapid but saturable elimination of low doses from the circulation during the first 
elimination phase, which has a half-life of ~4 days. Another mechanism that may 
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play a role in increasing 
89
Zr-trastuzumab clearance in trastuzumab-naive is the 
presence of high plasma levels of extracellular domains shed by HER2. In this 
instance, the resulting complex of 
89
Zr-trastuzumab with extracellular domains is 
cleared by the liver and excreted into the intestines [131]. 
The ability of 
89
Zr-trastuzumab PET to quantify the alternations in HER2 expression 
level after treatment with a heat shock protein 90 (Hsp90) inhibitor has been 
investigated [33]. PET imaging revealed a significant decrease of tracer uptake in the 
tumour, indicating that 
89
Zr-trastuzumab PET can be employed for non-invasive 
quantification of HER2 down-regulation after treatment. Related discoveries were 
also perceived in a separate study using a differently labelled 
89
Zr-trastuzumab and a 
different Hsp90 inhibitor [79]. Recently, site-specific labelling of engineered 
trastuzumab (through cysteine residues) with 
89
Zr was reported [101]. The resulting 
tracers were stable in serum and showed PET imaging properties comparable to 
conventionally prepared 
89
Zr-trastuzumab, where labelling was achieved through the 
lysine residues. 
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Chapter 6: Hydroxamate Resin for Gallium-68 Generator   
My next series of experiments are intended to study the potential of hydroxamate 
resin column (which was successfully being used as a column separator in our 
previous series of 
89
Zr purification and extraction experiments), to be used in 
Gallium generator for 
68
Ga elution and radiolabelling. From my previous experience 
in trapping the 
89
Zr in hydroxamate resin column, it is believed that the column can 
also be used to trap 
68
Ga, purify and extract the radionuclide from hydroxamate resin 
column and finally be labelled to conjugated monoclonal antibody to produce 
68
Ga 
radiopharmaceutical for PET imaging study. 
6.1 Radionuclide generators 
Radionuclide generator systems continue to play an important role in providing both 
diagnostic and therapeutic radionuclides for various applications in nuclear medicine 
and oncology. A major turning point in the way radionuclides are produced was the 
invention of the 
99
Molybdenum/
99m
Technetium (
99
Mo/
99m
Tc) radionuclide generator 
for clinical use. 
99m
Tc is the most common radionuclide used and current Nuclear 
Medicine departments employ on-site 
99m
Tc generators for easy and cost-effective 
production [175, 176].  
Generator systems involve long-lived parent radionuclides which naturally decay to 
produce shorter-lived daughter radionuclides. Both radionuclides are contained in a 
chromatography system which allows separation and extraction of the desired 
daughter radionuclide, through a process referred to as elution. Extraction through 
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elution is possible in a generator, as the parent and daughter radionuclides are two 
separate elements and therefore, do not have similar chemical properties. The parent 
is chemically attached to the column matrix; the daughter radionuclide forms a 
chemical bond with the eluting solution and is removed from the generator system. 
Once removed from the generator, the daughter radionuclide can be replaced through 
constant radioactive decay from the parent radionuclide in the system. The shelf life 
of individual generator systems is dependent on the physical half-life of the parent 
radionuclide and, therefore, length of clinical use of each generator type varies [175, 
176]. 
The most widely used radionuclide generator for clinical applications is the 
99
Mo/
99m
Tc generator system. However, in recent years, there has been an enormous 
increase in the use of generators to provide therapeutic radionuclides. This has 
contributed to the development of complementary technologies for targeting agents 
for therapy and in the general increased interest in the use of unsealed therapeutic 
radioactive sources. The invention of the 
99
Mo/
99m
Tc generator reduced the need for 
other types of Nuclear Medicine generators. However, as molecular imaging 
undergoes continuous growth, other generator types such as the 
68
Germanium/
68
Gallium (
68
Ge/
68
Ga) generator are gaining acceptance in the field for 
use in PET [177, 178]. To date, the investigations into other generator types appear 
promising with the successful construction of the 
82
Strontium/
82
Rubidium generator, 
113
Tin/
113
Indium generator, and the 
68
Ge/
68
Ga generator. With the invention of 
generators that produce specific radionuclides, PET imaging is expected to become a 
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more cost-effective imaging modality, independent of constant cyclotron access 
[179]. 
6.2. Gallium-68 generators 
68
Ga is a generator-produced isotope with a half-life of 68 min. 
68
Ga decays from 
Germanium-68 by positron emission via electron capture with 511 keV annihilation 
radiation [38, 40]. The photon abundance is 178% [41]. The 
68
Ga electrochemistry 
consists of 3 available valence electrons. In general, the generator is made up of 
alumina loaded in a plastic or glass column. The commercially available 
68
Ge/
68
Ga 
generators operate on similar concepts to the 
99m
Tc generator, despite the many more 
complex processes involved [180]. Current sources of 
68
Ge, used in 
68
Ge/
68
Ga 
generators, are produced by proton bombardment in a cyclotron and must be 
chemically attached to the column matrix for generator construction [181, 182]. 
68
Ge 
has a strong affinity for metal oxides as well as organic materials [183, 184]. Carrier 
free 
68
Ge in HCl is neutralized in EDTA solution and absorbed on the column. 
68
Ga 
is eluted from the column with 0.05 M EDTA solution. Alternatively, 
68
Ge is 
absorbed on a stannous dioxide column and 
68
Ga is eluted with 1 M HCl. 
68
Ge/
68
Ga 
generator can be eluted quite frequently since maximum yield is obtained in a few 
hours. Due to the long half-life (271 days) of 
68
Ge, the 
68
Ge/
68
Ga generator can be 
used for 1–2 years which allows PET imaging at facilities without the on-site 
cyclotron. The half-life of 
68
Ga is long enough to permit multiple-step radiotracer 
syntheses and data requisition over longer periods. With properly designed 
radiotracers, 
68
Ga could become the radionuclide as useful for PET imaging as for 
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99m
Tc for planar and SPECT imaging. There are a lack of efficient production 
methods for 
68
Ge, thus 
68
Ga is often considered the most cost-prohibitive 
radionuclide for PET imaging [185, 186]. A major advantage of the 
68
Ge/
68
Ga 
generators is the long shelf life of greater than one year which is a direct result of the 
270 day half-life of 
68
Ge, the parent radionuclide [179, 180]. This long lifespan is of 
great importance as it reduces dependence on constant cyclotron access, thereby 
increasing the likelihood of the expansion of PET to more rural areas where 
cyclotrons are less common  [177, 179, 181].  
68
Ga radiopharmaceutical labelling largely depends on obtaining a pure and useable 
form of the 
68
Ga. Proposed purification methods involve minimizing the undesired 
presence of metal ions through the insertion of a post elution purification. As current 
generator systems solely use inorganic materials for matrix construction, organic 
polymers for use in matrix construction would appear to overcome some current 
disadvantages such as contaminants which arise from matrix composition [181]. 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is increasingly 
being used as a versatile chelator that binds a large number of main group and 
transition metal ions as well as Ga with high stability constants [187]. Classes of 
biomolecules to which DOTA may be conjugated include macromolecules such as 
antibodies [188] or antibody fragments, small peptides, peptidomimetics or 
nonpeptide receptor ligands [189]. 
The most interesting DOTA-based 
68
Ga radiotracer, i.e. 
68
Ga-DOTATOC, is clearly 
superior to the other DOTA somatostatin analogs as well as Octreoscan
TM
 as 
indicated by its uniquely high tumour-to non-target tissue ratio [190]. In particular, 
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radiogallium isotopes labelled with somatostatin analogues may give us the 
opportunity for diagnosis and therapy of somatostatin receptor (SSTR) positive 
tumours. Other 
68
Ga small molecules have been prepared and used for their possible 
diagnostic value [144, 191].  
6.3 Elution Tests of 
68
Ga from Hydroxamate Resin Column 
68
Ga was eluted from the 
68
Ga generator using 0.5 M of hydochloric acid (HCl) and 
the level of radioactivity was measured using an ionization chamber. Sodium 
hydroxide (NaOH) was then added to the 
68
Ga solution to turn it into alkaline with a 
pH range of 8-9. In the meantime, the experimental setup for the elution test was 
rinsed with 4 M HCl and distilled water. After that, hydroxamate resin is suspended 
in 0.9% NaCl before being packed into the column. Thereafter, the column is rinsed 
with 5 mL MeCN, 10 mL 0.9% NaCl and 2 mL 2 M HCl.  
When the experimental setup for the elution test was rinsed and ready, 
Approximately 200 MBq out of the overall amount of 
68
Ga solution was then loaded 
to the pre-washed hydroxamate resin column. Under these conditions, 
68
Ga remained 
bound to the resin and the column was washed with 6 mL of sterile WFI where the 
68
Ga was trapped. Following that, various buffers at pH 4 including acetate and 
citrate and HCl itself were used to elute the 
68
Ga from the column, respectively 
(Figure 6.1). The activity of each elution was then measured in a dose calibrator.  
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Figure 6.1 Elution of 
68
Ga from hydroxamate resin column 
 
6.4 Gamma spectroscopy of 
68
Ga 
The 
68
Ga produced from the elution was verified through its decay mode, emission 
energies and half-life. After the elution, the samples were measured for their level of 
radioactivity. Radionuclidic purity was determined by measuring the energy peaks 
using a multi-channel analyser. The presence of gamma energies in the sample can 
be analysed by gamma spectroscopy, showing the presence of radioactive isotopes. A 
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gamma spectroscopy test with MCA gamma counter was undertaken for 
68
Ga 
verification by measuring the peak at 511 keV in 
68
Ga. It was then compared to a 
known amount of 
18
F as well as 
89
Zr in the same region of interest (ROI) where 
quantification is possible. The ROI consisted of 21 channels (495-526 keV) around 
the peak of 511 keV. In this relative quantification, the contribution from background 
activity is (within a very good approximation) assumed to be equal.  
6.5 Df-Trastuzumab Conjugation 
Trastuzumab was conjugated with the novel bifunctional chelate p-
isothiocyanatobenzyl-desferrioxamine B (Df-Bz-NCS) where Df–Bz–NCS is 
coupled to the lysine–NH2 groups of Trastuzumab. To begin the conjugation 
procedure, a threefold molar excess of Df-Bz-NCS (in 20 μl DMSO) was added to 
the Trastuzumab (2–10 mg in 1 ml 0.1 M NaHCO3 buffer, pH 9.0), and incubated for 
30 min at 37°C. This process finally produced the conjugated Df-Bz-NCS-
Trastuzumab. Nonconjugated chelate was then removed by size exclusion 
chromatography using a PD-10 column (GE Healthcare Life Sciences) with 0.25 M 
sodium acetate or 0.9% sodium chloride 5 mg/ml (pH 5.0) as eluent for purification 
purposes. The Df-Bz-NCS-Trastuzumab can be stored in the freezer at -20
o
C until 
the day of radiolabelling for at least 2 weeks. Figure 6.2 shows the experiment 
conducted on the conjugation of Trastuzumab with p-isothiocyanatobenzyl-
desferrioxamine (Df-Bz-NCS). 
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Figure 6.2 Conjugation of Trastuzumab with Df-Bz-NCS 
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6.6 
68
Ga radiopharmaceutical Labelling 
6.6.1 
68
Ga-Df-Trastuzumab Direct Labelling 
To begin with, 
68
Ga was eluted from the 
68
Ga generator using 0.5 M HCl, and 5 mL 
of it was added to 2.6 mL 1 M NaOH in order to achieve the final pH around 8 to 9 
(alkaline solution). The sample was then loaded to the hydroxamate resin column and 
washed with 6 mL of H2O. The 
68
Ga was eluted with 2.5 mL of 0.1 M sodium citrate. 
Finally, 2 mL of Df-Trastuzumab was slowly added to the 
68
Ga and incubated for 30 
min before quality control was performed. The quality control method to test this 
was TLC and HPLC for radiolabelling performance and radiochemical analysis, 
respectively. 
6.6.2 
68
Ga-Pentetreotide Labelling 
5 mL of 
68
Ga in 0.5 HCl was added to  2.6 mL 1 M NaOH in order to have the 
final pH around 8 to 9 (alkaline solution). The sample was then loaded to the 
hydroxamate resin column and washed with 6 mL of H2O. The 
68
Ga was eluted with 
pentetreotide in 0.1 M citrate form. The sample eluted was then sent for TLC and 
HPLC test analyses.  
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6.7 Result 
Table 6.1 shows the average amount and percentage of 
68
Ga eluted from 50 mg, 100 
mg and 200 mg of hyrdoxamate resin respectively using 0.01 M, 0.05 M and 0.1 M 
of citrate buffer. The table indicated that for the elution of 
68
Ga from 50 mg of 
hydoxamate resin using 0.01 M citrate buffer, 170 MBq (85 %) of the 
68
Ga 
radioactivity was to be eluted from the column and decreased to 120 MBq (60 %) for 
100 mg and 132 MBq (66 %) for 200 mg, respectively. For the elution of 
68
Ga using 
0.05 M citrate buffer, when using 50 mg of hydoxamate resin, 185.6 MBq (92.8 %) 
of the 
68
Ga radioactivity was eluted from the column and decreased to 130 MBq (65 
%) for 100 mg, but increased to 160 MBq (80 %) for 200 mg, respectively. Finally, 
for the elution test using 0.1 M citrate buffer, 195.6 MBq (97.8 %) of the 
68
Ga 
radioactivity was eluted from the column and then decreased to 148 MBq (74 %) for 
100 mg, but increased to 184 MBq (92 %) for 200 mg, respectively. Figure 6.3 
shows the bar chart of the 
68
Ga average amount eluted from 50 mg, 100 mg and 200 
mg of hydroxamate resin respectively using 0.01 M, 0.05 M and 0.1 M of citrate 
buffer. Further calculation is shown in Appendix B. 
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Table 6.1  
Average amount and percentage of 
68
Ga eluted from 50, 100 and 200 mg hydroxamate resin 
column using Citrate Buffer at pH 4 
 
 
 
Figure 6.3 Average amount of 
68
Ga in MBq eluted from 50, 100 and 200 mg 
hydroxamate resin column using 0.01, 0.05 and 0.1 M Citrate Buffer at pH 4 
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% 
Eluted 
100 mg 
Hydroxamate 
Resin (MBq) 
% 
Eluted 
200 mg 
Hydroxamate 
Resin (MBq) 
% 
Eluted 
0.01 M 170 85 120 60 132 66 
0.05 M 185.6 92.8 130 65 160 80 
0.1 M 195.6 97.8 148 74 184 92 
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Table 6.2 shows the average amount and elution percentage of 
68
Ga eluted from 50 
mg hydroxamate resin column using 0.01, 0.05 and 0.1 M of HCl, respectively. The 
table indicated that when using 0.01 M HCl concentration to elute the 
68
Ga from the 
column, approximately 12.8 MBq (6.4 %) of 
68
Ga was eluted. For the elution of 
68
Ga 
using 0.05 M HCl, approximately 81.4 MBq (40.7 %) of the 
68
Ga radioactivity was 
eluted from the column and increased to 154.8 MBq (77.4 %) for 0.1 M HCl, 
respectively. Figure 6.4 shows the bar chart of the 
68
Ga average amount eluted from 
50 mg hydroxamate resin respectively using 0.01 M, 0.05 M and 0.1 M of HCl. 
Further calculation is shown in Appendix C. 
 
 
 
 
 
 
 
 
 
 
  
133 
 
Table 6.2  
Elution of 
68
Ga from 50 mg hydroxamate resin column using HCl 
 
 
 
Figure 6.4 Average amount of 
68
Ga eluted from 50 mg hydroxamate resin using 0.01, 
0.05 and 0.1 M of HCl 
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Ga Eluted 
0.01 M 12.8 6.4 % 
0.05 M 81.4 40.7 % 
0.1 M 154.8 77.4 % 
  
134 
 
Table 6.3 indicates the 
68
Ga elution test from hydroxamate resin column using 
various buffers including acetate and citrate, citrate in HCl with different 
concentration and eluting with HCl itself. The table shows that 0.1 M Citrate Buffer 
eluted more than 60% (121.2 MBq) of 
68
Ga from the hydroxamate resin column for 
the first 0.5 ml fraction compared to other solutions. 1 M Na Citrate in 0.5 M HCl 
was comparable with 0.5 M HCl with each of them extracting approximately 55.5 % 
(111 MBq) and 55.2 % (110.4 MBq) 
68
Ga from the hydroxamate column, 
respectively. The amount of 
68
Ga eluted from the column is shown in Figure 6.5 and 
further calculation is shown in Appendix D. 
 
Table 6.3  
Average amount and percentage of 
68
Ga extracted from hydroxamate resin column using 
various solutions 
 
68
Ga Extraction from Hydroxamate 
Resin Column 
 
Amount of 
68
Ga 
extracted (MBq) 
 
% 
68
Ga extracted 
from the column 
1 M Na Citrate in 0.5 M HCl 111 55.5 % 
0.5 M Na Citrate in 0.25 M HCl 89 44.5 % 
0.2 M Na Citrate in 0.1 M HCl 51.4 25.7 % 
0.1 M Na Citrate + 0.05 M HCl 44.8 22.4 % 
0.1 M Citrate Buffer at pH 4 121.2 60.6 % 
1 M Na Citrate + 1 M Citric Acid 101.4 50.7 % 
0.5 M HCl 110.4 55.2 % 
0.1 M HCl 52.8 26.4 % 
0.01 M Citrate Buffer at pH 4 73.4 36.7 % 
1 M Acetate Buffer at pH 4 0  0 % 
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Figure 6.5 Average amount of 
68
Ga in MBq extracted from hydroxamate resin column using 
various solutions  
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For 
68
Ga-Df-Trastuzumab radiolabelling performance analysis, the TLC test showed 
a very high peak in the origin (Figure 6.6).  
 
 
Figure 6.6 TLC analysis result of 
68
Ga-Df-Trastuzumab 
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Figure 6.7 shows the HPLC analysis result on free 
68
Ga. The figure indicated that a 
high peak of free 
68
Ga was shown between 15 to 20 minutes in 280 nm UV.  
 
 
Figure 6.7 HPLC analysis result of free 
68
Ga 
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For radiochemical analysis, the HPLC test showed the overlapping labelled peak in 
both 
68
Ga and Df-Trastuzumab as between 10 to 15 minutes in 280 nm UV (Figure 
6.8). 
 
 
Figure 6.8 HPLC analysis result of 
68
Ga-Df-Trastuzumab 
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For 
68
Ga-Pentetreotide radiolabelling analysis, the TLC test showed a high peak in 
the origin (Figure 6.9). Apart from that, there are also two peaks observed in the 
solvent front. 
 
 
Figure 6.9 TLC analysis result of 
68
Ga-Pentetreotide 
 
 
 
 
 
  
140 
 
For radiochemical analysis, the HPLC test showed the overlapping peaks in both 
68
Ga and Pentetreotide between 10 to 15 minutes and free 
68
Ga between 16 to 20 
minutes in 280 nm UV, respectively (Figure 6.10). There were also overlapping 
peaks found in 280 nm UV between 24 to 27 minutes. 
 
 
Figure 6.10 HPLC analysis result of 
68
Ga-Pentetreotide 
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6.8 Discussion 
The first experiment of this study sought to determine whether different hydroxamate 
resin quantities of 50 mg, 100 mg and 200 mg respectively affect the extraction and 
to determine different concentrations of 0.01 M, 0.05 M and 0.1 M of citrate buffer 
for evaluating the appropriate citrate buffer concentration for 
68
Ga elution from 
hydroxamate resin column. Results from the experiments indicated that, when using 
0.01 M citrate buffer at pH 4 as an extraction agent, the highest amount of 
68
Ga 
radionuclide (85 %) was found to be eluted from 50 mg hydroxamate resin when 
compared with 100 mg (60 %) and 200 mg (66 %) in terms of the percentage (Table 
6.1). The similar result was found in another two 
68
Ga elution experiments using 0.05 
M and 0.1 M citrate buffer, where the 
68
Ga elution percentage of 92.8 % and 97.8 % 
from 50 mg hydroxamate resin, which demonstrated that 50 mg of the resin was 
suitable for the optimum extraction of the 
68
Ga radionuclide. The experiment, which 
was also carried out to find the appropriate concentration of citrate buffer to elute 
68
Ga from the hydroxamate resin column, indicated that 0.1 M citrate buffer provided 
the highest elution percentage of 
68
Ga radionuclide (97.8 %) compared to 0.05 M 
(92.8 %) and 0.01 M (85 %) of citrate buffer concentration, respectively.  
Second experiment was conducted to determine the appropriate concentration of HCl 
needed to elute the 
68
Ga from 50 mg hydroxamate resin column. Results showed the 
elution percentage of 
68
Ga from 50 mg hydroxamate resin column using 0.01, 0.05 
and 0.1 M of HCl, respectively and concluded that 0.1 M HCl was able to elute the 
highest amount of 
68
Ga radionuclide (77.4%). 
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Third experiment involved the 
68
Ga elution test from hydroxamate resin column, 
using various buffers including: acetate and citrate, citrate in HCl with different 
concentration and eluting with HCl itself. These series of experiments were 
undertaken to determine the suitable buffer for 
68
Ga elution, which showed that 0.1 
M citrate buffer eluted more than 60 % of 
68
Ga from the hydroxamate resin column 
for the first 0.5 ml fraction compared to other solutions. This indicated that a 0.1 M 
citrate buffer was suitable for 
68
Ga elution from hydroxamate resin column. Citrate 
buffer was chosen in this series of experiments because citrate with appropriate pH 
has the advantage of perhaps being an easier environment in which to label 
radiopharmaceuticals compared to HCl. 
The next series of experiments were the 
68
Ga radiopharmaceutical radiolabelling 
where two sets of experiments were undertaken; one was 
68
Ga-Df-Trastuzumab 
radiolabelling and the other one was 
68
Ga-Pentetreotide radiolabelling. For 
68
Ga-Df-
Trastuzumab radiolabelling analysis, the TLC test showed a very high peak in the 
origin indicating that 
68
Ga was successfully labelled to Df-Trastuzumab. Another 
radiochemical analysis test was undertaken using HPLC test analysis which showed 
the overlapping peaks in both 
68
Ga and Df-Trastuzumab between 10 to 15 minutes in 
280 nm UV, indicating the successful radiolabelling of the compound. 
TLC test analysis for 
68
Ga-Pentetreotide radiolabelling showed a high peak in the 
origin. However, there are also two peaks observed at the solvent front which 
indicated that the radiolabelling efficiency between 
68
Ga and Pentetreotide was weak. 
Further testing on radiochemical analysis showed the overlapping peaks in both 
68
Ga 
and Pentetreotide between 10 to 15 minutes and free 
68
Ga between 16 to 20 minutes 
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in 280 nm UV. In addition, there was also an overlapping peak found in 280 nm UV, 
of between 24 to 27 minutes, suggesting a weak radiolabelling efficiency of the 
68
Ga-
Pentetreotide labelling. 
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Chapter 7: Conclusions and Future Directions 
The set of experiments and observations presented in this thesis represent the 
production of 
89
Zr using five different types of 
89
Y solid target by a process of 
cyclotron bombardment with 
89
Y(p, n)
89
Zr reaction in a 12 MeV medical cyclotron at 
10 µA beam current. 
89
Zr was then purified and separated from the starting materials 
and other impurities using a hydroxamate resin column. The experiments continued 
on with radiolabelling of monoclonal antibodies with 
89
Zr using the novel p-
isothiocyanatobenzyl-desferrioxamine B (Df-Bz-NCS) as a bifunctional chelating 
agent. Herceptin® (Trastuzumab) was the monoclonal antibody of interest for these 
series of experiments as it showed a stable conjugation with the chelating agent.  
This thesis also studied and discussed the experiments on the PET imaging studies of 
89
Zr-labelled with monoclonal antibodies. These were conducted in order to examine 
the in vivo behaviour of 
89
Zr-Df-Trastuzumab using female Balb/c nude mice models 
that have a low immune system but no diseases, with LS174T (HER2-expressing) 
tumours. PET imaging was performed on them to determine if the 
89
Zr-labelled with 
trastuzumab was successful in vivo in providing useful information from the images 
at 24 hours after injection of 
89
Zr-Df-Trastuzumab radiopharmaceutical. 
Furthermore, the experiments on the potential of phosphoric acid to be used as 
89
Zr 
extraction agent from hydroxamate resin column (thus labelling it with Df-Bz-NCS-
Trastuzumab) have been discussed. 
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In addition, in Chapter 6, this thesis established and discussed the series of 
experiments on the elution of 
68
Ga from hydroxamate resin column, followed by a 
study on the experiments on 
68
Ga-labelled with Trastuzumab and Pentetreotide using 
hydroxamate resin column as an ion exchanger. 
7.1 Production of 
89
Zr 
There are five different types of 
89
Y solid targets that were successfully prepared as 
starting materials for 
89
Zr production.  These are, specifically: yttrium foil, yttrium 
nitrate, electrodeposited yttrium nitrate using two different methods of preparation 
and yttrium sputtering technique. The two different methods used in preparing 
electrodeposited yttrium nitrate include: electrodeposition of yttrium in aqueous bath 
(diluted nitric acid) and electrodeposition of yttrium in non-aqueous bath (ethanol), 
respectively. 
According to the experiments, the amount of yttrium nirate used for yttrium nitrate 
compacting technique was 0.45g with 10 minutes preparation time. Preparation time 
on both aqueous and non-aqueous electrodeposition took up to 1 hour at room 
temperature during the electrodeposition process, with approximately 0.05 and 0.03 g 
respectively of the deposited 
89
Y onto the copper target plate. For the yttrium 
sputtering technique, the final amount of yttrium produced after 10 minutes of 
sputtering process was 0.01 g, which was the lowest yield of 
89
Y produced compared 
to other techniques. The easiest yttrium target preparation was the preparation of 
yttrium foil target plate where the preparation time took around 10 minutes and was 
usually for a layer of placement. Up to 0.20 g can be placed directly on the 
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aluminium target plate and up to 3 layers with altogether 0.6 g of yttrium foil can be 
placed on the aluminium plate to obtain a higher yield of the 
89
Zr radioisotope 
produced after bombardment in the cyclotron which can provide approximately 400 
MBq after the end of bombardment.  
Five types of yttrium solid targets were bombarded, which successfully produced 
89
Zr in a 12 MeV medical cyclotron.  Yttrium foil produced the highest amount of 
89
Zr radioactivity after bombardment compared to the other types of yttrium solid 
targets. As high amount of 
89
Zr activity is needed for successful labelling with 
monoclonal antibody; yttrium foil was selected to be used as a starting material in the 
production of 
89
Zr for radiolabelling and PET imaging study.  
7.2 Purification of 
89
Zr 
The successfully produced 
89
Zr radioisotopes using a 12 MeV medical cyclotron 
were loaded to the hydroxamate resin column and result indicated that 1.0 M of 
oxalic acid extracted more than 80% of 
89
Zr radioactivity from the hydroxamate resin 
column. Usually, purification of 
89
Zr involved a two-step procedure which involves 
the separation process of 
89
Zr radionuclide from its impurities and starting materials, 
followed by extraction of the radionuclide from the retention column and 
hydroxamate resin column. This procedure has been widely used for separating 
89
Zr 
which is embedded in the metal yttrium target, where 
89
Zr can be separated from the 
target by ion exchange chromatography with an overall yield of ~80% [35, 151]. 
There was concern over the ability of zirconium in oxalate complexes to tran-chelate 
to Df [35]. However, a study has shown that chelation efficacy is not impaired by 
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oxalate since the oxalate can be removed and replaced by chloride on an anion 
exchange column [34]. Meanwhile, another study recommended that the chloride 
form is objectionable due to hypochlorite formation from radiolysis [36]. Later in 
2010, a new bifunctional chelate was introduced for facile radiolabeling of 
monoclonal antibodies with 
89
Zr, which is also able to remove the oxalate from the 
complex [97]. 
7.2.1 Alternative 
89
Zr Extraction Agent 
The significance of this study, by refining the separation and labelling techniques for 
89
Zr-Trastuzumab and then validating the product through subsequent in vivo testing 
in mice, a simpler, safer and more effective immuno-PET imaging agent will be 
available to allow delayed imaging of specific tumours. These are important in any 
pre-radioimmunotherapy work-up to determine the following: if the patient is likely 
to respond to the therapy, to provide quantifiable information that can be used to 
calculate the radiation dose that will be delivered during therapy, and to help 
determine which are the dose-limiting organs [16].  It is anticipated that this can be 
achieved without the use of oxalic acid as an extraction agent, which is known to be 
highly toxic but is currently being widely used in 
89
Zr extraction from hydroxamate 
resin column. 
From the experiment, it has been determined that it is possible to use phosphoric acid 
as an alternative extraction agent for separating and purifying 
89
Zr. It is also possible 
to label 
89
Zr-phosphate to Df-Bz-NCS-Trastuzumab. However, further research 
needs to be undertaken, especially with regard to its in vivo behaviour. Oxalate from 
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89
Zr-oxalate can be removed and replaced by chloride using an activated Waters Sep-
pak Light QMA strong anion exchange cartridge. However, another study 
recommended that the chloride form is undesirable due to hypochlorite formation 
from radiolysis [36]. Presently, oxalic acid is still the most successful agent for the 
separation and purification of 
89
Zr used in labelling 
89
Zr-Df-Trastuzumab. Although 
oxalic acid is toxic, it can be removed from the product via purification 
chromatography [32]. 
7.3 
89
Zr Radiolabelling 
A high amount of 
89
Zr activity was needed in order to be labelled with monoclonal 
antibody; hence yttrium foil was chosen as a target for bombardment on the 12 MeV 
medical cyclotron. It has been shown that yttrium foil provided a high amount of 
89
Zr 
activity after bombardment. Approximately 400 MBq 
89
Zr was produced after two 
and a half hours of irradiation with proton beam energy of 12 MeV and 10 µA beam 
current after the end of bombardment.  
Herceptin (Trastuzumab) was conjugated with the novel bifunctional chelate p-
isothiocyanatobenzyl-desferrioxamine B (Df-Bz-NCS) and finally the conjugated Df-
Bz-NCS-Trastuzumab was labelled with 
89
Zr to form 
89
Zr-Df-Trastuzumab. 
Results on the HPLC analysis on the conjugated Df-Trastuzumab suggest that the 
Df-Bz-NCS was successfully conjugated with Trastuzumab and the radiolabelling 
performance; while TLC analysis showed the highest peak of 
89
Zr in the origin 
suggesting the mAb was successfully labelled with 
89
Zr. For radiochemical analysis, 
HPLC test results showed the overlapping labelled peak in both 
89
Zr and mAb at 
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between 10 to 15 minutes in 280 nm UV length suggesting that the mAb was 
successfully labelled with 
89
Zr. 
7.4 
89
Zr PET Imaging 
Experiments on biodistribution and PET imaging of the female Balb/c nude mice 
with the HER2 positive LS174T colorectal tumour were undertaken to validate the 
successful radiolabelling procedure between 
89
Zr and monoclonal antibody using 
89
Zr produced in a 12 MeV medical cyclotron in preclinical condition. PET images at 
24 hours showed a selective accumulation of 
89
Zr-Df-Trastuzumab in tumour-bearing 
mice with good tumour uptake in the right flank (Figure 5.4). Tumour uptake of 
89
Zr-
Df-Trastuzumab was also observed in the cardiac (which having HER2 receptor 
expression on the heart), demonstrated that the conjugated monoclonal antibody was 
successfully labelled with 
89
Zr. 
Experiments on PET imaging of the radiolabelled 
89
Zr-Df-Trastuzumab validated the 
successful radiolabelling between 
89
Zr and monoclonal antibody using 
89
Zr produced 
in a 12 MeV medical cyclotron and in preclinical conditions. 
Nowadays, varieties of mAbs have been labelled with 
89
Zr and several of these 
radiolabelled 
89
Zr-mAbs have entered clinical studies with promising results. With 
the availability of 
89
Zr and simpler radiolabelling techniques, it is expected that more 
89
Zr PET tracers will be developed commercially in the future. 
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7.5 
68
Ga Elution from Hydroxamate Resin Column 
Early and specific tumour detection, as well as therapy selection and response 
evaluation, are some challenges of improved medicine which usually involve high 
sensitive and specific molecular imaging such as positron emission tomography 
(PET). The use of peptides for PET molecular imaging has unquestionable 
advantages, including: the possibility of targeting through interaction of peptide-
receptor, small size and low-molecular weight recommending good penetration in the 
tissue or at cellular level with low toxicity and no antigenicity, and also the 
possibility of a wide variety of choices for radiolabeling [192]. Among β+-emitter 
radioelements, 
68
Ga is a very attractive positron-emitter compared with carbon-11 or 
fluorine-18, taking into account its easy production via a 
68
Ge/
68
Ga generator and 
well-established radiochemistry. 
68
Ga chemistry is based on well-defined 
coordination complexes with macrocycle or chelates having strong properties of 
binding which are suitable for linking peptides that allow resistance to in vivo 
transchelation of the metal ion. Understanding the mechanism of specific and 
nonspecific molecular in oncogenesis is one major key to developing new molecular 
imaging tools. The recent review focuses on peptide signalling involved in different 
oncogenic pathways. The signalization might be common for tumoural and non-
tumoural processes, or could be indicative of an oncological process. Furthermore, 
the review describes gallium chemistry and different 
68
Ga-radiolabelled peptides 
already in use or under development, aiming at developing molecular PET imaging 
of different oncological processes. 
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The first series of experiments on different quantity of hydroxamate resin column 
indicated that 50 mg of the resin was suitable for the optimum extraction of the 
68
Ga 
radionuclide. The next series of experiments in finding the appropriate concentration 
of citrate buffer to elute 
68
Ga from the hydroxamate resin column revealed that the 
highest elution percentage of 
68
Ga radionuclide was eluted by 0.1 M citrate buffer, 
compared to 0.05 M and 0.01 M citrate buffer, respectively. The subsequent series of 
experiments in determining the suitable concentration of HCl to elute the 
68
Ga from 
50 mg hydroxamate resin column concluded that 0.1 M HCl was able to elute the 
highest amount of 
68
Ga radionuclide.  
A series elution test of 
68
Ga from hydroxamate resin column using various buffers 
including: acetate and citrate, citrate in HCl with different concentration and eluting 
with HCl itself, indicated that 0.1 M citrate buffer at pH 4 was suitable for 
68
Ga 
elution and comparable to 0.5 M HCl which is currently being used in 
68
Ga elution 
from 
68
Ge/
68
Ga generator. The advantage of citrate having appropriate pH may result 
in an easier environment in which to label radiopharmaceuticals compared to HCl. 
7.6 
68
Ga Radiolabelling 
Experiments on the 
68
Ga radiopharmaceutical radiolabelling concluded that 
68
Ga-Df-
Trastuzumab radiolabelling was successful according to TLC and HPLC analysis 
results. As for 
68
Ga-Pentetreotide radiolabelling, TLC analysis results showed a high 
peak in the origin. However, there were also two peaks observed at the solvent front 
indicating that the radiolabelling efficiency between 
68
Ga and Pentetreotide was 
weak. Further HPLC radiochemical analysis test results showed the overlapping 
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peaks in both 
68
Ga-Pentetreotide, between 10 to 15 minutes and free 
68
Ga, between 
16 to 20 minutes in 280 nm UV. In addition, an unknown overlapping peak was 
found in 280 nm UV between 24 to 27 minutes, suggesting a weak radiolabelling 
efficiency of the 
68
Ga-Pentetreotide labelling. 
7.6 General Conclusion 
The observations of this thesis have led to new suggestions concerning the 
production, purification, labelling and imaging of 
89
Zr for targeted positron emission 
tomography (PET) radiopharmaceuticals.  
Over the last several years, PET imaging with 
89
Zr-based agents has been a highly 
dynamic research area. Presently, the majority of agents that have been labelled 
with 
89
Zr are mAbs, since the decay half-life of 
89
Zr matches very well with the 
biological half-life of antibodies.  
Currently, labelling of 
89
Zr is primarily through desferrioxamine B, which serves as 
the chelator where the 
89
Zr-Df conjugate is quite stable for in vivo applications. 
Hence, the key to in vivo stability of 
89
Zr-based tracers lies in the linkage between Df 
and the antibody or the nanoparticle. Although site-specific labeling of 
89
Zr will not 
compromise the immunoreactivity of the resulting antibody conjugate, the 
requirement of protein engineering expertise will limit the wide-spread adoption of 
such site-specific labelling strategy. 
There is currently significantly simplified radiochemistry such as the 2-step method, 
increased commercial available of the 
89
Zr isotope supply and chelating agents 
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for 
89
Zr radiopharmaceutical labelling, as well as successful proof-of-principle in 
pilot human studies. As a result, PET imaging of 
89
Zr-based tracers is expected to be 
a constantly evolving and highly vibrant field for the next decade. Therefore, further 
efforts are needed to accelerate the translation of more promising 
89
Zr-based tracers 
into clinical use. 
In conclusion, the field of radioimmunoimaging with longer-lived positron-emitting 
radionuclides is believed to hold significant promise. However, several scientific and 
nonscientific challenges have to be conquered before realising the true potential of 
PET radioimmunoimaging with intact antibodies. This study is by definition a part of 
Nuclear Medicine aimed as a reference by which researchers can produce 
89
Zr 
radionuclide in a medical cyclotron to be labelled to various types of proteins, 
monoclonal antibodies and peptides so that it could be safely used in a clinical 
environment. 
7.7 Future Directions 
The successful production of 
89
Zr in a medical cyclotron demonstrated all the 
characteristics necessary for translation of 
89
Zr radioisotopes to be labelled with 
monoclonal antibodies as PET agents into the clinical setting. This study has 
presented preliminary data on the preparation of 
89
Y solid target as a starting material 
in the production of 
89
Zr using a 12 MeV medical cyclotron. Subsequently, the study 
on the production, purification, labelling and imaging of 
89
Zr for targeted positron 
emission tomography (PET) radiopharmaceuticals has also been presented.  
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The next stage of further investigations should be related to the mass production of 
89
Zr so that 
89
Zr radioisotope can be easily available in order to be used for further 
study on the radiolabelling process with various proteins and peptides. For this 
reason, 
89
Zr production using yttrium foil in a medical cyclotron with increased 
irradiation time of 4 to 6 hours is suggested so that a higher yield of 
89
Zr can be 
produced in a clinical condition. This can then be used to further the studies on PET 
imaging of radiolabelled compounds.  
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Appendix A. Amount of 
89
Zr in MBq extracted from 
hydroxamate resin column using 1.0 M oxalic acid and 1.0 
M phosphoric acid as extraction agents  
 
Amount of 
89
Zr in MBq extracted from hydroxamate resin column using 1 M oxalic 
acid and 1 M phosphoric acid as extraction agents 
 
  
 
Activity of Zr-89 
extracted using oxalic 
acid (MBq) 
Activity of Zr-89 extracted 
using phophoric acid (MBq) 
Activity in the 
column 
200 200 
Elution 1 179.4 146.6 
Elution 2 173.2 138.4 
Elution 3 182.8 143.5 
Elution 4 176.8 130.2 
Elution 5 189.8 142.3 
Average: 180.4 140.2 
Std Dev: 6.32 6.31 
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Appendix B. Amount of 
68
Ga in MBq eluted from 50, 100 
and 200 mg hydroxamate resin column using 0.01, 0.05 and 
0.1 M Citrate Buffer at pH 4 
 
Amount of 
68
Ga in MBq eluted from 50 mg hydroxamate resin column using 0.01, 
0.05 and 0.1 M Citrate Buffer at pH 4 
 
 
 
  
50 mg hydroxamate 
resin, 0.01 M Citrate 
Buffer (MBq) 
50 mg hydroxamate 
resin, 0.05 M Citrate 
Buffer (MBq) 
50 mg hydroxamate 
resin, 0.1 M Citrate 
Buffer (MBq) 
Activity in 
the column 
200 200 200 
Elution 1 170 187 197 
Elution 2 176 184 193 
Elution 3 168 179 196 
Elution 4 164 188 197 
Elution 5 172 190 195 
Average: 170 185.6 195.6 
Std Dev: 4.47 4.28 1.67 
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Amount of 
68
Ga in MBq eluted from 100 mg hydroxamate resin column using 0.01, 
0.05 and 0.1 M Citrate Buffer at pH 4 
 
 
 
 
 
 
 
 
 
 
  
100 mg hydroxamate 
resin, 0.01 M Citrate 
Buffer (MBq) 
100 mg hydroxamate 
resin, 0.05 M Citrate 
Buffer (MBq) 
100 mg hydroxamate 
resin, 0.1 M Citrate 
Buffer (MBq) 
Activity in 
the column 
200 200 200 
Elution 1 126 137 143 
Elution 2 120 131 156 
Elution 3 118 136 147 
Elution 4 120 125 153 
Elution 5 116 121 141 
Average: 120 130 148 
Std Dev: 3.742 6.928 6.403 
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Amount of 
68
Ga in MBq eluted from 200 mg hydroxamate resin column using 0.01, 
0.05 and 0.1 M Citrate Buffer at pH 4 
 
 
 
 
 
  
200 mg hydroxamate 
resin, 0.01 M Citrate 
Buffer (MBq) 
200 mg hydroxamate 
resin, 0.05 M Citrate 
Buffer (MBq) 
200 mg hydroxamate 
resin, 0.1 M Citrate 
Buffer (MBq) 
Activity in 
the column 
200 200 200 
Elution 1 136 149 181 
Elution 2 133 165 178 
Elution 3 124 161 186 
Elution 4 129 159 187 
Elution 5 138 166 188 
Average: 132 160 184 
Std Dev: 5.612 6.782 4.301 
  
178 
 
Appendix C. Amount of 
68
Ga in MBq eluted from 50 mg 
hydroxamate resin column using 0.01, 0.05 and 0.1 M HCl 
 
Amount of 
68
Ga in MBq eluted from 50 mg hydroxamate resin column using 0.01, 
0.05 and 0.1 M HCl 
 
 
 
 
 0.01 M HCl (MBq) 0.05 M HCl (MBq)  0.1 M HCl (MBq) 
Activity in 
the column 
200 200 200 
Elution 1 16 86 165 
Elution 2 12 73 167 
Elution 3 15 82 143 
Elution 4 10 89 152 
Elution 5 11 77 147 
Average: 12.8 81.4 154 
Std Dev: 2.588 6.504 10.33 
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Appendix D. Amount of 
68
Ga in MBq eluted from 
hydroxamate resin column using various solutions 
 
Amount of 
68
Ga in MBq eluted from hydroxamate resin column using various 
solutions 
 
 
 
 
  
Activity of Ga-68 
extracted using 1 M 
Na Citrate in 0.5 M 
HCl (MBq) 
Activity of Ga-68 
extracted using 0.5 M 
Na Citrate in 0.25 M 
HCl (MBq) 
Activity of Ga-68 
extracted using 0.2 M 
Na Citrate in 0.1 M 
HCl (MBq) 
Activity in 
the column 
200 200 200 
Elution 1 103 96 55 
Elution 2 109 85 53 
Elution 3 115 83 47 
Elution 4 118 95 56 
Elution 5 110 86 46 
Average: 111 89 51.4 
Std Dev: 5.788 6.042 4.615 
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Amount of 
68
Ga in MBq eluted from hydroxamate resin column using various 
solutions 
 
 
 
 
 
 
  
Activity of Ga-68 
extracted using 0.1 M 
Na Citrate in 0.05 M 
HCl (MBq) 
Activity of Ga-68 
extracted using 0.1 
M Citrate Buffer  
(MBq) 
Activity of Ga-68 
extracted using 1 M 
Na Citrate in 1 M 
Citric Acid (MBq) 
Activity in 
the 
column 
200 200 200 
Elution 1 47 127 98 
Elution 2 43 124 107 
Elution 3 41 118 105 
Elution 4 45 120 96 
Elution 5 48 117 101 
Average: 44.8 121.2 101.4 
Std Dev: 2.864 4.207 4.615 
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Amount of 
68
Ga in MBq eluted from hydroxamate resin column using various 
solutions 
 
 
 
 
 
 
 
 
 
  
Activity of 
Ga-68 
extracted using 
0.5 M HCl 
(MBq) 
Activity of 
Ga-68 
extracted using 
0.1 M HCl 
(MBq) 
Activity of 
Ga-68 
extracted using 
0.01 M Citrate 
Buffer (MBq) 
Activity of 
Ga-68 
extracted using 
1 M Acetate 
Buffer (MBq) 
Activity in 
the column 
200 200 200 200 
Elution 1 115 48 77 0 
Elution 2 104 51 69 0 
Elution 3 109 54 67 0 
Elution 4 110 53 79 0 
Elution 5 114 58 75 0 
Average: 110.4 52.8 73.4 0 
Std Dev: 4.393 3.701 5.177 0.000 
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Appendix E. PET images using 
89
Zr-Df with phosphoric 
acid as an extraction agent, applied to a female Balb/c nude 
mouse model with subcutaneous LS174T tumour (HER2-
expressing colorectal model) on the right flank. 
PET images using 
89
Zr-Df applied to a female Balb/c nude mouse model with 
subcutaneous LS174T tumour (HER2-expressing colorectal model) on the right flank 
at 24 h and 4h h post injection (Mouse #1). 
24 hours 
 
48 hours 
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PET images using 
89
Zr-Df applied to a female Balb/c nude mouse model with 
subcutaneous LS174T tumour (HER2-expressing colorectal model) on the right flank 
at 24 h and 4h h post injection (Mouse #2). 
 
24 hours 
 
48 hours 
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Appendix F. PET images using free 
89
Zr, applied to a 
female Balb/c nude mouse model with subcutaneous 
LS174T tumour (HER2-expressing colorectal model) on the 
right flank. 
PET images at 1, 4 and 24 h post injection (Mouse #1). 
1 hour 
 
4 hours 
 
24 hours 
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PET images at 1, 4 and 24 h post injection (Mouse #2). 
1 hour 
 
4 hours 
 
24 hours 
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Appendix G. PET images using 
89
Zr tracer bound to mAb 
as 
89
Zr-Df-Trastuzumab, applied to a female Balb/c nude 
mouse model with subcutaneous LS174T tumour (HER2-
expressing colorectal model) on the right flank. 
PET images using 
89
Zr-Df-Trastuzumab, applied to a female Balb/c nude mouse 
model with subcutaneous LS174T tumour (HER2-expressing colorectal model) on 
the right flank at 24 h post injection (Mouse #1). 
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PET images using 
89
Zr-Df-Trastuzumab, applied to a female Balb/c nude mouse 
model with subcutaneous LS174T tumour (HER2-expressing colorectal model) on 
the right flank at 24 h post injection (Mouse #2). 
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PET images using 
89
Zr-Df-Trastuzumab, applied to a female Balb/c nude mouse 
model with subcutaneous LS174T tumour (HER2-expressing colorectal model) on 
the right flank at 24 h post injection (Mouse #3). 
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PET images using 
89
Zr-Df-Trastuzumab, applied to a female Balb/c nude mouse 
model with subcutaneous LS174T tumour (HER2-expressing colorectal model) on 
the right flank at 24 h post injection (Mouse #4). 
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Appendix I. Review on Production of 
89
Zr in a Medical 
Cyclotron for PET Radiopharmaceuticals 
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Appendix J. Establishing Reliable Production of the PET 
Isotope 
89
Zr for Research Use: From Target Fabrication to 
Preclinical Imaging 
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